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Abstract 
Transcription factor E2F plays an important role in growth control by 
co-ordinating early cell cycle events. In addition, certain E2F family mcmbcrs, 
including E2F-I, are endowed with apoptotic activity. E2F-l is regulated 
during cell cycle progression and inducible by cellular stress, such as DNA 
damage. Within the DNA damage signalling pathway, checkpoint kinases act 
as effectors of the damage response through phosphorylating key substrates 
involved in growth control. Here, I report that checkpoint kinase Chk2 
regulates E2F -1 activity in response to etoposide. A Chk2 kinase 
phosphorylation site resides In E2F-I, and undergoes physiological 
phosphorylation in response to DNA damage. Phosphorylation of E2F-l by 
Chk2 leads to protein stabilization, increased half-life and transcriptional 
activation, and phosphorylated E2F-I resides in discrete nuclear structures. A 
dominant-negative derivative of Chk2 blocks the induction of E2F -I, and 
prevents E2F-I-dependent apoptosis. Moreover, E2F-l fails to be induced by 
etoposide in tumour cells that carry mutant cllk2. Chk2 therefore 
phosphorylates and activates E2F-l in the cellular response to DNA damage, 
and the damage induction of E2F -I leads to apoptosis. The results suggest a 
role for E2F -1 in response to stress, perhaps in checkpoint control, and provide 
a plausible mechanistic and physiological explanation for the tumour suppressor 
activity ofE2F-1. 
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Chapter 1 
Introduction 
1.1 The mammalian cell cycle 
The mammalian cell cycle is divided into four distinct phases, referred 
to as G 1, S, G2 and M-phase. The two gap periods, Gland G2, are growth 
phases that precede DNA synthesis and replication (S-phase), and cell division 
or mitosis (M-phase). In late G I-phase and prior to entering S-phase, cells pass 
through the restriction point. The restriction point is the point in the 
mammalian cell cycle when cells become committed to entering S-phase and 
completing the cell cycle, independently of further growth factor signalling 
(Sherr, 1996). 
Passage through the restriction point and entry into S-phase is co-
ordinated by the sequential activation and inactivation of the G 1 cyclin-
dependent kinases (cdks). Cdk activity is regulated by the temporal synthesis 
and binding of specific regulatory subunits, called cyclins, the association and 
dissociation of cdk inhibitors (cdi), as well as inhibitory and activating 
phosphorylation events (Sherr, 1996). Mitogenic growth factors induce genes 
encoding D-type cyclins, and the cyclins assemble with their catalytic partners 
to form active cdk 4/6-cyclinD complexes. Active cdks subsequently 
phosphorylate key growth regUlating proteins, such as the retinoblastoma 
tumour suppressor protein (pRb), which thereafter allows cells to traverse the 
G I phase. The subsequent activation of other genes required for cell cycle 
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progression including cyclinE (which forms an active complex with cdk2 and 
facilitates progressive pRb phosphorylation), and enzymes involved in DNA 
replication, is sufficient to commit cells to S-phasc. The activity of pRb is 
intimately connected with the restriction point, and once cells pass the 
restriction point the cell cycle is self-regulated, unless DNA becomes damaged 
or defects are encountered during mitosis, which activates checkpoints and 
delays the cell cycle. 
1.2 History of E2F 
Historically, E2F was referred to as DRTFI/E2F, reflecting the early 
studies which elucidated its activity (Nevins, 1992). E2F was defined as a 
cellular factor required for the adenovirus early region 1 A (E I A) transforming 
protein to mediate the transcriptional activation of the viral E2A promoter 
(Nevins, 1992). On the other hand, DRTFI (differentiation-regulated 
transcription factor 1) was identi fied as a transcription activity whose DNA 
binding activity decreased during the differentiation of F9 embryonal carcinoma 
(EC) stem cells (La Thangue and Rigby, 1987). The consensus DNA binding 
site for DRTFI and E2F subsequently were found to be similar which, together 
with other observations, suggested that DRTFt and E2F were related. In this 
thesis the combined activity will be referred to as E2F. 
The E2F consensus binding site is "TTTCGCGC", present 111 the 
adenovirus E2A promoter (Nevins, 1992), and predominantly within the 
promoters of cellular genes required for cell division and apoptosis (Dyson, 
1998). Identified E2F target genes include cell cycle regulators such as the 
18 
cyclins E, A and Dl, Cdc2, and Cdc25A, enzymes involved in DNA synthesis 
like dihydrofolate reductase (DHFR), DNA polymerase a and thymidine kinase, 
and proteins essential for DNA replication including Cdc6, ORCI and the mini-
chromosome maintenance (MCM) proteins (Dyson, 1998; Table 1.1). 
Apoptotic E2F target genes include apoptosis protease-activating factor I 
(Apaf-l), p73 and ARF (Moroni et al., 2001; Irwin et al., 2000; Lissey el al., 
2000; Bates et al., 1998). 
1.3 The retinoblastoma family of proteins 
Interest in E2F increased considerably when, through studies on the 
cellular targets of viral oncoproteins, E2F was identified to be important for the 
function of pRb (Bandara and La Thangue, 1991; Chellappan et al., 1991). The 
Rb gene possesses the properties of a classical tumour suppressor gene, being 
absent or mutated in at least one third of all human tumours (Weinberg, 1995; 
Sherr, 1996). Single allelic mutations in Rb predispose sufferers to a wide 
variety of tumour types (Weinberg, 1995), and familial inactivating mutations in 
Rb are associated with the rare paediatric eye tumour retinoblastoma (Friend et 
al., 1986). 
pRb is the prototype member of a family of proteins, referred to as the 
pocket proteins, that includes pl07 and p130 (Wang et al., 1997). pRb shares 
significant homology with pi 07 and p 130, particularly in the "pocket region". 
The large pocket region of pRb (amino acids 395-876) binds to E2F, and the 
small pocket region (amino acids 379-792) binds to the LXCXE peptide (Wang 
et al., 1997). Viral oncoproteins, including adenovirus E I A, SV 40 large T 
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Table 1.1 E2F regulated genes 
(Adapted from Helin, 1998 and data also from Muller et al., 2001; Rcn et al., 
2002; Ma et al., 2002; Stanelle et al., 2002; Polager et al., 2002). 
DNA synthesis Proliferation Apoptosis DNA repair 
DNA polymerase a CyclinDl P19ARF MSH2 
thymidine kinase cyclinE p73 MSH6 
DHFR cyclinA Apaf-1 RPA2 
ORC! cdc2 Caspase 3 RPA3 
Cdc6 cdk2 Caspasc 7 BReA1 
MCM pl07 Bok PCNA 
PCNA pRb Bad 
c-myc Bak 
E2F-l ,2,3,4 & 5 Bid-l 
DP-I 
Cdc25A 
Cdc25C 
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antigen, HPV E7 and some cellular proteins, such as histone deacetylases 
(HDACs) and cyclinDl, possess an LXCXE motif in their protein sequence that 
directs their association with pRb (Mulligan and Jacks, 1998; Figure 1.1). The 
ability of viral oncoproteins to transfom1 cells is in part dependent on 
overcoming the growth suppressive activities of pRb. They achieve this by 
displacing cellular proteins that interact with the pocket, thereby leading to loss 
of pocket protein function and normal growth control (Bandara and La 
Thangue, 1991; Nevins, 1992). Despite the sequence similarity between pRb, 
pl07 and p 130, Rb is the only gene of the family that is frequently mutated in 
tumour cells (Weinberg, 1995). 
To study the physiological role of each pocket protein, mice lacking Rh, 
pIOl and p130 have been developed. Mice deficient in Rh exhibit embryonic 
lethality, dying between embryonic day E13.5 and EI5.5, and suffer from 
abnormnal differentiation in a variety of tissues, most probably due to 
inappropriate cell cycle entry and elevated apoptosis (Clarke et al., 1992). The 
analysis of plOT 1- andp130-1- mice supports the idea that pl07 and p130 act in a 
distinct manner from pRb. Thus, in contrast to RH1-, pIOT1- and p130-1- mice 
survive to term and show no increase in the incidence of tumour formation. 
However, pI o T1-/p J30-1- double knock-out mice exhibit embryonic lethality 
suggesting functional redundancy between pI 07 and p 130 (Cobrinik et al., 
1996). It has also been observed that deficiency of pI 07 enhances the 
developmental abnormalities of Rb +1- embryos, arguing for some degree of 
functional redundancy between pl07 and pRb (Lee et al., 1996). These 
observations, together with the lack of pI 07 and p 130 mutations in human 
tumours, indicate that pl07 and p130 are unlikely to act as tumour suppressors. 
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Figure 1.1 Regulation of E2F activity. 
In non-proliferating cells, the E2FIDP heterodimer binds pocket proteins 
such as pRb. During early cell cyele progression Gl cyelin-dependent kinase 
complexes (cyclinD/Cdk4 and cyelinE/Cdk2) phosphorylate pRb, releasing 
E2F. E2F becomes transcriptionally active through interaction with 
transcription co-factors such as p300/CBP. In tumour cells, mutant pRb fails to 
bind E2F. Similarly, viral oncoproteins bind pRb to hjnder its interaction with 
E2F. In addition, p16 can be inactivated, or cyclinDl over-expressed, in cancer 
cells. The pRblE2F complex becomes an active transcriptional repressor by 
recruiting proteins, such as HDAC, Mtase, PCG and SWlISNF, that alter the 
chromatin environment to favour transcriptional inactivity. 
In quiescent GO cells, E2F heterodimers such as E2F -6 may nucleate the 
assembly of another type of chromatin remodelling complex containing Mtase, 
PCG, and lIPl, and involve other sequence specific transcription factors like 
Max and its partner Mga By modifying the chromatin environment of target 
genes this complex co-ordinates long term silencing of cell cycle regulated 
genes. (Figure from Stevens and LaThangue, 2003). 
1.4 Control of pRb activity 
In nonnal cells, the ability of pRb to bind to E2F is regulated by its cell 
cycle-dependent phosphorylation. pRb is hypophosphorylated in GO and early 
G 1, which is the fonn which binds to and inhibits E2F. pRb sustains incrcasing 
levels of phosphorylation by G 1 cdks, involving mostly cyclinD and E, as cells 
progress into S phase (Mittnacht, 1998; Figure 1.1). Mitogenic growth factors 
induce the sequential activation of one or more D-type cyclins (Mittnacht, 
1998), which associates with the catalytic subunit cdk4 or cdk6, 
phosphorylating pRb with the subsequent release of E2F and the activation of 
target genes, including cyclinE (Ohtani et al., 1995). Because the cyclinE genc 
is E2F responsive (Botz et al., 1996), cyclinE/cdk2 complexes act through a 
positive-feedback loop to facilitate progressive pRb phosphorylation and further 
release of E2F (Lundberg et al., 1998), producing a rapid rise of cyclinE/cdk2 
required to allow cells to initiate DNA replication (Sherr, 1996). 
The kinase activity of cyclinlcdk complexes in turn IS negatively 
regulated by cdis, which belong to one of two families based on their structural 
relationship (Sherr and Roberts, 1999). The first family includes the Ink4a 
proteins (inhibitors of cdk4), which specifically inhibit the catalytic subunits 
cdk4 and cdk6. Four such proteins, namely p161NK4a, plSINK4b, p181NK4~ and 
p191NK4d, have been described. The second Cip/Kip family act more generally 
and affect the activities of cyclin D, E and A-dependent kinases, and include 
p21 Cipl, p27Kipl and pS7KiP2 , which bind to both the cyclin and cdk subunit 
(Sherr and Roberts, 1999). Under conditions of cellular stress, such as DNA 
damage, replication inhibition, or in response to inhibitory signals like 
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transfonning growth factor ~ (TGF~), cell cycle progression is stalled through 
the action of cdis, leading to the inhibition of one or more cyclinJcdk complexes 
and the maintenance of pRb in the hypo-phosphorylated growth suppressing 
state (Sherr and Roberts, 1999; Figure 1.1). Thus, pRb integrates both positive 
and negative growth regulating signals with the transcription machinery. 
1.5 The E2F family 
In cells E2F activity 1S comprised of a family of heterodimcric 
transcription factors where each heterodimer consists of one member of the E2F 
family bound to a member of the DP family (Dyson, 1998; Table 1.2). In 
mammalian cells, six E2F family members have been identified (E2F -1 to E2F-
6), whilst two members of the OP family, DP-l and DP-2, have been 
characterised. All possible combinations of E2F/OP complexes can exist in 
vitro, potentially allowing for the fonnation of an array of E2F complexes in 
cells (Dyson, 1998). This complexity may be even greater if mechanisms such 
as alternative splicing, which occurs in DP-2 RNA (de la Luna et at., 1996), or 
for E2F-3 the expression of a second transcript derived from an additional start 
site within the locus (Adams et al., 2000), contribute to E2F complexes. 111 
vitro individual E2FJDP complexes recognise similar nucleotide sequences 
(Lees et al., 1993; Buck et al., 1995; Zhang and Chellappan, 1995), although 
some evidence suggests that different heterodimer complexes preferentially 
bind to specific E2F sequences (Tao et a/., 1997). It is not yet clear whether 
E2F complexes target preferred E2F-regulated promoters in cells. 
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Table 1.2 Summary of the properties of E2F and DP family members 
Protein Expression Pocket protein Cell cycle phase Nuclear localisation S phase I nduction of Tumour Knock-out mouse Direct interaction CyciinAlcdk2 
complexed with signal induction apoptosis suppressor with repressive 
pocket protein activity chromatin modifying 
enzymes 
Viable Phenotype 
E2F-I GlIS pRb GO,S,G, Yes +++ +++ Yes Yes tumours No Yes 
E2F-2 GI/S pRb GO,S,G, Yes +++ + No Yes immunologic No Yes 
defects 
E2F-3 GIIS pRb GO,S,G, Yes +++ + No Yes reduced gene No Yes 
expression 
E2F-4 Constitutive pI07, p130 S,GO No + + No No developmental No No 
defects 
E2F-5 Constitutive p130, plO7 GO,S No + + No No hydrocephaly No No 
E2F-6 Constitutive - - Yes - - No - - Yes No 
DP-I Constitutive pRb,pI07,130 GO,S,G, No + - No - - No No 
DP-2 Constitutive pRb, p107, p130 GO,S,G, Yes, dependent on + - - - - No No 
mRNA splicing 
- -- ---
The E2F family can be further divided into three sub-groups based on 
sequence homology; E2F-l, E2F-2 and E2F-3 represent one group, and E2F-4 
and E2F-5 a second (Figure 1.2). Functional similarities are evident within each 
group; E2F-l, E2F-2 and E2F-3 share an N-terminal cyclinAJcdk binding 
domain and a canonical basic nuclear localisation signal (NLS), both of which 
are absent in E2F-4 and E2F-5, which instead possess a nuclear export signal 
(NES; Gaubatz et al., 2001). Moreover, E2F/DP heterodimers interact with 
pocket proteins with a specificity that is largely determined by the E2F 
component (Dyson, 1998 and Table 1.2); E2F-l, E2F-2 and E2F-3 
preferentially associate with pRb, whereas E2F-4 and E2F-5 predominantly 
interact with p 107 and p 130 (Dyson, 1998). E2F-6 represents the third sub-
group, and acts principally as a transcriptional repressor through a distinct 
pocket protein-independent manner (Morkel et al., 1997). In fact, E2F-6 
diverges considerably from the other E2F family members, sharing almost no 
homology outside the core DNA binding and dimerisation domains, and 
possesses a truncated C- and N-terminal region relative to the other E2F sub-
groups (Morkel et al., 1997 and Figure 1.2). 
1.6 E2F·1, E2F·2 and E2F·3 
E2F-I, E2F-2 and E2F-3 activate E2F responsive genes and drive cellular 
proliferation (DeGregori et al., 1997). Over-expression of each protein is 
sufficient to induce quiescent cells to re-enter the cell cycle (Johnson et aI., 
1993; Asano et al., 1996; Lukas et al., 1996; Wang et al., 1998), and dominant-
negative mutants block S phase entry (Wu et al., 1996). Further, the combined 
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Figure 1.2 Structural comparison of E2F and DP family 
members. 
a) The E2F family can be divided into three subgroups based on sequence 
homology. E2F-l, E2F-2 and E2F-3 represent one group, E2F-4 and E2F-5 a 
second and E2F-6 represents a third subgroup. The E2F-l subgroup have an N-
tennjnal cyclin/cdk binding site and a nuclear localisation signal (NLS). E2F-4 
and E2F-5 have truncated N-terminal regions and lack cyclinlcdk binding site 
and an NLS, instead possessing a nuclear export signal (NES). The positions of 
pocket protein binding and transactivation domains are indicated. 
b) Summary of DP-l and DP-2 family members. E2F and DP proteins 
share a conserved DNA binding and dimerisation domain. Four altematively-
spliced forms ofDP-2 have been described which either are cytoplasmic (P and 
y) or nuclear (a. and 0). The expression of specific DP proteins may influence 
E2F localisation. (Figure from Stevens and LaThangue, 2003). 
ablation of E2F-l, E2F-2 and E2F-3 prevents entry into S phase (Wu cl al., 
200l), and their over-expression over-rides the effccts of growth inhibitory 
proteins, such as p16, p21 and p27, and cell cycle arrest induced by y-
irradiation, TGFp or dominant-negative cdk2 (Oegregori et al., 1995; Schwarz 
et ai., 1995; Lukas et ai., 1996; Mann and Jones, 1996). This ability is 
dependent on its dimerisation, DNA-binding and transactivation domains, 
suggesting that the induction of transcription of E2F target genes is required for 
S phase entry (Johnson et ai., 1993; Qin et al., 1994) 
E2F activity can become inactivated through pocket protein binding, to 
prevent the expression of target genes. This inactivation is primarily causcd by 
masking of the E2F activation domain, since the pocket protein binding domain 
is integrated with the activation domain, thereby blocking the ability of E2F to 
communicate with the basal transcriptional machinery (Figures 1.1 and 1.2). 
Using in vitro transcription and DNase footprinting assays pRb has been shown 
to hinder the assembly of the transcription initiation complex (Ross el lIi., 
1999). 
In addition, pRb is able to mediate active repression of E2F targets 
through nucleating the assembly of a dominantly-acting repressor complex 
(Zhang et al., 1999, Ross et ai., 2001; Figure 1.1). Once targeted to the 
promoter by E2F, pRb recruits proteins endowed with chromatin modifying 
activity, including HDACs, the histone methyltransferase (MTase) SUV39H I, 
human brahma (HBRM) and human brahma-related gene 1 (BRG 1) - human 
homologues of the yeast SWI2/SNF2 proteins that possess nucleosome-
remodelling activities (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et 
al., 1998; Nielsen et al., 2001; Zhang et al., 2000). 
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The HDACs arc a family of proteins, of which HDAC 1, 2 and 3 have 
been reported to interact with pRb (Harbour and Dean, 2000). HDAC removes 
the acetyl groups from lysine (K) residues within the tail regions of histones 
which appears to facilitate the condensation of nuc1eosomes into inactive 
chromatin (Harbour and Dean, 2000). Lysine residues that are hypo-acetylated 
through HDACs may subsequently become methylated by MTases. Specifically 
MTases such as SUV39HI methylate K9 in the tail region of histone H3, to 
create a high affinity binding site for members of the heterochromatin protein I 
(HP I) family of repressor proteins, which recognise methylated lysine residues 
(Lachner et al., 2001; Bannister et al., 2001). HPI proteins localise to regions 
of heterochromatin and are believed to induce long term transcriptional 
silencing (Lachner et al., 200 I; Bannister et al., 200 I). The interplay amongst 
the post-translational modifications of histone tails, which also includes 
phosphorylation, provides the basis of the "histone code", which proposes that 
the pattern of modifications within the histone tail dictate whether chromatin is 
in an open or closed state (Jenuwein and Allis, 2001). 
Both BRG 1 and HBRM are two ATPase components of the human 
SWVSNF chromatin-remodelling complex. These proteins influence the access 
of transcription factors to promoters by altering nucleosomal structure and 
nucleosome position in a manner dependent on ATP hydrolysis (Harbour and 
Dean, 2000). Interestingly, recent results indicate that pRb can recruit HDAC 
and SWIISNF either separately or together (Zhang et al., 2000). The 
pRb/SWIISNF complex is sufficient to repress cyclinA and cdc2 genes, whereas 
repression of cyclinE and E2F-I genes also requires HDAC (Zhang et al., 
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2000). It appears possible that distinct types of repressor complex regulate 
different sets of genes. 
1.7 E2F-4 and E2F-5 
E2F-4 and E2F-5 were cloned by virtue of their association with pocket 
proteins or DP-l (Beijersbergen et al., 1994; Buck et al., 1995; Hijmans et al., 
1995). Their sequence and organisation differs markedly from E2F-I, E2F-2 
and E2F-3 (Figure 1.2), which reflects their unique modes of regulation. 
Whereas E2F-I, -2 and -3 are under cell cycle control, with levels peaking as 
cells approach the G liS phase boundary, E2F-4 and E2F-5 are unifomlly 
expressed with significant levels detectable in quiescent (GO) cells (Dyson, 
1998). 
Endogenous E2F-4 and E2F-5 complexes can act as repressors of E2F-
responsive genes, which reflects in part their regulation through sub-cellular 
localisation (de la Luna et al., 1996; Allen et al., 1997; Muller et al., 1997; 
Verona et al., 1997). Thus, E2F-4 and -5 are predominately cytoplasmic, and 
need to assemble with a pocket protein to be transported into nuclei (Allen et 
al., 1997; Verona et al., 1997). At a mechanistic level, this means that E2F-4 
and -5 bind to target genes in a transcriptionally inactive state. Nevertheless, 
and in a similar fashion to E2F-I, both E2F-4 and -5 possess an intrinsic 
transcriptional activation domain which becomes active once pocket proteins 
are released (Dyson, 1998). In addition, E2F-4 and -5 can undergo nuclear 
import by association with DP-2 which, in contrast to DP-l, possesses an 
intrinsic NLS (de la Luna et al., 1996; Lindeman et al., 1997; Magae et al., 
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1996), suggesting that the expression of specific DP proteins can influence the 
overall spectrum of nuclear E2F activity (de La Luna et al., 1996). 
The observation that E2F-4 and -5 pocket protein complexes 
predominate in GO/G 1 cells suggests that they are primarily involved in 
repression during early cell cycle progression (Morberg et al., 1996). In this 
respect, mutation of the E2F binding sites in some E2F-responsive promoters 
(such as B-myb, cdc2, and E2F-i) leads to increased expression during GO/G 1, 
consistent with transcriptional repression through the E2F site (Dalton, 1992; 
Lam et al., 1993; Hsiao et al., 1994). In vivo significant levels of the E2F-
4/p 130 complex occupy E2F sites during GO/G 1, with low levels of local 
histone acetylation (Takahashi et al., 2000). Reduced occupancy by E2F-4 
occurs in late G 1 phase when gene expression is induced, correlating with the 
appearance of E2F-l, E2F-2 and E2F-3, and an increase in acetylation of 
histones H3 and H4 (Takahashi et al., 2000). Significantly, the decrease in 
binding of E2F-4 to E2F sites correlates with the dissociation of E2F-4/DP-
pocket protein complexes, together with re-Iocalisation of E2F-4/DP to the 
cytoplasm (Takahashi et al., 2000). By genomic footprinting the E2F sites of 
the B-myb, cdc2 and eye/inA promoters are occupied in GO and early G I phase 
cells, when the E2Fs are likely to act in repressing transcription as part of larger 
pocket protein complexes (Tommasi et al., 1995; Zwicker et al., 1996; Huet et 
al., 1996). 
Interestingly, E2F-5 can be phosphorylated on a single threonine residue 
within its activation domain by cyclinE/cdk2 which augments the recruitment of 
p300/CRE binding protein (p300/CBP) family of co-activators, stimulating 
activation of E2F responsive genes in late G I (Morris et al., 2000). This study 
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implies a positive auto-regulatory mechanism for E2F-dependent transcription, 
and supports the notion that E2F-4/-5 family members play a role in the 
activation of target genes. 
Another level of complexity is suggested by a recent report (Chen el ai., 
2002) which described how E2F-4/-5 and p 107 can act as transducers of the 
inhibitory growth factor TGFp, independently of cdis. The Ceiegans SMA and 
Drosophila MAD (Smad3) protein mediates transcriptional activation of its 
target genes, which include cdis, in response to TGFp treatment. Smad3 can 
also mediate transcriptional repression of the growth promoting gene c-myc. A 
Smad3, E2F-4/-5, DP-I, pI07 complex pre-exists in the cytoplasm and IS 
translocated into the nucleus in response to TGFp, where it associates with 
Smad4. Smad4 allows the complex to recognise a composite Smad-E2F 
binding site in the c-myc promoter leading to repression. In this context at least, 
E2F-4/-5 and pl0? act in a Smad3 protein complex as transducers of TGF0 
receptor signals upstream of cyclin-dependent kinases. 
1.8 E2F-6 
E2F-6 differs from the other E2Fs; whilst its DNA-binding and 
dimerisation domains are conserved, it lacks the C-terminal transactivation and 
pocket-protein binding domains (Morkel et al., 1997; Figure 1.2). This has led 
to the suggestion that E2F-6 may act as a repressor of E2F-responsive genes by 
binding to promoters, preventing activation by E2F family members. However, 
recent studies revealed that E2F-6 recruits mUltiple cellular factors to fom1 a 
potent repressive complex, which it targets to E2F-responsive promoters 
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(Trimarchi et al., 2001; Ogawa et al., 2002). These factors include Ring 1 and 
YY1-binding protein (RYBP), members of the polycomb group (PcG) of 
proteins, which are involved in maintaining transcriptional repression. PcG 
proteins bind to core promoter regions and general transcription factors ill vitro, 
and depletion of PcG proteins leads to the de-repression of developmentally 
regulated genes (Breiling et al., 2001). In addition, E2F-6 recruits chromatin 
modifying proteins to E2F target genes, primarily in quiescent cells (Ogawa et 
al., 2002). The complex contains two MTases together with the transcriptional 
repressor protein HPly (Ogawa et al., 2002). Most interestingly, E2F-6 
interacts with members of the Myc family of transcription factors. Both Max 
and Mga, which form a heterodimer, co-purify with E2F-6 (Ogawa etal., 2002). 
This result implies that the E2F-6/Max complex could potentially target both 
E2F and Myc responsive genes (Ogawa et al., 2002). Together with the 
observation that E2F-6 is replaced by other E2F family members, like E2F-I, as 
cells move into Gl consolidates the over-riding view that E2F-6 directs 
transcriptional silencing in quiescent cells by modifying chromatin. 
1.9 Regulation of E2F activity 
In normal cells E2F activity is tightly regulated during the cell cycle 
through the temporal association and release of pocket proteins (Dyson, 1998). 
However, other levels of control exist on E2F activity, such as the association 
between cyclinNcdk2 and E2F-I as cells enter S-phase (Krek el al., 1994; Xu 
et al., 1994). The function of cycIinNcdk2 complexes in cell cycle regulated 
transcription is distinct from that exerted by cyclinE/cdk2 or cyclinD/cdk4. 
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Binding between E2F-l and cyclinA/cdk2 results in the phosphorylation of DP-
1 and subsequent loss of E2F DNA-binding activity (Krek et (1/., 1995). This 
event, in addition to the rapid turnover of cyclinE-mediated by ubiquitin-
dependent proteolysis, is required for cell cycle exit from S-phase (Elledge and 
Harper, 1998). Therefore, whereas cyclins 0 and E activate E2F -dependent 
transcription in part by targeting pocket proteins and ccrtain E2F subunits, 
cyclinA is used to tum off E2F target genes. 
Another level of control that impinges on E2F activity includcs targeted 
proteolysis and acetylation. Unphosphorylated pRb can bind to and protect 
E2F-1 and E2F-4 from ubiquitin-dependent degradation by masking the 
availability of selected E2F sequences in the C-tenninal region (Hateboer et al., 
1996; Hofman et al., 1996). The rapid degradation of E2F-l at the S to G2 
transition requires an interaction between E2F-l and the F-box-containing 
protein p4SSKP2, which is the cell cycle-regulated component of the ubiquitin-
protein ligase SCFsKP2 (Marti et al., 1999). Binding of p45sKP2 to the N-
tenninal region of E2F-l in a region distinct from cyclinA targets E2F-l for 
degradation (Marti et al., 1999). Therefore. cyclinA regulates the duration of S-
phase and the skip/cullinIF-box (SCF) complex targets E2F-1 for destruction 
once S-phase is complete (Marti et al., 1999). Further, E2F-l and DP-l are 
down-regulated by the murine double minute 2 (MDM2) oncoprotein (Loughran 
and La Thangue, 2000), which possesses E3 ligase activity (Honda et al., 1997), 
and p 19ARF (Martelli et al., 2001; Mason et al., 2002), the gene for which is a 
transcriptional target of E2F-l (Bates et al., 1998). The direct regulation of E2F 
activity is likely to involve mUltiple processes that ensure E2F activity is tightly 
regulated throughout the cell cycle. 
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The transcriptional activity of E2F requIres the interaction with the 
p300/CBP family of co-activator proteins (Trouche et al., 1996; Morris et al., 
2001). p300/CBP proteins bind to a diverse array of sequence-specific 
transcription factors and can simultaneously interact directly with components 
of the basal transcriptional machinery, such as TFIIB, TBP and RNA 
polymerase II, and facilitate the assembly of multi-protein cofactor complexes 
(Chan and La Thangue, 2001). By providing a bridge between transcription 
factors and the basal transcription machinery, p300/CBP is able to stimulate 
transcriptional activation (Chan and La Thangue, 2001). p300/C BP proteins 
possess an intrinsic histone acetyltransferase (HAT) activity and can acetylate 
histones, a process likely to loosen chromatin structure and cause increased 
gene expression (Chan and La Thangue, 2001). Additionally, direct acetylation 
of E2F-l by the p300/CBP-associated factor (PCAF) occurs at lysine residues 
within the DNA binding domain, which increases its DNA binding activity, 
transcriptional activity and protein stability (Martinez-Balbas et al., 2000). 
Significantly, the acetylated residues are conserved only in the E2F-l sub-
family (Martinez-Balbas et al., 2000). Moreover, pRb is regulated by 
acetylation (Chan et al., 2001) where adenovirus EIA, which binds p300/CBP 
through an N-tenninal transformation-sensitive domain (Eckner et al., 1994), 
stimulates the acetylation of pRb by recruiting p300 and pRb into a multi-
protein complex (Chan et al., 2001). The acetylation of pRb is cell cyc\e-
regulated and the acetylation of particular lysine residues in the C-terminal 
region ofpRb hinders the subsequent phosphorylation ofpRb by cdk complexes 
(Chan et al., 2001). 
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1.10 Role of E2F in proliferation 
One approach to investigate E2F has been to inactivate individual E2F 
genes (Table 1.2). E2F-rl . mice develop normally but exhibit defccts in T-cell 
apoptosis and a broad spectrum of tumours in older mice, suggesting that E2F-l 
can under some conditions function as a tumour suppressor (Field et al., 1996; 
Yamasaki et ai., 1996). Mouse embryonic fibroblasts (MEFs) derived from 
E2F-rl . mice show a delayed exit from GO phase, indicating that E2F-l has an 
important role in timing S-phase entry from GO (Wang et al., 1998). E2F-II. 
mice arise at one-quarter of the expected frequency, demonstrating that E2F-3 is 
important for development (Humbert et al., 2000a). Furthermore, E2F-3'I. 
MEFs have reduced expression of numerous E2F-responsive genes, including 
B-myb, cyclinA and DHFR (Humbert et al., 2000a), and micro-injection of anti-
E2F-3 antibodies causes cell cycle arrest in primary cells, whilst an E2F-I 
antibody has little effect (Leone et al., 1998). In synchronised cells E2F-3 
DNA-binding activity accumulates at the G 1 IS-phase transition of each 
consecutive cell cycle, whereas E2F-l only accumulates during thc initial G 1 
following mitogenic stimulus (Leone et al., 1998). Significantly, the combined 
loss of E2F-l, E2F-2 and E2F-3 is sufficient to completely block cellular 
proliferation (Wu et al., 2001a). Taken together, these results suggest that E2F-l 
and E2F-3 have distinct roles in regulating cell cycle progression: E2F-3 
regulates expression of S-phase genes in proliferating cells, and E2F -1 regulates 
exit from GO. 
Interestingly, the DP-rl . mouse is embryonic lethal, probably due to 
defects in proliferation (Kohn et al., 2003). 
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Whilst E2F-4-1- mice die ill vivo and have numerous developmental 
defects (Rempel et al., 2000; Humbert ef al., 2000b), E2F-S-I - mice are viable 
but fail to survive to tenn because of hydrocephaly caused by excessive 
secretion of cerebral spinal fluid in the choroid plexus (Lindeman el al., 1998). 
Analysis of MEFs that are derived from E2F and pocket protein knock-out 
mice, namely E2F-4-1-, E2F-4-1-IE2F-S-I-, or pi OTI-;pi30-1-, has suggested defects 
in the ability to exit the cell cycle in response to various growth arrest signals, 
including p 16 over-expression (Bruce et al., 2000; Gubatz et at., 2000). 
Introduction of E2F-4 or E2F-5 into E2F-4-1-/E2F-S-I - cells is able to reinstate 
the p16 response whereas introduction ofE2F-l failed to do so, highlighting the 
functional differences in these two E2F sub-families (Gubatz et al., 2000). In 
addition, the combined loss of plOl and pJ30 causes the upregulation of E2F-
responsive genes, including B-myb, cdc2 and E2F-I, whereas there is little 
difference in MEFs deficient in either plO? or pi30 (Hurford et al., 1997). The 
mutant cells respond appropriately to growth stimulatory signals and show 
minimal change in their proliferative capacity, suggesting that loss of these 
E2FIDP-pocket protein complexes impairs mostly the repression of E2F-
responsive genes, and therefore the ability to exit the cell cycle (Bruce et (Jl., 
2000; Gaubatz et al., 2000). Taken together, these studies establish a link 
between E2F-4/E2F-5 and the regulation of cell cycle exit and tenninal 
differentiation. 
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1.11 E2F in differentiation 
E2F family members have been implicated in the regulation of 
differentiation. A recent study demonstrated that repression of E2F-lIDP-I 
dependent transcription by the C/EBPa transcription factor is essential for cell 
cycle exit and the differentiation of adipocytes and neutrophil granulocytes ;/1 
vivo (Porse et al., 2001). The importance of repressing E2F activity for the 
initiation of differentiation has also been observed in myogenic cells and in 
keratinocytes (Dicker et al., 2000; Wang et al., 1995), and loss of E2F 
repression through pRb mutation leads to uncontrolled proliferation and 
apoptosis in vivo (Clarke et al., 1992; lacks et al., 1992; Lee et al., 1992). 
Whilst this highlights the role of both pRb and C/EBPa in repression of E2F 
activity during development, C/EBPa can repress E2F in the absence of 
functional pRb protein (Johanson et al., 2001; Slomiany et al., 2000). This 
suggests that the C/EBPa and pRb pathways of E2F repression act 
independently. Moreover, in differentiating granulocytic cells p 130, rather than 
pRb, has been found to be the critical pocket protein (Bergh et al., 1999; Mori et 
al., 1999), indicating that, in addition to E2F-I, repression of E2F-4/-5 is critical 
for proper differentiation of granulocytes (Porse et al., 2001). The 
differentiation of pre-adipocytes into adipocytes requires that growth-arrested 
pre-adipocytes re-enter the cell cycle before undergoing terminal differentiation. 
Fajas et al., (2002) demonstrated that in confluent pre-adipocytes the E2F-
4/p 130 complex acts to repress the transcription of E2F target genes, including 
PPARy, the master regulator of adipogenesis. Hormonal stimulation results in 
the loss of this repressive complex and the induction of activating E2Fs, 
38 
particularly E2F-1. E2F-l can directly activate PPARy transcription, and 
thereby activate differentiation. Interestingly, during the latc stages of 
differentiation the E2F-4/pI30 complex reforms, possibly to switch off PPARy 
transcription in terminally differentiated adipocytes. 
1.12 Role of E2F in cancer 
The de-regulation of E2F activity provides tumour cells with a 
proliferative advantage. E2F activity is disrupted in most if not all tumour cells 
via activating mutations in the cyclinDl gene, alteration of the Ink4a gene, or 
mutation of the pRb gene itself (Sherr, 1996). Elevated levels of cyclinD 1 are 
observed in certain tumour cells due to gene amplification, chromosomal 
rearrangement (Hall and Peters, 1996) or mutations that prevent nomlal 
degradation (Welcker et al., 1996). The p161nk4a gene is frequently found to be 
mutated in human tumours (Koh et al., 1995) and a missense mutant cdk4, 
which is unable to associate with p 16, renders cdk4 constitutively active 
(Wolfel et al., 1995). The fact that multiple mutations in these genes do not 
occur in a single tumour suggests that inactivation of anyone of these 
components in the pRb pathway is sufficient to favour tumourigenesis 
(Yamasaki, 1999). Interestingly, E2F is not a frequent target of mutations in 
cancer (Dyson, 1998), indicating that it is the inactivation of the pathway with 
subsequent de-regulation of E2F, rather than the direct mutagenic activation of 
E2F, that is a hallmark oftumourigenesis. 
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1.13 E2F-1: Oncogene or tumour suppressor 
It appears that the level of expression and the cellular environment 
influences whether E2F-l can participate in the process of oncogenesis or 
tumour suppression (Pierce et al., 1999). E2F -1 possesses oncogenic properties 
both in vitro and in vivo, and E2F-l over-expression is sufficient to induce the 
transformation of primary cells (Johnson et al., 1994), whilst the ovcr-
expression of E2F-I in transgenic mice promotes tumourigenesis (Pierce et al., 
1999). Tumours in mice where E2F-l activity is compromised grow more 
slowly than their wild-type counterparts (Yamasaki et al., 1998). 
Nevertheless, in addition to its role in proliferation, E2F-l can trigger 
apoptosis, and it is through this ability that E2F-l may act as a tumour 
suppressor. E2F-rl . mice exhibit defects in apoptosis, together with an 
increased incidence of tumours (Field et al., 1996; Yamasaki et al., 1996), 
providing evidence that E2F-l possesses tumour suppressor activity ill vivo. In 
addition, the aberrant apoptosis and S-phase entry observed in mice carrying 
homozygous mutation of Rb is suppressed by E2F-l deficiency (Tsai et al., 
1998). E2F-3 deficiency also suppresses inappropriate apoptosis in Rb mutant 
mice embryos, providing evidence that E2F-3, in addition to E2F-I, plays a role 
in the induction of apoptosis that arises from Rb deficiency (Saavedra et al., 
2002; Ziebold et al., 2001). Interestingly, the induction of apoptosis by c-Myc is 
E2F-l dependent and is inhibited in cells lacking E2F-I, but not E2F-2 or E2F-3 
(Leone et al., 2001). However, the ability ofMyc to induce S-phase is impaired 
in the absence of E2F-2 or E2F-3, but not E2F-1. Therefore it is likely that 
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different E2F activities control cell proliferation and cell death decisions (Leone 
et al., 2001). 
E2F-I can trigger apoptosis through both p53-dependent and 
independent pathways, and although transcription-independent functions of 
E2F-l have been ascribed to apoptosis (Hsieh et al., 1997; Phillips et al., 1997; 
Phillips et al., 1999), a number of genes involved in apoptosis are regulated at 
the transcriptional level by E2F-I. Thus, E2F-l augments p53-dependent 
apoptosis through the transcriptional activation of the p19ARF tumour suppressor 
gene (Bates et al., 1998). ARF sequesters the E3 ubiquitin ligase MDM2 into 
the nucleolus, thereby preventing MDM2 from targetting p53 for ubiquitination 
and subsequent degradation (Weber et al., 1999). Therefore, the induction of 
ARF by E2F -1 leads to p53 stabilisation and activation. However, E2F -1 can 
induce p53-dependent apoptosis in the absence of ARF (Russel et al., 2002; 
Tolbert et al., 2002; Tsai et ai., 2002), and loss of ARF can enhance E2F-l 
induced apoptosis (Russel et al., 2002; Tsai et al., 2002). In support of these 
observations, over-expression of ARF can inhibit E2F -I-dependent apoptosis 
(Mason et ai., 2002), and targets E2F -1 for proteasomal degradation (Martelli et 
al., 2001). In addition, E2F-I can interact with p53 directly via the cyclinA 
binding domain of E2F-I, and the interaction enhances p53 apoptotic activity 
(Hsieh et ai., 2002). 
E2F-I can signal apoptosis independently of p53 via direct 
transcriptional activation of the p53 family member p73 (Irwin et al., 2000; 
Stiewe et al., 2000), and the physiological apoptotic process called TCR-
activation-induced cell death (TCR-AICD), requires both E2F-l and p73 
(Lissey et ai., 2000). 
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The Apaf-l gene, which mechanisticalIy regulates cytochrome c release 
from mitochondria leading to caspase activation, provides another direct target 
for E2F-I (Moroni et al., 2001; Furukawa et al., 2002). Consistent with this, 
E2F-1 induced apoptosis is significantly compromosed by inhibition of caspase 
activity or by disruption of the Apaf-l gene (Moroni et al., 2001; Furukawa et 
al., 2002). In addition, analysis of Apajrl-/Rb-I - mouse embryos demonstrates 
that Apaf-1 is required for apoptosis induced by Rb deficiency in some tissues 
(Guo et al., 2001). 
E2F-1 has also been shown to participate directly in apoptotic pathways 
by stimulating the accumulation of caspases through a direct transcriptional 
mechanism (Nahle et al., 2002). 
E2F-I can also promote apoptosis by inhibiting NF-kB activity. The NF-
kB transcription factor regulates cell survival by activating various anti-
apoptotic genes (Karin et al., 2002). By down regulating TRAF-2 protein levels, 
E2F -1 impairs NF -kB activation in response to tumour necrosis factor a 
(TNFa; Philips et al., 1999). In addition, E2F-l can inhibit NF-kB DNA-
binding activity providing another mechanism of inhibition of NF-kB activity 
by E2F-l (Tanaka et al., 2002). 
Consistent with E2F-I s role in inhibition of anti-apoptotic signals, 
exploring E2F target gene specificity using DNA microarrays has revealed that 
E2Fs up-regulate the expression of pro-a pop to tic members of the Bcl-2 family, 
including Bok, Bad, Bak and Bid-1 (Ma et al., 2002; Polager et al., 2002; 
Stanelle et al., 2002). 
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1.14 E2F-1 is induced in response to DNA damage 
Overexpression of E2F -1 sensitises cells to apoptosis in response to 
DNA damage caused by ionising radiation (IR), or chemotherapeutic drugs such 
as the topoisomerase II inhibitors etoposide and adriamycin (Nip et al., 1997; 
Pruschy et al., 1999). Recent studies have found a direct role for E2F-I in the 
DNA damage response pathway, as treating cells with DNA damaging agents 
increases E2F-l protein levels and DNA-binding activity (Blattner et al., 1999; 
Hofferer et al., 1999; O'Connor et al., 2000; Lin et al., 2001). It has been 
suggested that ataxia telangiectasia mutated (ATM) phosphorylates and 
stabilises E2F-1 in response to DNA damage (Lin et al., 2001), through a 
mechanism that perhaps involves the ubiquitin ligase p4SSK I'2 (Marti et £II., 
1999), or the BRCT-domain containing protein DNA topoisomerase II~ binding 
protein 1 (TopBP 1; Liu et al., 2003). 
1.15 Cell cycle checkpoints 
With every cell-division cycle, the cell must duplicate the genome and 
segregate the identical sets of chromosomes into two daughter cells. It is 
imperative that these events are carried out accurately and efficiently, to ensure 
this, cells have developed mechanisms that are known as the cell cycle 
checkpoints. Checkpoints detect incompletely replicated or damaged DNA 
(DNA replication and DNA damage checkpoints respectively), and transmit a 
signal to effector molecules that stall the cell cycle to allow time for DNA to be 
repaired, or to activate programmed cell death. Checkpoint pathways also co-
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ordinate the resumption of cell cycle progressIOn, provided replication IS 
complete and DNA lesions have been repaired. 
The cell cycle can potentially arrest at several stages, but it usually 
arrests prior to S-phase (G 1 checkpoint), during S-phase (intra-S-phasc 
checkpoint) or before mitosis (the G2 checkpoint; Figure 1.3). 
Arrest in G 1 delays the start of S-phase and thus prevents the replication 
of a damaged DNA template. However, G 1 cells only contain one copy of the 
genome, therefore repair of the damaged DNA cannot be achieved via 
homologous recombination. Rather cells must use the non-homologous end-
joining (NHEJ) pathway, in which two DNA ends that share little or no 
sequence homology are joined. This might explain why the G 1 checkpoint is 
closely linked to apoptosis. 
The intra-S-phase checkpoint reduces the rate of DNA replication 
without completely blocking progression through S-phase, presumably to afford 
time for DNA to be repaired. 
The G2/M checkpoint provides time for the repair of damaged 
chromatids prior to their segregation in mitosis. G2 cells contain two full 
complements of genetic material, therefore DNA damage can be repaired by 
homologous recombination, without loss or change of genetic information. 
1.16 DNA damage signalling pathway 
DNA damage poses a considerable threat to genomic integrity and cell survival. 
DNA damage arises spontaneously, for example during DNA replication, and in 
response to exogenous agents, such as IR. 
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The DNA damage checkpoints can arrest the cell prior to S-phase (GI checkpoint), 
during S-phase (intra S-phase checkpoint) or before mitosis (the G2 checkpoint). 
Checkpoints allow cell cycle progression to be modulated even after the restriction 
point has been traversed, after which the cell progresses through the cycle in an 
autonomous manner. Arrest in G I prevents the replication of a damaged DNA 
template, and is c10sely linked to apoptosis. The intra S-phase checkpoint reduces the 
rate of DNA replication, but does not completely stop the cell cyc1e. The G2 
checkpoint prevents the segregation of damaged chromatids. 
Although significant progress is being made, it is not fully understood how 
DNA damage is detected, but DNA lesions, such as double-stranded (dis) 
breaks, leads to the rapid activation of a multi-protein cascade collectively 
known as the DNA damage signalling pathway. 
Central to the DNA damage checkpoint are two large protein kinases, 
ATM and ataxia telangiectasia and Rad3-related (ATR) (Durocher and Jackson, 
2001; Figure 1.4). ATM and ATR belong to a superfamily of large protein 
kinases identified in various organisms that have a carboxy-terminal sequence 
with significant homology to the catalytic domain of the lipid kinase 
phosphatidylinositol 3-kinase (PI-3) (Kastan and Lim, 2000). The mammalian 
members of this family also include mTORIFRAP, DNA-PKcs, TRRAP, which 
is a component of histone acetyltransferase complexes, and the newly identified 
ATX which likely contributes to checkpoint activation by diverse types of 
genotoxic stress (Shiloh, 2003). 
ATM and ATR are at the top of the signalling pathways induced by DNA 
damage. Evidence for this was derived from studies using cells isolated from 
patients with the disorder AT (ataxia telangiectasia). AT cells lack the A TM 
protein, and are defective in all three DNA damage checkpoint responses 
(McGowan, 2002). ATM and ATR respond to DNA damage by 
phosphorylating and activating two downstream effector kinases, known as 
checkpoint kinase 1 (Chkl) and checkpoint kinase 2 (Chk2; Figure 1.4). The 
original model suggested that the ATM-Chk2 pathway is activated by the 
generation of DNA dis breaks that are induced by ionising radiation or 
radiomimetic drugs. The ATR-Chk1 pathway, by contrast, is activated In 
response to stalled replication forks that are induced by either UV -irradiation 
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Figure 1.4 The DNA damage signalling pathway 
Schematic representation of the mammalian DNA damage signalling pathway. 
Central to the DNA damage checkpoint are two large protein kinases, A TM and A TR. 
ATM and ATR respond to DNA damage by phosphorylating and activating two 
downstream effector kinases, Chkl and Chk2. It is not yet fully understood how DNA 
damage is detected, but the original model suggested that the ATM-Chk2 pathway is 
activated by the generation of DNA double stranded breaks that are induced by 
ionising radiation or radiomimetic drugs. The ATR-Chkl pathway, by contrast, is 
activated in response to stalled replication forks (caused by UV, hydroxyurea and 
aphidicolin), as well as DNA double stranded breaks. However, recent reports have 
highlighted the functional redundancy between these kinases. The checkpoint kinases 
then phosphorylate target proteins such as p53, Cdc25C, BRCAI and PML to arrest 
cell cycle progression, activate DNA repair pathways, or induce apoptosis. 
(which stalls replication by generating nucleotide dimers) or drugs such as 
hydroxyurea (which depletes the cellular deoxyribonucleotide pool) and 
aphidocolin (which inhibits DNA polymerase a), as well as DNA dis breaks. 
However, recent reports have highlighted the functional redundancy among 
these kinases. For example, Chkl is phosphorylated and activated by ATM in 
response to IR (Gatei et ai., 2003; Sorensen et ai., 2003), and checkpoint 
signalling to human tousled like kinases (Tlk) occurs via an A TM -Chk 1 
pathway (Groth et al., 2003). In addition, Chk2 can be activated independently 
of ATM (Hirao et ai., 2002). 
Once active, the checkpoint kinases phosphorylate target proteins such 
as p53, Cdc25A1C, BRCAl, PML, Tlk kinases and Plk3 kinases, to cause cell-
cycle arrest in the G 1, Sand G21M phases; activation of DNA repair; chromatin 
restructuring and apoptosis (Bartek and Lukas, 2003). 
1.17 Chk1 and Chk2 
Chkl and Chk2 are structurally distinct Ser/Thr kinases that share 
overlapping substrate specificity in vitro (Bartek et ai., 2001) and may share 
some functions in vivo. 
There are, however, some important differences between Chkl and Chk2. 
For example, Chk2 is a relatively stable protein (half-life greater than six 
hours), which is expressed and can be activated in all phases of the cell cycle, 
including GO (Lukas et ai., 2001). Moreover, Chk2 is present and can be 
activated in some differentiated cells and tissues (Lukas et ai., 2001). By 
contrast, Chkl is an unstable protein (half-life less than two hours), and its 
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expression is restricted to Sand G2 phases of the cell cycle (Lukas et at., 2001; 
Kaneko et al., 1999). Chkl is also absent in differentiated cells (Lukas et at., 
2001). The observation that Chk1 expression is restricted to Sand G2 phases of 
proliferating cells suggests that DNA damage signalling in G 1, and GO, may 
depend exclusively on Chk2. 
The tumour suppressor protein p53 can down-regulate the expression of 
Chk1, but not Chk2, dependent on the transcriptionl activity of p53, and the 
presence of functional p21 (Gottifredi et at., 2001). The tumour suppressor 
protein pRb is also required for Chk1 down-regulation, suggesting the possible 
involvement of E2F-dependent transcription in the regulation of Chkl 
(Gottifredi et a/., 2001). Consistent with this idea, chromatin 
immunoprecipitation (Chip) assays have shown E2F family members bound to 
the Chkl promoter (Ren et a/., 2002). 
The analysis of knock-out mice carrying inactivated Chk1 or Chk2 
genes indicates they play distinct roles in development. Mice harbouring 
homozygous disruption of Chk2 are viable (Hirao et at., 2000; Takai et al., 
2002; Jack et at., 2002), however homozygous disruption of Chkl causes 
embryonic lethality (Liu et a/., 2000; Takai et al., 2000). In contrast, Chk 1 
deficiency in avian somatic DT -40 lymphoma cells can be tolerated, but 
interferes with nonnal DNA damage responses, and cell survival after IR 
(Zachos et at., 2003). 
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1.18 Chk2 structure and activation 
The human Chk2 gene encodes a 543 amino acid homologue of the 
Saccharomyces cerevisiae Rad53 and Sclli::osaccharomyces pombe Cds 1 
checkpoint kinases (Matsuoka et ai., 1998). The overall structure of the Chk2 
proteins is similar in all eukaryotes, and the degree of overall homology of 
Chk2 protein sequences across species roughly reflects the evolutionary 
distance among the distinct organisms. For example, human Chk2 shows 83% 
and 82% amino-acid identity with the rat and mouse kinases; 61 % identity with 
the Xenopus laevis protein; 51 % with the zebrafish; 34% with Drosophila 
melanogaster; 32% with both S. pombe and the nematode Caenorhahditis 
elegans; and 28% with S. cerevisiae Rad53 (Bartek et al., 2001). 
At the protein level the structure of human Chk2 is dominated by three 
evolutionarily conserved domains (Figure 1.5). An SQ/TQ cluster domain 
(SCD) is located at the N-terminus (residues 20-75), a forkhead-associated 
domain (FHA) within the central portion (residues 115-165), and a kinase 
domain within the C-terminal region (residues 225-490). 
The kinase domain is very large, occupying almost the entire carboxy-
terminal half of Chk2. Its key functional elements - including the activation loop 
- have been identified based on their homology with other Ser/Thr kinases. A 
kinase-defective, dominant-negative mutant, has been generated by mutating 
one of the key residues of this domain, Asp347 Ala (Matsuoka et al., 1998). 
The SCD located in the amino-terminal domain of Chk2 contains a 
series of seven serine or threonine residues followed by glutamine (SQ or TQ 
motifs). These motifs are the preferred sites for phosphorylation by ATMI A TR 
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Figure 1.5 Structure of the Chk2 protein 
Structure of the human Chk2 protein, highlighting the positions of the sQrrQ-rich 
(SeD), forkhead-associated (FHA), and kinase domains. Closed lollipops indicate 
sites phosphorylated by ATMlATR kinases. Phosphorylation sites at Thr68 
(ATMIATR) and Thr383 and Thr387 (auto-phosphorylation) involved in the 
activation ofChk2 are indicated. (Figure adapted from Bartek et al., 2001). 
kinases (Kastan and Lim, 2000). In normal cells, Chk2 is rapidly 
phosphorylated and activated in response to replication blocks and DNA 
damage (Matsuoka et ai., 1998; Brown et ai., 1999; Chaturvedi et ai., 1999). 
The response to DNA damage caused by IR occurs in an A TM-
dependent manner as Chk2 is not activated in cells derived from AT patients 
(Matsuoka et ai., 1998; Brown et ai., 1999; Chaturvedi et ai., 1999), and 
transfection of AT cells with functional A TM restores the activation of Chk2 
(Matsuoka et ai., 1998). ATM can directly phosphorylate Chk2 in vitro, and 
Thr68 is the major site phosphorylated in vitro by A TM (Matsuoka et ai., 2000; 
Melchionna et ai., 2000; Ahn et ai., 2000). Moreover, in vivo Thr68 is 
phosphorylated in an ATM-dependent manner in response to IR (Matsuoka et 
ai., 2000; Melchionna et ai., 2000; Ahn et ai., 2000). The importance of this 
phosphorylation site has been demonstrated by the failure of mutant, non-
phosphorylatable forms of Chk2 to be activated in vivo (Matsuoka et ai., 2000; 
Melchionna et ai., 2000; Ahn et al., 2000). 
In response to UV -irradiation or HU treatment, Chk2 is phosphorylated 
and activated in an ATM-independent manner (Matsuoka et ai., 1998; Brown et 
ai., 1999; Chaturvedi et ai., 1999). ATR can also phosphorylate Chk2 on Thr68 
in vitro, and phospho-specific antibodies confirm that Thr68 is phosphorylated 
in response to UV-irradiation and HU in cells lacking ATM (Matsuoka et al., 
2000). Phosphorylation of Thr68 in response to IR does occur, but with delayed 
kinetics in cells lacking ATM (Matsuoka et al., 2000). Interestingly, 
phosphorylation ofSer15 on p53, the site phosphorylated by ATM and ATR in 
vitro (Canman et ai., 1998; Banin et ai., 1998; Tibbetts et ai., 1999), is also 
delayed in response to IR in cells lacking ATM (Siliciano et ai., 1997). It has 
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been suggested that A TR phosphorylates Serl5 in late phase in response to IR 
(Tibbetts et al., 1999). Therefore, A TR is likely to phosphorylate Thr68 on 
Chk2 in vivo in response to UV-irradiation and HU, and in late phase in 
response to IR. 
Phosphorylation at Thr68 is a prerequisite for the subsequent activation 
step, which is attributable to auto-phosphorylation of Chk2 on residues Thr383 
and Thr387 in the activation loop of the kinase domain (Lee et al., 2001; Ahn et 
al., 2002). Both Thr383 and Thr387 are phosphorylated in vivo following IR, 
and mutation of these sites results in a catalytically inactive Chk2 (Lee et al., 
2001). It has been proposed that the activating auto-phosphorylation of Chk2 on 
Thr383 and Thr387 depends on the integrity of another key domain, the FHA 
domain (Lee et al., 2001; Ahn et al., 2002). Consistent with this, a tumour-
derived Chk2 mutation within the FHA domain, Phe 145Trp, destabilises the 
structure of the FHA domain and renders the protein incapable of being Thr68 
phosphorylated and activated in an ATM -dependent manner (Lee et al., 2001; 
Li et al., 2001; Wu et al., 2001; Falck et al., 2001a). Furthcnnore, the 
identification of mutations within the FHA domain of Chk2 in several variant 
Li-Fraumeni syndrome (LFS) families and sporadic cancers strengthens the 
concept that this domain is important for Chk2 function (Bell et at., 2000; 
Miller et al., 2002; Lee et al., 2001). 
FHA domains recognise phosphorylated Ser/Thr motifs and function to 
mediate protein-protein interactions (Durocher and Jackson, 2002). Therefore 
the FHA domain may mediate the docking of Chk2 onto ATM or other proteins 
involved in cell cycle checkpoint signalling. In support of this idea, 
phosphorylation of Thr68 promotes oligomerisation of Chk2 via binding of the 
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Thr68 phosphorylated region of one Chk2, to the FHA domain of another (Ahn 
et al., 2002). The dimers formed following DNA damage are transient in nature 
during activation, and trans-auto-phosphorylation at multiple sites including 
Thr383 and Thr387 is proposed to release active Chk2 monomers that proceed 
to enforce checkpoint control (Ahn et al., 2002). Consistent with these findings, 
Xu et al., (2002) show that both the SCD and FHA domains are required for 
formation of active Chk2 oligomers, and that Thr68 Chk2 phosphorylation is 
required for stable dimerization. Finally, a recent study has suggested that while 
Thr68 phosphorylation is required for oligomerization and activation of Chk2, it 
is not required for the maintenance of dimerization or kinase activity (Ahn and 
Prives, 2002). 
Taken together, these studies point towards a model in which inter-
molecular auto-phosphorylation of Thr383 and Thr387 and subsequent 
activation of Chk2 occurs, providing a very quick, powerful mechanism of 
signal transduction. 
1.19 Mediators of Chk2 activation 
In budding yeast, phosphorylation and activation of the Chk2 
homologue Rad53 by Mec1 (the homologue of ATM) requires Rad9, a protein 
with C-terminal tandem BRCT (BRCAI C-terminus) motifs. Recently, a group 
of large BRCT domain containing proteins, including 53BPI, NFBDI/MDCI, 
and BRCAI have been identified as mediators of checkpoint responses in 
mammalian cells. 
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53BP 1, a protein identified through its ability to bind to the tumour 
suppressor protein p53 via 53BPI s C-terminal BRCT repeats (lwabuchi et al., 
1994), resembles the Rad9 BRCT-repeat protein in budding yeast. In response 
to IR, Chk2 is phosphorylated on Thr68, and co-localises within discrete nuclear 
foci along with 53BPI (Zhou and Elledge, 2000; Ward et al., 2001). In cells 
where 53BPI is inhibited with siRNA, a reduction, but not abrogation, of Chk2 
Thr68 phosphorylation and foci formation is observed in response to IR, 
suggesting that 53BPl plays a partially redundant role in the activation of Chk2 
(Wang et aI., 2002). Antibodies to Chk2 efficiently immunoprecipitate 53BPI, 
however Chk2 dissociates from 53BPI in response to IR (Wang et al., 2002). 
This suggests that 53BPI may act as an adapter that facilitates Chk2 
phosphorylation and activation in a transient complex and, upon activation, 
Chk2 dissociates from the 53BPI complex. Further, mice in which the 53BPI 
gene is disrupted feature a defective DNA damage response with impaired Chk2 
activation after low doses of IR (Ward et al., 2003), providing physiological 
evidence that 53BPl is required for proper activation ofChk2. 
BRCAI, another recently identified substrate of Chk2 (Lee et al., 2000), 
is one of the key checkpoint controlling proteins (Scully and Livingston, 2000). 
Human Chk2 and BRCAI exist within overlapping nuclear foci (Lee et ai., 
2000), In response to IR Chk2 phosphorylates BRCAI on Ser988, leading to the 
release of BRCA 1 from its complex with Chk2, and this event is important for 
BRCAI to restore cell survival after DNA damage (Lee et ai., 2000). BRCAI 
has been proposed as a master molecule that assembles and integrates the many 
components of the early checkpoint response into a dynamic multi-component 
complex called the BASC (BRCAI-associated genome surveillance complex) 
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(Wang et al., 2000). It remains to be seen whether Chk2 is a genuine component 
of the BASC, however BRCAl and Chk2 do physically interact (Lee et al., 
2000), and this might bring Chk2 in close proximity to the upstream A TMI A TR 
kinases that are required to initiate Chk2 activation (Bartek et al., 2001). 
Alternatively, BRCAl might operate in a similar manner to yeast Rad9 
and assemble Chk2 molecules into oligomers to promote inter-molecular auto-
phosphorylation, which is required for its full activation and efficient 
amplification of the checkpoint signalling cascade (Bartek et at., 2001). This 
scenario is complicated further by the observation that BRCA 1 and its 
regulatory partner CtIP are phosphorylated in response to DNA damage by 
AIM! AIR and AIM kinases respectively (Li et al., 2000; Cortez et al., 1999; 
Iibbets et al., 2000). 
Interestingly, AIM-dependent activation of Chk2 by IR requires Nbs 1 
(Buscemi et al., 2001), a component of the MrelllRad50lNbsl complex. In 
Nijmegan breakage syndrome (NBS) cells, null for Nbsl protein, Chk2 
phosphorylation and activation are both defective. Importantly, these defects in 
NBS cells can be complemented by re-introduction of wild-type Nbs l, but not 
by a C-terminal deleted mutant ofNbsl unable to form a complex with Mre1l 
and Rad50, or by an Nbsl mutated at the ATM phosphorylation site. These 
findings suggest a role for functional Nbsl and Mrell complex in Chk2 
activation. 
NFBDl (nuclear factor with BRCT domains protein 1), also called 
MDC1, binds to the MrellIRad50lNbsl complex (Goldberg et al., 2003), and 
has been identified as an early participant in damage induced nuclear foci 
containing the histone H2A variant H2AX, 53BPl, BRCA1 the 
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Mreil/Rad50lNbsi complex and Chk2 (Peng et al., 2003; Lou et al., 2003; 
Goldberg et al., 2003; Stewart et al., 2003). MDCI is phosphorylated in an 
ATM and Chk2 dependent manner after DNA damage, and suppression of 
MDC I expression results in a defective S-phase checkpoint, reduced apoptosis, 
and decreased p53 stabilisation in response to DNA damage (Lou et al., 2003; 
Goldberg et al., 2003; Stewart et al., 2003). These defects can be restored by the 
expression of wild-type MDCI, but not MDCI with a deleted FHA domain 
(Lou et al., 2003; Goldberg et al., 2003; Stewart et al., 2003). The FHA domain 
of MDCl mediates its association with the phosphorylated Thr68 residue of 
Chk2 (Luo et al., 2003), therefore these results suggest that MDCI is recruited 
via its FHA domain to activated Chk2, and plays a critical role in Chk2 
mediated DNA damage responses. A partially redundant role for MDC 1 in 
regulating the phosphorylation of Thr68 and activation of Chk2 is suggested by 
the fact that siRNA directed against MDC I in human cells diminishes, but docs 
not abrogate, Thr68 Chk2 in IR-induced foci (Peng et al., 2003). 
Taken together, these studies suggest roles for 53BPI, BRCAI, 
NFBDIIMDCl and the MrellIRad50lNbsl in the regulation of Chk2 
activation, possibly to modulate diverse checkpoint events. 
Consistent with the fact that some substrates of Chk2 are soluble, mobile 
proteins, live cell imaging of Chk2 in human cells demonstrated that Chk2 is 
also a mobile protein that is redistributed throughout the nucleus in response to 
DNA damage (Lukas et al., 2003). These results support a role for Chk2 in 
spreading the checkpoint signal from sites of DNA damage to effector proteins 
throughout the cell. Although these results are inconsistent with other reports 
that activated Chk2 forms nuclear foci in response to DNA damage, it remains 
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possible that Chk2 first needs to localise with other checkpoint proteins in order 
to become activated. 
Finally, an apparently unique feature of mammalian Chk2 that is not 
conserved in lower eukaryotes is a c-Abl SRC homology domain-consensus 
binding sequence, which is upstream of the FHA domain (Brown et al., 1999). 
C-Abl is also phosphorylated and activated by ATM in response to DNA 
damage, therefore it is possible that Chk2 might also interact with c-Abl, either 
physically or functionally to mediate checkpoint responses (Bartek et al., 2001). 
The emerging role of these BRCT domain containing proteins is to 
modulate diverse checkpoint events, including activation ofChkl and Chk2. By 
regulating protein-protein interactions, these mediators may control the timing 
and extent of Chk2 activation. 
1.20 The G1 Checkpoint 
Arrest of the cell cycle at the Gl checkpoint is caused by DNA damage, 
which causes increased cellular levels of the p53 tumour suppressor. p53 is a 
transcription factor that induces the expression of a number of gene products 
whose function is either to arrest cell growth or promote apoptosis (Hickman et 
ai., 2002). The downstream mediators of these p53-regulated cellular effects 
include the p21 inhibitor of cdks, apoptosis promoting factors such as Bax and 
Fas, and other targets whose roles in response to DNA damage are not yet 
known (Hickman et ai., 2002). Activation of p53 involves phosphorylation of 
the transactivation domain, and both acetylation and phosphorylation of the 
basic allosteric control region (Lakin and Jackson, 1999). 
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IR induces phosphorylation of p53 on Serl5 (Siliciano et al., 1997) and 
this phosphorylation is delayed in ATM deficient cells (Siliciano et al., 1997). It 
has been suggested that ATR phosphorylates Ser15 in late phase in response to 
IR (Tibbets et al., 1999), and in vitro kinase assays confirmed that A TM and 
ATR directly phosphorylate p53 on the same site, Ser15 (Canman et al., 1998; 
Banin et al., 1998; Tibbets et al., 1999). However, mutation of Ser15 to Ala, 
preventing the phosphorylation ofp53, has little effect on the half-life ofp53 or 
its ability to cause cell cycle arrest or apoptosis (Ashcroft et al., 1999; Chehab 
et al., 1999). In fact, phosphorylation of Ser15 seems to affect the ability of p53 
to bind to the transcriptional co-activator p300, which modulates the 
transactivation of target genes by p53 (Dumaz and Meek, 1999). 
IR induces phosphorylation of another serine residue in p53, Ser20, in an 
ATM dependent manner (Chehab et al., 1999; Shieh et al., 1999). Interestingly, 
Ser20 is in the middle of the domain that binds to MDM2, an important 
regulator of p53 degradation (Haupt et al., 1997; Kubbutat et al., 1997), and 
mutation of this site abrogates p53 stabilisation in response to DNA damage 
(Chehab et al., 1999). Neither ATM or ATR can phosphorylate Ser20 in vitro 
(Canman et al., 1998; Banin et al., 1998), so Ser20 is phosphorylated after IR 
by some other kinase that is dependent on ATM. 
Evidence suggests that in human cells ATM functions upstream of 
Chk2. ATM phosphorylates Chk2 at Thr68 in vitro, and IR leads to Chk2 
phosphorylation at Thr68 and its subsequent activation in wild-type but not 
ATM deficient cells (Matsuoka et al., 2000; Me1chionna et al., 2000; Ahn et al., 
2000). In vitro, Chk2 phosphorylates p53 on Ser20 (Chehab et al., 2000; Shieh 
et al., 2000), and expression of a kinase defective form of Chk2 (Asp347 Ala) 
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prevents the stabilisation and phosphorylation at Ser20 of p53 in response to IR 
(Chehab et al., 2000). Moreover, phosphorylation of p53 on Ser20 by Chk2 was 
shown to dissociate pre-fonned p53/MDM2 complexes ill vitro (Chehab et aI., 
2000). Taken together, these studies suggest that phosphorylation of p53 on 
Ser20 by Chk2 leads to p53 protein stabilisation by preventing its interaction 
with MDM2 (Figure 1.6). 
Similarly, Chld can phosphorylate p53 on Ser20 ill vitro, and expression 
ofa kinase defective Chkl or anti-sense Chkl leads to a reduction ofp53 levels 
(Shieh et al., 2000). 
The analysis of mouse Chk2,f, deficient cells further supports a role for 
Chk2 as being upstream of p53. Mouse ChkT1, deficient cells that are exposed 
to IR (but not UV-irradiation) fail to stabilise and activate p53, and are defective 
in the induction of p53-dependent transcripts such as p2l (Hirao et al., 2000). 
Chk2,f, cells exposed to IR also fail to maintain arrest in the G2 phase of the cell 
cycle, and are resistant to DNA damage induced apoptosis (Hirao et al., 2000). 
Another group using MEFs derived from the same mice reported that G 1 
arrest and p21 induction in response to IR was normal, however the cells failed 
to undergo DNA damage induced apoptosis (Jack et al., 2002). In the same 
study, ATM 'f, cells behaved as normal cells in invoking an apoptotic response, 
therefore the authors conclude that Chk2 is not involved in ATM and p53 
dependent G 1 arrest, but is involved in the activation of p53, independently of 
A TM, in triggering DNA damage induced apoptosis. 
Results from a second, independently generated Chk2,I, mouse indicate 
that Chk2 loss protects mice from IR induced death due to reduced apoptosis in 
a variety of tissues (Takai et al., 2002). MEFs derived from these Chk2,f. mice 
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Figure 1.6 Role of ATM and Chk2 at the G1 checkpoint 
In response to DNA double stranded breaks, ATM regulates p53 accumulation 
directly by phosphorylating p53 on Ser15, and MDM2 on Ser395. ATM can regulate 
p53 accumulation indirectly through the activation of Chk2, which phosphorylates 
p53 on Ser20. Combined, these multiple phosphorylations lead to the disruption of the 
p53-MDM2 interaction leading to p53 stabilisation, and increase the transactivating 
function of p53 resulting in cell cycle arrest or apoptosis. 
had an impaired p53-dependent G 1 cell cycle checkpoint, but not G2/M or S-
phase checkpoints. Interestingly, IR induced stabilisation of p53 was only 
partially affected (50-70% of that in wild-type cells), suggesting that a Chk2-
independent pathway for p53 stabilisation in response to IR exists (Takai et al., 
2002). Despite p53 protein stabilisation and phosphorylation of Ser23 (mouse 
equivalent of Ser20), p53 was completely transcriptionally inactive, and 
induction of target genes, such as p21, was not observed in ChkTI . cells. These 
results suggest that while Chk2 plays a partially redundant role in p53 
stabilisation, it is critical for p53 transcriptional activity in response to IR (Takai 
et al., 2002). 
Two recent reports question the role of Chk2 in the p53 DNA damage 
response (Ahn et al., 2003; Jallepalli et al., 2003). First, Ahn and colleagues 
used siRNA to downregulate Chk 1, Chk2 or both Chk 1 and Chk2 in human 
tumour cell lines. They observed that in cells where there was a marked 
reduction in Chk2, p53 is still Ser20 phosphorylated and stabilised, and 
activates target genes such as p21 after DNA damage with the radiomimetic 
compound NCS. In addition, a p53-derived peptide containing Ser20 proved a 
poor substrate for Chk2, and the sequence surrounding Ser20 does not fit the 
consensus Chk2 phosphorylation site found in other Chk2 substrates (O'Neill et 
al., 2002). The authors conclude that Chid and Chk2 are unlikely to be 
regulators ofp53. 
Second, Jallepalli and colleagues disrupted the Chk2 gene in human 
cells through homologous recombination, and found that phosphorylation of 
p53 at Ser20, stabilisation ofp53 protein, transcriptional activation ofp53 target 
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genes, and cell cycle arrest and apoptosis were completely intact regardless of 
Chk2 status. 
However, the most recent analysis of the Chk2-p53 link suggests that 
activation of Chk2 as a kinase towards Thr18 and Ser20 of p53 requires 
allosteric changes in Chk2 induced by its interaction with native full-length p53 
(Craig et al., 2003). Thus, two different classes of Chk2 substrates may exist, 
those similar to Cdc25 and others more similar to p53 (Bartek and Lukas, 2003). 
Phosphorylation of p53 at Thr18 by Chk2 has been reported to destabilise the 
p53IMDM2 complex (Craig et al., 1999; Schon et al., 2002), and it has been 
suggested that phosphorylation at Ser20 creates a phospho-consensus binding 
site for the transcriptional co-activator and histone acetyl transferase p300 
(Doman et al., 2003). Thus, Chk2 may operate as a molecular switch, 
converting p53 from an MDM2 binding protein to a p300 binding protein 
subject to enhanced acetylation by p300 (Doman et al., 2003; Shimizu and 
Hupp, 2003). It is possible therefore, that in addition to regulating p53 
stabilisation Chk2 regulates the activation of p53-dependent transcription. This 
is consistent with the observation that Chk2-1- mouse cells have a pronounced 
defect in p53-dependent transcription (Hirao et al., 2000; Takai et al., 2002). 
In summary, the ability of p53 to activate cell cycle arrest in G 1 phase 
through p21 in ChkT1- deficient mice and MEFs is unclear, as is the role of 
Chk2 at both the S-phase and G21M checkpoints. What is consistent is that 
Chk2-1- mice show increased resistance to IR, and that Chk2 regulates apoptotic 
processes (Hairo et al., 2000; Jack et al., 2002; Takai et al., 2002). However, 
the resistance to apoptosis observed in ChkT1- cells is likely attributable only in 
part to defects in p53 activation. A recent report has linked Chk2 and the 
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Promyelocytic Leukemia (PML) protein in the induction of p53-independent 
apoptosis (Yang et al., 2002). 
Interestingly, MDM2 is also phosphorylated by A TM after IR (Khosravi 
et al., 1999). After IR, phosphorylation of Ser395 in MDM2 by A TM decreases 
the ability of MDM2 to shuttle p53 from the nucleus to the cytoplasm, thereby 
allowing the p53 protein to accumulate (Maya et al., 2001). MDM2 can also be 
phosphorylated by Chkl in vitro, although the sites phosphorylated have not yet 
been identified (Shieh et al., 2000). 
Therefore, in response to DNA damage, it is likely that ATMI ATR and 
Chkl/Chk2 contribute to the stabilisation and activation of p53 by modulating 
its interaction with proteins such as MDM2 and p300. 
1.21 The S-phase checkpoint 
One of the first abnormalities to be characterised in A TM -deficient cells 
was a failure to arrest DNA synthesis after IR (Houldsworth and Lavin, 1980; 
Painter and Young, 1980). This phenomenon was called radioresistant DNA 
synthesis (RDS). RDS is a measure of DNA synthesis soon after irradiation and 
it reflects cells that are already in S-phase, rather than cells entering S-phase 
from Gl, and it does not depend on p53 (Lamer et al., 1994; Morgan et al., 
1994). 
Human cells respond to UV -irradiation or IR by rapidly degrading the 
protein phosphatase Cdc25A, in a ubiquitin and proteasome-dependent manner 
(Mailand et al., 2000). When active, Cdc25A removes phosphate groups from 
another enzyme, cdk2. This activates the cyciinE/cdk2 and cyclinAlcdk2 
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kinases, which are required for entry into and progression through S-phase 
(Mittnacht, 1998). Degradation of Cdc25A results in persistent tyrosine 
phosphorylation and inactivation of cdk2, and therefore inhibition of the cell 
cycle. 
UV -irradiation causes a decrease in Cdc25A levels and suppression of 
DNA replication dependent on the enzyme Chk1 (Mailand et al., 2000). IR also 
leads to degradation of Cdc25A, and Cdc25A is a substrate for Chk2 after IR 
(Falck et af., 2001a). IR activates Chk2 in an ATM dependent manner, and 
activated Chk2 phosphorylates Cdc25A at Ser123 in vitro and on the same site 
in vivo in response to JR, and this modification targets Cdc25A for rapid 
ubiquitin-dependent, proteasome-mediated degradation (Falck et al., 2001 a; 
Figure 1.7). Furthermore, with the introduction of mutant Chk2 into a 
mammalian cell line, the downregulation of Cdc25A and S-phase delay that 
normally occurs in response to IR is blocked (Falck et af., 2001a). Similarly, 
expression of a Cdc25A-resistant mutant of cdk2, or persistant expression of 
Cdc25A, blocks the IR induced S-phase checkpoint (Falck et al., 2001a). The 
involvement of Chk2 in the S-phase checkpoint was recently confirmed when 
siRNA-mediated downregulation of Chk2 (or Chkl) resulted in a partial RDS 
phenotype (Sorenson et ai., 2003; Zhao et al., 2002). 
Importantly, the activation of Chk2, degradation of Cdc25A and 
inhibition of cdk2 are defective in AT -cells (Falck et af., 2001 a). NBS IS a 
disorder that shares with AT a variety of phenotypic defects including radio-
sensitivity and RDS (Carney, 1999). In response to JR, Nbs 1 is phosphorylated 
on Ser343 in an ATM-dependent manner, and introduction of Nbs1 that has 
Ser343 mutated to alanine is sufficient to abrogate an S-phase checkpoint 
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Figure 1.7 Role of ATM and Chk2 at the S-phase checkpoint 
In response to DNA double stranded breaks, A TM phosphorylates and activates 
Chk2. Phosphorylation of Cdc25A on Ser] 23 by Chk2 leads to the proteasome 
mediated degradation of Cdc25A and, in tum, the failure to dephosphorylate and 
activate cycJinE-cdk2 complexes which results in inhibition of DNA synthesis. 
induced by IR in nonnal cells (Lim et al., 2000). These observations link A TM 
and the Mre Il1Rad50lNbs 1 checkpoint protein complex to a common signalling 
pathway, and provide an explanation for phenotypic similarities in AT and 
NBS. As discussed earlier, ATM-dependent activation of Chk2 by IR requires 
Nbsl (Buscemi et al., 2001). Therefore it is possible that RDS observed in NBS 
cells and AT -cells results from an inability to properly activate Chk2. 
Of particular interest, the MrellIRad50lNbsl complex associates with 
E2F family members through the Nbsl N-tenninus (Maser et al., 2001). This 
association and Nbsl phosphorylation by ATM are correlated with S-phase 
checkpoint proficiency (Maser et al., 2001). Moreover, the Nbsl-E2F 
interaction was shown to occur near origins of replication, suggesting that E2F 
is required to target the MrellIRad50lNbsl complex to origins of replication to 
suppress origin firing in the presence of damaged DNA. Taken together, these 
studies suggest a role for Chk2 and E2F-l in regulating DNA damage responses 
via Nbs 1 and the Mre 11 complex. 
Suppression of MDCl expression results in a defective S-phase 
checkpoint as well as reduced p53 stabilisation and apoptosis in response to 
DNA damage (Lou et al., 2003). MDCl has been identified as an adapter 
protein required for the full activation of Chk2 (Lou et al., 2003; Peng et al., 
2003) thus the defect in S-phase checkpoint observed may be due to defects in 
Chk2 activation (Lou et al., 2003; Peng et al., 2003). In addition, MDCrl . 
deficient cells fail to activate the intra-S-phase checkpoint (in addition to the 
G21M phase checkpoint) properly in response to IR, however this was 
associated with an inability to regulate Chkl properly (Stewart et al., 2003). 
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Finally, MDC 1 is phosphorylated in an A TM dependent manner in 
response to IR, which leads to its rapid relocalisation to nuclear foci that also 
contain the Mrell1Rad50lNbsi complex, H2AX and 53BPI (Goldberg et al., 
2003). Suppression of MDC 1 expression prevents IR induced foci formation by 
the MreilIRad50lNbsi complex, and this event is attributed with causing an 
RDS phenotype. Interestingly, down-regulation of MDCl does not affect IR 
induced phosphorylation of Chk2 at Thr68 or activation of degradation of 
Cdc25A, suggesting that these events may be involved in, but are not critical for 
the intra-S-phase checkpoint response. 
In summary, the idea that Chk2 regulates the intra-S-phase checkpoint in 
response to IR via the targeted degradation of Cdc25A carries some weight. 
However more studies are needed to clarify the role of proteins such as the 
recently identified MDCl before one can be sure of the molecular mechanisms 
that are involved. 
1.22 The G2 checkpoint 
In mammalian cells, 02 arrest is regulated mainly by the maintenance of 
an inhibitory tyrosine phosphorylation of cdkl. Cdkl activation is catalysed by 
the dual specificity phosphatase Cdc25C, which removes the inhibitory tyrosine 
phosphorylation required to allow cells to progress from 02 into mitosis 
(Morgan, 1997). 
Arrest in G2 begins with phosphorylation of Cdc25C on Ser216 (Sanchez 
et al., 1997; Peng et al., 1997). This phosphorylation both inhibits the 
phosphatase activity of Cdc25C and contributes to its cytoplasmic sequestration 
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by an interaction with 14-3-3 proteins (Peng et al., 1997), which are a family of 
ubiquitous phospho-binding proteins. Because it is trapped in the cytoplasm, 
Cdc25C cannot perform its nuclear function, which is to dephosphorylate and 
activate cdkl. 
Both Chk2 and Chk 1 phosphorylate Cdc25C at Ser216 in vitro (Peng et 
al., 1997), and this site is phosphorylated to high stochiometry in vivo (Peng et 
ai., 1997; Sanchez et al., 1997). A model for the G2 checkpoint proposes that 
Chk2 or Chkl act by phosphorylating Ser216 to maintain Cdc25C in its 
inhibitory phosphorylated state until DNA damage is repaired (Figure 1.8). 
However, expression of Cdc25C with a non-phosphorylatable alanine residue at 
Ser216 has only a modest effect on the G2 damage checkpoint (Peng et al., 
1997). Furthermore, 14-3-3-dependent regulation of Cdc25C localisation is 
neither necessary nor sufficient for checkpoint regulation (Lopez-Girona et al., 
2001; Graves et al., 2001). Therefore, phosphorylation of Ser216 is unlikely to 
be the only event preventing the activation of cdkl in the presence of DNA 
damage. 
Genetic studies partially support the involvement of Chk2 in the control 
of the G21M checkpoint. Embryonic stem (ES) cells that lack Chk2 cannot 
maintain an IR induced G2 arrest properly (Hairo et al., 2000). However they 
do arrest for up to 12 hours following IR suggesting that although Chk2 is not 
required for the initial arrest, it is required for maintenance of the arrest (Hairo 
et al., 2000). Contrary to the results obtained by Hairo and colleagues, MEFs 
isolated from a second, independently derived ChkT1- mouse showed no defects 
in G21M checkpoints (Takai et al., 2002). 
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Figure 1.8 Role of ATM and Chk2 at the G2 checkpoint 
In response to DNA double stranded breaks, ATM phosphorylates and activates 
Chk2. Phosphorylation of Cdc25C on Ser216 by Chk2 leads to the fonnation of 
14-3-3-Cdc25C complexes. 14-3-3 inhibits the phosphatase activity of Cdc25C, 
and sequesters it to the cytoplasm where it is unable to carry out its nonnal 
function. The failure of Cdc25C to dephosphorylate and activate cyclinB-cdkl 
complexes results in arrest of the cell cycle in G2 phase. 
In somatic cells, p53 is required to sustain a long-term G2 arrest 
following IR-induced damage (Bunz et al., 1998). Therefore the failure of Chk2 
-1- ES cells to remain arrested could be due to a lack of Chk2-dependent 
activation of p53, as well as Chk2-dependent inactivation of Cdc25C. 
Despite being poorly activated by IR (Zhao and Piwnica-Worms, 2001), 
evidence suggest that ChId is primarily responsible for G2 DNA damage arrest. 
Chkl deficient ES cells and blastocysts show a defective G2/M checkpoint in 
response to IR, UV -irradiation and hydroxyurea (Liu et al., 2000; Takai et al., 
2000), and siRNA-mediated knockdown of Chk1 in human cells has confirmed 
the requirement for Chkl in the G21M checkpoint in response to IR and DNA 
damaging agents (Gatei et al., 2003; Xiao et al., 2003). 
Given that Cdc25CI - mice have no obvious deficiency in their G2 
checkpoint response (Chen et al., 2001), the mechanism through which Chk1 
and Chk2 enforce G21M arrest following DNA damage will have to be re-
evaluated. 
1.23 Chk2, a candidate tumour suppressor 
Shortly after the identification of the human Chk2 gene in 199811999 
(Matsuoka et al., 1998; Brown et al., 1999; Chaturvedi et al., 1999), the first 
Chk2 mutations were reported. Mutations in Chk2 were initially identified in 
some cases ofLFS (Bell et al., 1999; Lee et al., 2001b; Vahteristo et al., 2001), 
a hereditary cancer susceptibility usually associated with inherited mutations in 
the TP53 gene. These findings suggested that germline mutations of Chk2 could 
account for the subset ofLFS families who do not have mutation in p53. 
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Sporadic mutations of Chk2 have been identified in a subset of diverse 
human malignancies including breast cancers, lung cancers, colon cancer, 
osteosarcomas and lymphoid tumours (Bell et al., 1999; Sullivan et al., 2002; 
Miller et al., 2002; Matsuoka et al., 2001; Haruki et al., 2000; Hofmann et al., 
2001). 
The majority are heterozygous mutations that lead to the generation of a 
truncated protein, or are missense mutations in important domains such as the 
SCD, kinase and FHA domain. Biochemical analysis confinned that mutants 
within the FHA domain have lost their ability to interact with, and efficiently 
phosphorylate substrates such as Cdc25A, p53 or BRCAI (Li et al., 2002; Falck 
et al., 2001a; Falck et ai., 2001b; Wu et al., 2001b), while mutants within the 
kinase domain show decreased or lost kinase activity (Matsuoka et al., 2001; 
Wu et ai., 200tb). Some of the FHA domain or kinase domain mutants are 
unstable proteins and are therefore expressed at much lower levels than wild-
type Chk2 (Matsuoka et al., 2001; Lee et al., 2001 b). Other mutants function in 
a dominant-negative manner by disrupting the function of the endogenous wild-
type protein (Falck et ai., 2001a). 
Therefore, mutations in Chk2 could lead to partial loss of function (one 
allele results in a truncated inactive protein), or the generation of a protein that 
acts in a dominant-negative fashion, or both simultaneously. The loss of 
function nature of some tumour associated Chk2 mutations support its 
candidacy as a tumour suppressor. 
Most interestingly, concomitant loss of function mutations in Chk2 and its 
substrate p53 were identified in the sporadic colon carcinoma cell line HeT -15, 
which has one allele mutated in the FHA domain, and one nonnal allele (Bell et 
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al., 1999; Falck et al., 200 I b). It is possible that this combination of mutations 
might provide an additional selective advantage to tumour cells, compared to 
cells that have defects in Chk2 or p53 alone (Falck et al., 200Ib). 
Intriguingly, constitutively active (Thr68 phosphorylated) Chk2 has been 
found in human cancer cell lines, and human primary breast and colon 
carcinomas (DiTullio et al., 2002). Persistent activation of Chk2 likely increases 
the selective pressure in human cancers to mutate p53 (DiTullio et al., 2002). 
A subset of tumours have been identified that have undetectable Chk2 
protein, in the absence of any mutations in the Chk2 gene (Bartkova et al., 
2001; Vahteristo et al., 2002; Sullivan et al., 2002; Tort et al., 2002). Epigenetic 
mechanisms are also known to undermine the expression of some tumour 
suppressors, however silencing of gene expression through promoter 
methylation has been excluded as a cause of this phenotype (Sullivan et al., 
2002; Tort et al., 2002). The finding of normal mRNA levels of Chk2 in such 
cases suggests that post-transcriptional abberations of Chk2 downregulate Chk2 
levels during oncogenesis (Bartek and Lukas, 2003). 
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1.24 Objectives 
It is well established that E2F transcription factors playa central role in 
co-ordinating cell cycle progression at the G 1 to S-phase transition (Dyson, 
1998). In addition to regulating proliferation, E2F controls the expression of 
genes involved in apoptosis. Whilst this study was underway, recent studies 
have shown that E2F-I is regulated in response to DNA damage, as treatment of 
cells with DNA damaging agents such as those used in cancer chemotherapy 
increases E2F-I protein levels (Blattner et at., 1999; O'Conner et at., 2000). 
Although little is known about the mechanism of E2F -1 induction, it has been 
suggested that ATM may be involved in the phosphorylation and stabilisation of 
E2F-1 in response to DNA damage (Lin et at., 2001). 
The aim of this study was to further explore the pathways that signal 
DNA damage to E2F-I, and gain insight into the role of E2F-I as an effector 
protein in the cellular response to DNA damage. More specifically the aim was 
to: 
• Explore the induction ofE2F-l in response to DNA damage 
• Identify the signal transduction pathways responsible for the regulation of E2F 
in response to DNA damage 
• Investigate the mechanism involved in E2F -1 induction 
• Address the physiological consequence of E2F -1 induction and activation 
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Chapter 2. Materials and Methods 
2.1. Plasm ids and site-directed mutagenesis 
The following plasmids have been previously described: pCMV -p-gal and 
pCMV -C020 (Allen et ai., 1997), pCMV -OP 1 (Bandara et at., 1993), pcyclinE-
luciferase (Morris et ai., 2000), Apaf-1-luciferase (-396/+208; Moroni et ai., 
2001) and Exon1-p-luciferase (Bates et ai., 1998). pCMV-HA-E2F-1 wild-type 
is as described (Helin et ai., 1992), and was used as a template to construct 
pCMV -HA-S364A using the In vitro mutagenesis system Quickchange 
(Stratagene) as recommended by the manufacturer. The primers used were 
(bases which differ from wild-type E2F-l are underlined): 
Fwd 5' -TTGTCCCGGATGGGCGCCCTGCGGGCTCCC- 3' 
Rev 3' -AACAGGGCCTACCCGCGGGACGCCCGAGGG- 5' 
For expression in E.coli, pCMV -HA-E2Fl wild-type and S364A were 
digested with BamHI and SacI and the resulting insert was cloned into pGEXKG 
(Pharmacia) at the same sites. 6-His-tagged Chk2 wild-type, Flag-Chk2 wild-
type and Flag-Chk2-0347A were gifts from T. Halazonetis (Chehab et at., 
2000). Baculovirus vectors for His-cyclinA and His-cdkl were as described 
(Desai et ai., 1995). 
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2.2. GST and His-tagged recombinant protein purification 
Transformed BL21 bacteria (Invitrogen) were grown to mid-logarithmic 
phase in 500ml of LB-broth containing the appropriate anibiotic at 37De. 
Thereafter, protein expression was induced by the addition of 0.5mM (final 
concentration) isopropyl-p-D-thiogalactopyranoside (lPTG) for 4 h at 30De. 
For GST purification, bacterial pellets were resuspended in 10ml 
PBS/l % Triton X-IOO and 0.5mM PMSF on ice, and then sonicated briefly 
(3x 1 0 sec) on ice. Bacterial debris was pelleted by centrifugation at 10,000rpm 
for 20 min at 4°e. A 400fll suspension of glutathione-Sepharose beads (50% 
v/v; Amersham), that had been pre-washed in PBS, was added to the 
supernatant and mixed with constant rotation at 4DC for 30 min. The suspension 
was washed three times with 50ml PBS by spinning in a bench-top centrifuge at 
5,000rpm for 5 min at 4°C. The GST proteins were eluted from the beads by 
incubating the bead pellet with an equal volume of 50mM Tris pH8, containing 
10mM of glutathione. 
For His-tagged purification, the same procedure was followed as for 
GST purification except; a 4001-11 suspension of Ni-NTA nickel-agarose beads 
(50% v/v, Qiagen) was used to bind His-tagged proteins, and His-tagged 
proteins were eluted by incubating the beads with an equal volume of imidazole 
buffer (200mM imidazole, 100mM NaCl and 20mM Tris-HCL pH8). To 
remove imidazole, purified proteins were dialysed with buffer containing 
(100mM NaCI and 20mM Tris-HCL pH8), overnight at 4De. 
Purified Cdc25C protein was purchased from Biodiagnostics. 
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2.3. Protein purification from baculovirus infected Sf9 
cells 
Sj9 insect cells were co-infected with the appropriate recombinant 
baculoviruses and whole cell extracts were prepared 48 h post-infection. 
Briefly, cells were lysed in buffer A (25mM HEPES pH7.6, 400mM KCL, 
12.5mM MgCh, O.lmM EDTA, 30% glycerol (v/v), 0.1% NP40 (v/v), and 
then centrifuged to remove insoluble material. The resulting lysate was diluted 
dropwise with 2 volumes of buffer B (25mM HEPES pH7.6, 100mM KCL, 
12.5mM MgCh, O.lmM EDTA, 10% glycerol (v/v), 0.1% NP40 (v/v)), and 
then incubated with Ni-NT A beads (Qiagen) for 1 h at 4°C. The beads were 
washed three times with buffer B containing 200mM KCL and 20mM 
imidazole. His-tagged proteins were eluted with 250mM imidazole in buffer B 
and dialysed against the same buffer without the imidazole. 
2.4. Cell culture 
MCF7 (human mammary epithelial), U20S (human osteosarcoma 
epithelial), T98G (human glioblastoma fibroblasts), and SAOS2 (human 
osteosarcoma epithelial) tumour cell lines were grown in Dulbecco's modified 
eagles medium (DMEM, Gibco) supplemented with 10% FCS (Gibco) and 
antibiotics, IOmglml streptomycin and 100U/ml penicillin (Gibco) at 37°C in a 
5% COzlH20-saturated atmosphere. HCT-15 (human colon carcinoma) cells 
were grown in RPMI-40 (Gibco) supplemented with 10% FCS. AT (human 
fibroblast) cells, repository number GM02530 were purchased from the Coriell 
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Institute for Medical Research (New Jersey, USA) and were grown in DMEM 
supplemented with 10% FCS. S19 (Spodoptera frugiperda insect cells) were 
grown in TCIOO (Gibco) supplemented with 5% FCS. 
2.5. Transient Transfection 
Cells for transient transfection were plated out 24 h before transfection at 
approximately 1.5x 106 cells per 100mm dish (for immunoprecipitation and 
immunoblotting), 5x105 cells per 60mm dish (for luciferase and p-galactosidase 
assays, and gel retardation) or 2x I 04 cells per 35mm dish (on coverslips for 
immunofluorescence). For calcium phosphate precipitation, the relevant plasmid 
DNA was mixed with a final concentration of 250mM CaClz and the resulting 
solution (100fll per 35mm dish, 250fll per 60mm dish and 500fll per 100mm 
dish) was added dropwise to an equal volume of 2xHBS solution (50mM 
HEPES pH 7.1, 280mM NaCl, and 1.5mM Na2HP04), and incubated at room 
temperature for 30 min before addition to the media on cells. For Lipofectamine 
transfection (Gibco), 2fll of Lipofectamine was used for every Iflg of DNA 
transfected. To maintain a constant amount of plasmid DNA in each sample, 
pCDNA3 (Invitrogen) was transfected as appropriate. Cells were washed three 
times with PBS at 14-16 h post-transfection. Cells were harvested after a further 
incubation of 24 h. 
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2.6. Cell extract preparation 
Cells were lysed in ice-cold extraction buffer (50mM Tris (pH 7.4), 
150mM NaCh, 5mM EDTA, 0.5% NP-40, ImM PMSF, 5mM NaF, ImM 
sodium vanadate, 1 x Protease Inhibitor Cocktail) for 30 min and centrifuged for 
10 min to remove insoluble material. The protein content of cell extracts was 
measured using Biorad reagent (Biorad). 
2.7. Immunoblotting 
Typically, 50-100Jlg of cell extract was immunoblotted depending on 
whether the protein to be detected was transfected or endogenous. Samples were 
resolved by denaturing gel electrophoresis (typically 10% gels) and electro-
transferred to Protran nitrocellulose membrane (Inverclyde Biochemicals Ltd), 
blocked in PBS-IO% non-fat milk for 30 min, then incubated with primary 
antibody overnight at 4°C in PBS-5% non-fat milk-O.l % Tween-20. After 
washing (3x 1 Omin) in PBS-Tween-20, the blot was incubated with secondary 
antibody, either anti-rabbit or anti-mouse alkaline phosphatase conjugated 
antibody (Promega; 1 :5000), or horseradish peroxidase-conjugated anti-rabbit 
or anti-mouse antibody (Amersham; 1 :5000), for I h at room temperature in 
PBS-5% non-fat milk-O.I % Tween-20. After washing (3x I Omin) in PBS-
Tween-20, proteins were visualised by incubation with alkaline phosphatase 
substrate (Sigma) or ECL reagent (Pierce). Equal protein loading was confirmed 
with Ponceau S staining. 
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2.8. Antibodies 
E2F-l antibody (KH-95), E2F-2 antibody (C-20), E2F-3 antibody (N-20), 
PCNA antibody (PC-IO), p53 antibody (DO-I), and PML antibody (PG-M3) 
were purchased from Santa Cruz. Apaf-l antibody (NT), and p73 antibody (GC-
IS) were purchased from Upstate Biotechnology. p 19ARF antibody (Ab-2) was 
purchased from Neomarkers. Flag M2 antibody was purchased from Sigma. 
HA-II antibody was purchased from Cambridge Bioscience. Chk2 
phosphorylated at Thr68 antibody was purchased from Cell Signalling 
Technology. Anti-P-S364 rabbit polyclonal antibody was generated by 
Eurogentec, Belgium. Briefly, two peptides were generated based on the 
sequence around Ser364, one of which was chemically phosphorylated at 
Ser364. Peptides were conjugated to KLH carrier protein, and the 
phosphorylated peptide was used for immunisation. Antibodies were affinity 
purified over a column containing the immobilised phosphorylated peptide. 
Then the bound material was passed over a second column containing 
immobilised non-phosphorylated peptide. P-S364 specific antibodies appeared 
in the flow-through of the second peptide column (see figure 4.4a). 
2.9. Immunoprecipitation 
For immunoprecipitation of proteins, the relevant antibodies were 
incubated with 30J.11 of Protein A beads (Sigma) overnight at 4°C with rotation, 
together with 500J.11 cell extract (l-2mg) prepared in extraction buffer (SOmM 
Tris (PH 7.4), lSOmM NaCh, SmM EDTA, O.S% NP-40, ImM PMSF, SmM 
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NaF, 1 mM sodium vanadate, 1 x Protease Inhibitor Cocktail). The bead pellets 
were then washed 5 times in lysis buffer before being resuspended in Ix SDS-
loading buffer (250mM Tris-HCL pH 6.8, 20% glycerol (v/v), 4% SDS (w/v), 
0.1 % bromophenol blue (w/v), 200mM DTT, and 5% ~-mercaptoethanol (v/v» 
and analysed by denaturing gel electrophoresis and immunoblotting. For in vitro 
immunoprecipitation of cold kinase assays, 40~1 of protein A beads were 
resuspended in 400~1 PBS together with 1~1 of antibody, and incubated at 4°C 
for 4 h with rotation. Beads were then centrifuged and buffer removed. Kinase 
assay reaction products (30~1) were made to 400~1 with PBS and added to 
protein A beads with antibody bound, and incubated overnight at 4°C with 
rotation. The bead pellets were then washed 3 times in PBS before being 
resuspended in Ix SDS-Ioading buffer and analysed by denaturing gel 
electrophoresis and immunoblotting. 
2.10. In vitro protein expression 
In vitro transcription and translation was carried out using a TNT T7 
coupled reticulocyte lysate system (Promega) as recommended by the 
manufacturer, in the presence of 35S methionine. For expression of unlabelled 
protein, reactions were supplemented with methionine. To check expression 1 ~l 
was subjected to denaturing gel electrophoresis and autoradiographed or 
immunoblotted. 
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2.11. In vitro binding assays 
For GST-pull down assay proteins were in vitro transcribed and translated 
to incorporate 35S-methionine using the T7 TNT coupled reticulocyte lysate 
system (Promega) as described by the manufacturer. An equal amount of 35S_ 
labelled in vitro translated protein was added to IJlg GST, GST-E2F-I or GST-
S364A protein in 200JlI TNE buffer (lmM DTT, ImM PMSF, and Ix protease 
inhibitor cocktail (Sigma), and incubated overnight with rotation at 4°C. Beads 
were then washed 3 times in TNE buffer and bound proteins eluted in 30JlI of 
1 x SDS loading buffer and visualised by gel electrophoresis and 
autoradiography (Biorad). 
2.12. In vitro kinase assays 
Purified recombinant wild-type or mutant E2F-I proteins (l Jlg), and 
Cdc25C (lJlg) were incubated with purified His-tagged Chk2 protein (O.2Jlg) 
for 30 min in Ix kinase buffer (50mM HEPES pH7.4, 10mM MgCI2, 10mM 
MnC}z, 10mM DTT) supplemented with 50JlM unlabeled ATP and 5JlCi [y_32p] 
ATP. Reactions to be used for immunoblotting with P-S364 antibody were 
performed cold with ImM ATP without [y_32p]. 
Purified recombinant wild-type or mutant E2F -1 proteins (1 Jlg), and pRb 
(lJlg) were incubated with baculovirus purified cyc1inAlcdk2 (0.2Jlg) for 30 
min in Ix kinase buffer (20 mM HEPES (pH 7.6), 10mM MgCh, ImM EDTA, 
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2mM MnCh, 10% glycerol, 1 mM OTT) supplemented with 50~M unlabeled 
ATP and 5~Ci [y}2p] ATP. 
Reactions were stopped by the addition of 3x SDS loading buffer and 
the protein mixtures were resolved by denaturing gel electrophoresis and 
subjected to autoradiography to monitor y}2p incorporation, or immunoblotted 
with antibody anti-P-S364 to monitor phosphorylation of E2F-l on Ser364. 
2.13. Gel Retardation analysis 
The E2F recognition site from the adenovirus E2A promoter (or a mutant 
site) was used in all gel retardation analysis (Girling et aI., 1993). The E2F 
binding site is in bold, and the nucleotides changed in the mutant site are 
underlined. 
Wild-type 5' -GATCTAGTTTTCGCGCTT AAA TTTGA-3' 
3' -ATCAAAAGCGCGAA TTT AAACTCT AG-5' 
Mutant 5' -GATCTAGTTTTCGATATT AAA TTTGA-3' 
3' -ATCAAAAGCT AT AA TTT AAACTCTAG-5' 
Typically, 10~g of cell extract prepared in lysis buffer (50mM KCL, 50mM Tris 
pH7.6, 25% glycerol, 2mM DTT, 0.1% Triton X-IOO, 0.2mM PMSF, and Ix 
protease inhibitor cocktail (Sigma)) was used per gel retardation sample. The 
cell extract was combined with binding buffer (lOmM HEPES pH7.6, 100mM 
KCL, ImM EDT A, 4% Ficoll, 0.5mM DTT), 2~g of sheared salmon sperm 
DNA and 200ng of mutant promoter oligonucleotide to reduce the non-specific 
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DNA binding activity. For gel retardation usmg recombinant and in vitro 
translated proteins, proteins were combined with binding buffer, 2J,.lg of sheared 
salmon sperm DNA and 200ng of mutant promoter oligonucleotide to reduce 
the non-specific DNA binding activity. 
Antibodies for supershifts were added and complexes were allowed to 
form at room temperature. After 15 min, Ing of a 32P-Iabelled E2F site was 
added for a further 20 min. Complexes were resolved on a 4% polyacrylamide 
gel in 0.5x Tris-borate EDTA (TBE) at 4°C for 2 h (200V). 
2.14. Reporter gene assays 
For reporter gene assays U20S cells were transfected with the indicated 
amount of plasmid DNA together with 500ng of CMV -p-gal as a control for 
transfection efficiency. The total amount of DNA transfected was kept constant 
by the addition of pCDNA3. Transfected cells were washed twice in PBS and 
regrown in DMEM-FCS for a further 24 h. Cells were then harvested, or treated 
with etoposide for the indicated time before harvesting in 300J,.l1 Ix reporter 
lysis buffer (25mM Tris-H3P04 pH 7.8, 2mM 2,2-diaminocyclohexane tetra 
acetic acid, 2mM DTT, 10% glycerol and 1 % triton (Promega). Cell lysate was 
then micro-centrifuged at 10,000 rpm for 5 min to remove cell debris. 
For the luciferase assay, 60J,.l1 of cell lysate was mixed with 300J,.l1 of luciferase 
reagent (Promega) and measured on a luminometer (Berthold). 
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For the p-galactosidase assay, 100lli of cell lysate was incubated with 100JlI of 
2x p-gal reagent (200mM sodium phosphate buffer pH 7.2, 2mM magnesium 
chloride, 100mM p-mercaptoethanol, 1.31lg/ml ONPG) and incubated at 37°C 
until a yellow colour developed. Reactions were stopped by the addition of 
600lli H20 and the activity was measured in a spectrophotometer (Pharmacia) at 
a wavelength of 420nm. 
2.15. DNA damaging agents 
Cisplatin, etoposide and doxorubicin were obtained from Sigma and were 
dissolved in DMSO. Cells were treated with drugs as indicated in the results 
section. For treatment, drugs were diluted to the appropriate concentration in 
fresh media before being added to cells. For UV -irradiation, cells were washed 
in PBS, and then placed in a UV crosslinker (Amersham) with dish lid removed, 
and irradiated with UV-light at 50 J/m2• Cells were then replenished with fresh 
media. 
2.16. Cycloheximide treatment 
To ensure equal transfection efficiency among samples for cycloheximide 
treatment, large plates were transfected with HA-E2Fl or HA-S364A (lOllg) in 
combination with CMV-DPI (lOllg) and pCDNA3 (20Jlg). After 16 h of 
incubation, transfected cells were washed 3 times with PBS before treatment 
with trypsin (Gibco) to release cells from the plates. Cells were then thoroughly 
85 
resuspended in 80ml of DMEM-FCS before re-plating onto eight 100cm plates. 
After a further 24 h of incubation, cells were either left untreated or treated with 
etoposide (lOJ.lM) for 4 h. Cycloheximide (50J.lg) was then added and cell 
extracts prepared and resolved for HA-E2F-l or HA-S364A at the indicated 
times by immunoblotting with an HA-specific antibody. 
2.17. Immunofluoresence 
For immunofluorescence, cells were seeded on 13mm borosilicate glass 
coverslips at a density of 2 x 104 cells. 24 h later cells were treated with 10J.lM 
etoposide or 50J/m2 UV -irradiation where indicated. 16 h post etoposide 
treatment cells were washed with PBS two times, fixed with 4% 
paraformaldehyde at room temperature, washed in PBS, then permeabablized in 
PBS containing Triton X-I00 (0.1%) for 10 min. Fixed cells were then washed 
three times with PBS and blocked with PBS containing 10% FCS for 30 min. 
Cells were then incubated in primary antibody diluted in PBS-l % FCS for 30 
min. Subsequently the coverslips were washed in PBS-l % FCS, before 
incubation with secondary antibody diluted in PBS-IO% FCS for 30 min. After 
3 final washes in PBS, the coverslips were mounted onto slides using citifluor 
(Citifluor Ltd). 
Affinity purified anti-PS364 polyclonal antibody was used to detect 
endogenous phosphorylated E2F-1. For peptide competition antibody and 
peptide were pre-incubated for 10 min at room temperature. Secondary anti-
rabbit and anti-mouse Alexa 594 antibodies were from Molecular probes. Cells 
were counterstained with 4', 6' -diamidino-2-phenylindole (DAPI). Images 
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were captured using an OI)111pus BX60 system microscope with Hamamatsu 
C4742-95 digital camera. Images were analysed using Improvision Openlab 
digital imaging software. 
2.18. Flow cytometry 
lx106 U20S cells seeded in a 10cm dish were transfected with the 
indicated amounts of expression vectors together with 81lg of pCMV -CD20 
DNA. 48 h post-transfection cells were exposed to 20llM etoposide. Cells 
were harvested 12 h after exposure to etoposide in PBS, incubated with CD20 
FITC conjugated antibody for 40 min, and fixed in 50% (v/v) ethanollPBS. 
Cells were treated with Rnase (125U/ml) for 30 min before re-suspension in 
propidium iodide (20Ilg/ml) in PBS at 4°C for 1 h. Cells were analysed in a 
Becton Dickinson F ACScan using cell-quest software. 10,000 CD20-stained 
cells were counted in each case 
For SAOS2 cells, 8 x 105 cells were transfected as described above and 65 
h post-transfection exposed to 20llM etoposide and harvested 6 h later. 
2.19. Denaturing gel electrophoresis 
Denaturing gels throughout refers to SDS-page. 
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Chapter 3. E2F-1 is regulated by the DNA 
damage signalling pathway 
3.1. Introduction 
DNA damaging agents such as UV -irradiation, ionising radiation, or 
chemotherapeutic drugs can cause cell cycle arrest as well as apoptosis, largely 
dependent on p53. Several recent reports have described an increase in E2F-I 
protein levels following the treatment of a variety of tumour cells with DNA 
damaging agents (Blattner et at., 1999; O'connor et at., 2000; Lin et at., 2001). 
Little information is available on the mechanisms involved in the stress 
induction ofE2F-I, although a recent study suggested that ATM phosphorylates 
and stabilises E2F-I, perhaps through a mechanism that involves the ubiquitin 
ligase p45SKP2 (Lin et ai., 2001), or the BRCT -domain containing protein 
TopBPI (Liu et ai., 2003). 
The DNA damage signalling pathway is a highly conserved response to 
genotoxic stress (Durocher and Jackson, 2001). Central to the DNA damage 
checkpoint are ATM and A TR, which are believed to transduce signals to 
downstream targets, such as the checkpoint kinases Chk 1 and Chk2 (Durocher 
and Jackson, 2001). In this respect, whilst ATM and ATR are generally 
regarded as sensors of DNA damage, the checkpoint kinases are likely to act as 
effectors of the response through the phosphorylation of key substrates, such as 
p53, the cell cycle-regulating phosphatases Cdc25A and Cdc25C, BReAI, and 
PML (Bartek and Lukas, 2003). 
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In this chapter the role of the DNA damage signalling pathway, 
specifically Chk2, in the regulation of E2F -1 induction has been explored. 
Results 
3.2. Induction of E2F-1 in tumour cells following DNA 
damage 
To investigate the regulation of endogenous E2F-I in response to cellular 
stress, various tumour cell lines were treated with the chemotherapeutic drugs 
etoposide (complexes with topoisomerase II and DNA to enhance double-strand 
and single-strand cleavage of DNA), cisplatin (forms adducts with the DNA 
dinucleotide d(pGpG), inducing intrastrand cross links) or doxorubicin 
(intercalates in DNA), as well as UV -irradiation. Four cell lines were selected 
which each differed in their status ofp53 and pRb. Western blot analysis of cell 
extracts revealed the degree of induction depends on the cell line and the drug 
being used, suggesting that the signalling pathways that are activated may vary. 
However, E2F-l is clearly induced in each ofthese cell lines (Figure 3.1). These 
results are consistent with recent reports that E2F-l is induced in various cell 
lines in response to a variety of forms of DNA damage including IR, UV-
irradiation, and chemotherapeutic drugs (Blattner et al., 1999; O'connor et al., 
2000; Lin et al., 2001). These results also suggest that while different pathways 
may be involved in signalling to E2F -1, the induction of E2F -1 is a general 
response to DNA damage. The observation that E2F-l is induced in SAOS2 
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cells argue strongly that the accumulation ofE2F-l in response to DNA damage 
can occur independently ofp53 and pRb. 
3.3. Specific induction of E2F-1 following DNA damage 
The accumulation of E2F -1 is regulated during the cell cycle, with 
mRNA and protein levels peaking at the G I to S phase transition (Dyson, 1998). 
E2F-I, E2F-2 and E2F-3 family members are commonly regulated with respect 
to the cell cycle, whereas E2F-4 and E2F-5 are uniformly expressed throughout 
the cell cycle (Dyson, 1998). In response to DNA damage the pRb protein is 
hypo-phosphorylated (Amell em et al., 1996; Krtolica et al., 1998), likely 
through the activation of cdis such as p21. Therefore the accumulation of E2F-l 
observed in response to DNA damage could simply reflect the accumulation of 
cells arrested by pRb in the Gl phase, when E2F-l levels are naturally high. If 
this was the case, then the protein levels of similarly regulated family members 
such as E2F-2 and E2F-3 would also be expected to increase. To explore this 
possibility, MCF7 cells were treated with etoposide, and endogenous E2F-l, 
E2F-2 and E2F-3 protein levels were monitored by immunoblotting. E2F-l 
protein rapidly accumulates in response to etoposide treatment in contrast to 
E2F-2 and E2F-3 that are unaffected (Figure 3.2). These results confirm that the 
induction of E2F-l protein accumulation is specific for E2F-l. Recent work has 
shown that the induced accumulation of E2F-l protein in response to DNA 
damage does not result from an increase in E2F-I mRNA (Blattner et al., 1999; 
Lin et aI., 2001), therefore it most likely involves a post-translational 
mechanism. 
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3.4. Induction of E2F-1 and p53 following DNA damage 
exhibit similar kinetics 
Accumulation of p53 in response to IR and UV -irradiation is dependent 
on the A TM and ATR kinases (Kastan and Lim, 2000). More recently Chk2 
kinase has also been shown to be involved in the accumulation of p53 in 
response to IR, as well as regulating its transcriptional activity (Chehab et al., 
2000; Takai et al., 2002). To investigate whether E2F-l exhibited similar 
kinetics of induction to p53, human MCF7 cells, which express wild-type p53, 
were treated with DNA damaging agents and the levels of endogenous E2F-l 
and p53 were monitored by immunoblotting. Whilst some functional 
redundancy exists, the radiomimetic drug etoposide, and UV -irradiation are 
believed to activate different arms of the DNA damage signalling pathway 
(Durocher and Jackson, 2001). UV-irradiation was able to induce E2F-l with 
kinetics closely following the induction of p53 (Figure 3.3b). However in 
response to etoposide treatment, p53 is induced more rapidly than E2F-l, with 
p53 levels peaking after 4 hours (Figure 3.3a). As an internal control PCNA was 
studied, which was not affected by either etoposide or UV treatment and was 
therefore used as a loading control throughout this study. The observation that 
both p53 and E2F-I are induced by the same DNA damaging agents and with 
similar kinetics, suggests that they may be commonly regulated by the DNA 
damage signalling pathway. 
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3.5. E2F-1 is regulated by ATM kinase 
Induction of E2F-1 in response to DNA damage mediated by ATM-
dependent phosphorylation has previously been described (Lin et al., 2001). In 
order to confirm this observation, the induction of E2F-1 and p53 were 
examined after treatment with etoposide or UV -irradiation in a cell line 
deficient in ATM function. Accumulation of p53 in response to IR involves 
ATM (Siliciano et al., 1997; Chehab et ai., 1999; Shieh et al., 1999). Consistent 
with this, the accumulation of p53 was impaired in response to etoposide in 
ATM-deficient fibroblasts (Figure 3.4, lanes 2-5, middle). In contrast, p53 was 
significantly induced by UV -irradiation from as early as 4h after treatment 
(Figure 3.4, lanes 6-9, middle). Importantly, E2F-l also failed to be induced by 
etoposide, in clear contrast to the induction of E2F-l by UV -irradiation in the 
same cells (Figure 3.4, compare lanes 2-5 with 6-9, top). As an internal control, 
PCNA was studied, which was not affected by either etoposide or UV 
treatments (Figure 3.4, bottom). These results suggest that ATM is required for 
the proper induction of p53 and E2F-l in response to DNA dis breaks, and 
support the notion that p53 and E2F-1 are commonly regulated by the DNA 
damage signalling pathway. 
3.6. E2F-1 is regulated by Chk2 kinase 
Given the similarities in the kinetics of induction between E2F -1 and 
p53, and recent work implicating Chk2, in addition to ATM and ATR kinases, 
in the regulation of p53 (Chehab et ai., 2000; Hirao et ai., 2000; Sheih et al., 
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2000), the role of Chk2 in regulating E2F -I was investigated. To assess the 
possibility that E2F-I is subject to regulation by Chk2 kinase, the effect of a 
dominant-negative acting derivative of Chk2, (Asp347 Ala; Chehab et al., 2000) 
on the induction of endogenous E2F-I by DNA damage was studied. Because 
of the established role of Chk2 kinase in the pS3 response (Chehab et al., 2000; 
Hirao et al., 2000; Sheih et al., 2000), it was anticipated that dominant-negative 
Chk2 would hinder p53 induction. Western blot analysis confirmed that 
inhibition of pS3 induction was observed in etoposide treated MCF7 cells 
(Figure 3.Sa, compare lanes 3 and 6, middle), with negligible effect on UV 
treated cells (Figure 3.Sa, compare lanes 2 and S middle). Most interestingly 
however, the Chk2 dominant-negative also blocked the induction of E2F-I in 
response to etoposide (Figure 3.Sa, compare lanes 3 and 6, top), again with 
negligible effect on UV treated cells (Figure 3.Sa, compare lanes 2 and S, top). 
The interpretation of these results is affected by the transfection efficiency of 
Chk2 dominant-negative, nonetheless, these results suggest that Chk2 is 
involved in signalling DNA damage to E2F-I, specifically in response to agents 
that induce DNA dis breaks. In addition these results further strengthen the idea 
that E2F-I and pS3 are commonly regulated by the DNA damage signalling 
pathway. 
If E2F-I were to respond to etoposide treatment through the activity of 
Chk2 kinase, then E2F-I should fail to be induced by etoposide in cell-types 
that lack Chk2 activity. To address this idea the regulation of E2F-I in HCT -IS 
colon carcinoma cells, which express mutant pS3 and Chk2 mutated in the FHA 
domain (Phe 14STrp) which prevents Chk2 from engaging in phosphorylation 
dependent protein-protein interactions was explored (Bell et al., 1999; Falck et 
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al., 2001b). Western blot analysis showed that E2F-l was not induced by 
etoposide (Figure 3.5b, lanes 4-6, top), in contrast to the induction of E2F-l by 
UV-irradiation in the same cells (Figures 3.5b, lanes 1-3, top). The mutation in 
p53 prevents its induction in these cells (Figure 3.5b, lanes 1-6, middle), and 
PCNA remains unaltered by either etoposide or UV treatments (Figure 3.5b, 
bottom). Taken together with the previous results on the effects of dominant-
negative Chk2, which in MCF7 cells blocked the induction of E2F-l by 
etoposide but not by UV-irradiation (Figure 3.5a), these results suggest a 
physiological role for Chk2 in regulating the response of E2F -1 to etoposide. 
Further evidence for this idea was gained by introducing wild-type 
Flag-tagged Chk2 into either U20S (carrying low levels of endogenous Chk2) 
or HCr -15 cells and measuring the level of endogenous E2F -1 after etoposide 
treatment by western blotting. In U20S cells the introduction of Chk2 allowed 
a greater level of E2F-l to be induced by etoposide (Figure 3.5c, compare lanes 
2 and 4, top). In HCr -15 cells, introducing wild-type Chk2 re-instated the 
ability ofE2F-l to respond to etoposide (Figure 3.5d, compare lanes 1-3 with 4-
6, top). Under these conditions, recognition of exogenous Chk2 by an antibody 
specific for phosphorylated rhr68 residue, which is required for Chk2 to 
become catalytically active (Matsuoka et al., 2000; Melchionna et al., 2000; 
Ahn et al., 2000), occurred in etoposide treated cells, and correlated with the 
induction of E2F-l (Figure 3.5d, lanes 5 and 6, upper bottom). Moreover, a 
slower mobility form of Chk2 was recognised by a Flag specific antibody in 
etoposide treated cells (Figure 3.5d, lanes 5 and 6, middle). These results 
support a role for Chk2 in regulating E2F -1 in response to etoposide, and concur 
with the earlier result derived from dominant-negative Chk2 (Figure 3.5a). 
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3.7. Conclusions 
Data presented in this chapter demonstrates that E2F -1 and p53 are 
commonly regulated by the DNA damage signalling pathway. Consistent with 
reports by others (Blattner et al., 1999; O'connor et al., 2000; Lin et al., 2001), 
an induction of E2F-l by several DNA damaging chemotherapeutic drugs in a 
variety of cell lines irrespective of p53 or pRb status was observed. Induction is 
rapid and specific to E2F-l, and is mediated through a post-transcriptional 
mechanism that likely involves protein stabilisation (Blattner et al., 1999; Lin et 
al., 2001). 
The role of ATM in the induction of E2F -1 protein in response to DNA 
damage, in particular agents that cause dis breaks, has been confirmed, and 
several lines of evidence are presented that establish Chk2 in the control of E2F-
1 protein accumulation following DNA damage. First, a Chk2 dominant-
negative mutant blocked E2F-l induction in response to etoposide treatment, 
but not UV-irradiation. In addition, E2F-l failed to accumulate in response to 
etoposide in RCT -15 cells that lack Chk2 activity. Further evidence was gained 
by introducing wild-type Chk2 into either U20S cells (low levels of Chk2), or 
RCT -15 cells lacking Chk2 activity. In U20S cells the introduction of Chk2 
allowed a greater level of E2F-1 to be induced by etoposide, while in HCT -15 
cells, introduction of wild-type Chk2 restored the ability of E2F -1 to respond to 
etoposide. Therefore, based on these results, the induction of E2F -1 in response 
to DNA damage, specifically agents that induce DNA dis breaks, involves 
signalling through ATM and Chk2 kinases. 
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Figure 3.1. Induction of E2F-l in tumour cells following DNA damage 
Western blot analysis of E2F -1 from vanous human cell lines after 16 h 
treatment with 50 J/m2 UV-irradiation (UV), lO~M etoposide (Et), lO~M 
cisplatin (Cis), and lO~M doxorubicin (Dox), shows induction of E2F-l 
regardless of their p53 or pRb status. Extracts from U20S cells (p53 wild-type, 
pRb hyper-phoshorylated), SAOS2 cells (p5T1- with a C-terrn truncated pRb), 
MCF7 cells (pS3 wild-type, pRb hyper-phosphorylated) or T98G cells (pS3 
wild-type, pRb wild-type) were resolved by denaturing gel electrophoresis and 
immunoblotted for endogenous E2F-I using KH-95 antibody. Equal amounts of 
total protein were loaded in each lane as determined by Ponceau S staining. 
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Figure 3.2. Specific induction ofE2F-l following DNA damage 
Western blot analysis of E2F-l, E2F-2 and E2F-3 protein accumulation in 
human cells exposed to etoposide (lO/-tM). Extracts from MCF7 cells were 
resolved by denaturing gel electrophoresis and imunoblotted for endogenous 
E2F-l (top), E2F-2 (middle), and E2F-3 (bottom). Equal amounts of total 
protein were loaded in each lane as determined by Ponceau S staining. 
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Figure 3.3. E2F-l accumulates following DNA damage with similar kinetics 
to p53 
a) and b) Western blot analysis of E2F -1 and p53 protein accumulation in cells 
exposed to etoposide or UV -irradiation. Extracts from MCF7 cells exposed to 
etoposide (lOJ.lM; a) or UV (50J/m2; b) were resolved by denaturing gel 
electrophoresis and immunoblotted for endogenous E2F-l (top), p53 (middle) 
or PCNA (bottom). Equal amounts of total protein were loaded in each lane. 
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Figure 3.4. E2F-l accumulation is ATM dependent in response to etoposide 
AT -fibroblasts (GM02350) were exposed to etoposide (10/lM) or UV-
irradiation (50J/m2) and cell extracts were prepared 4, 8, 16 or 24 h later. 
Endogenous E2F-I (top), p53 (middle), and PCNA (bottom) were resolved by 
denaturing gel electrophoresis and detected by immunoblotting. Equal levels of 
total protein were loaded in each lane. 
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Figure 3.5. E2F-l accumulates following DNA damage and requires Chk2 
a) MCF7 cells were transfected with plasmids expressmg Flag-tagged Chk2 
dominant-negative protein (5flg), or vector alone (5flg) as indicated. The cells 
were exposed to etoposide (lOJ.!M) or UV -irradiation (50J/m2) and cell extracts 
were prepared 6 h later. Endogenous E2F-I (top), p53 (middle), peNA 
(bottom) and Flag-tagged Chk2 (not shown) were resolved by denaturing gel 
electrophoresis and detected by immunoblotting. Equal levels of total protein 
were loaded in each lane. 
b) HCT-15 cells were exposed to etoposide (lOJ.!M) or UV-irradiation (50J/m2) for 
either 3 or 6 h. Endogenous E2F-I (top), p53 (middle) or PCNA (bottom) were 
resolved by denaturing gel electrophoresis and detected by immunoblotting. 
Equal levels of total protein were loaded in each lane. 
c) U20S cells were transfected with 5J.!g vector alone (tracks I and 2) or flag-
tagged Chk2 (tracks 3 and 4) and exposed to IOJ.!M etoposide for 6 h. Extracts 
were prepared and immunoblotted for endogenous E2F -1 (top), Flag-tagged 
Chk2 (middle) and PCNA (bottom) as described. 
d) HCT-15 cells were transfected with 5J.!g vector alone (tracks 1,2 and 3) or Flag-
tagged Chk2 (tracks 4, 5 and 6) and exposed to IOJ.!M etoposide for 3 or 6 h. 
Extracts were prepared and immunoblotted for endogenous E2F-I (top), Flag-
tagged Chk2 (lower), phosphorylated Thr68 Chk2 (upper bottom), and PCNA 
(bottom) as described. 
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Chapter 4. Phosphorylation of E2F-1 
4.1. Introduction 
The activity of E2F is principally regulated through the phosphorylation 
of pocket proteins by G 1 cdks, however direct phosphorylation of E2F and its 
heterodimeric partner DP-1 also occurs. Consistent with this, multiple 
electrophoretic forms of E2F-1 have been reported to exist that are the products 
of differential phosphorylation (Peeper et at., 1995). The best characterised is 
the phosphorylation of E2F-1 and DP-l by cyclinNcdk2 kinase. E2F-I and DP-
1 are efficiently phosphorylated in vitro by cyclinAlcdk2 (Dynlacht et af., 1994; 
Kitagawa et at., 1995), and cyclinNcdk2 binds to a domain in the N-terminal 
region of E2F-l, which is conserved in E2F-2 and E2F-3 but not in E2F-4 or 
E2F-5. The cyclinAlcdk2 binding domain is required for in vitro 
phosphorylation of E2F-l (KIek et af., 1994), and in vivo phosphorylation of 
DP-l (KIek et af., 1995). CyclinAlcdk2 mediated phosphorylation of DP-l 
coincides with a reduction in E2F DNA-binding activity during S-phase and 
may therefore contribute to the downregulation of E2F activity in late S-phase 
(KIek et af., 1994). In support of this idea, in vitro phosphorylation of the E2F-
IIDP-l heterodimer by cyclinAlcdk2 reduced its ability to bind DNA (Dynlacht 
et af., 1994; Xu et af., 1994; Kitagawa et af., 1995), and overexpression of E2F-
1 with a phosphorylation deficient DP-l caused a prolonged S-phase followed 
by apoptosis (Krek et af., 1995). 
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In addition, phosphorylation of E2F-l on Ser375, one of the sites 
phosphorylated by cyclinNcdk2 greatly enhanced its affinity for pRb in vitro 
(Peeper et al., 1995), however no in vivo significance of phosphorylation at this 
site has been detennined. Conversely, phosphorylation of Ser332 and Ser337 in 
the C-tenninal halfofE2F-1 prevent E2F-l from binding to pRb ill vivo (Fagan 
et al., 1994), although the kinase responsible has not yet been identified. 
It has also been demonstrated that phosphorylation of E2F -Ion Ser403 
and Thr433 can be mediated by a kinase associated with TFIIH, and results in 
the down-regulation of E2F-I stability (Vandel and Kouzarides., 1999), and 
E2F-5 can be phosphorylated on Thr251 by cyclinE/cdk2 which augments the 
recruitment of the transcriptional co-activator p300 stimulating activation of 
E2F responsive genes in late Gl phase (Morris et al., 2000). 
More recently, E2F-l was shown to be phosphorylated on Ser31 In an 
ATM-dependent manner in response to DNA damage (Lin et al., 2001). Ser31 
was shown to be important for the stabilisation of E2F-l, and induction of 
apoptosis in mouse thymocytes (Lin et al., 2001). 
Data presented in the previous chapter showed that E2F-l stabilisation is 
regulated by both A TM and Chk2 kinases in response to DNA damage. In this 
chapter the phosphorylation of E2F -1 by Chk2 and the identification of potential 
phosphorylated residue(s) are explored. 
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Results 
4.2. Site-directed mutagenesis of E2F-1 
To further explore the mechanism for the involvement of Chk2 in E2F-I 
stabilisation, the possibility that E2F -I might be a direct substrate for Chk2 
kinase activity was investigated. Chk kinases are Ser/Thr-specific kinases for 
which a small number of physiological substrates have been identified (Bartek 
and Lukas, 2003). A consensus Chk phosphorylation site found in other 
substrates has been determined (Hutchins et a/., 2000; O'Neill et a/., 2002; Seo 
et al., 2003). The consensus amino-acid sequence for phosphorylation by Chk 
kinases is cj>-X-~-X-X-(S/T), where cj> is a hydrophobic residue, ~ is a basic 
residue and X is any amino-acid. This motif was used to search the E2F-} 
sequence and found, in the C-terminal region of the protein centred on Ser364, a 
site that closely resembled the consensus Chk phosphorylation site (Fig. 4.1 a 
and 4.lb). The serine at 364 is unique to E2F-l, and the sequence surrounding 
Ser364 was more similar to the Cdc25, PML and BRCA 1 sites than to the p53 
site (Fig. 4.1 a). 
To investigate whether E2F-l is regulated by Chk2 phosphorylation, a 
mutational analysis was performed at the potential Chk2 phosphorylation site. A 
mutant E2F-l derivative in which Ser364 was altered to an alanine (A) residue 
(from now on referred to as S364A) was prepared. Alanine substitution results 
in the replacement of the OH group in serine with a CH3 side chain, destroying 
the potential Chk2 phosphorylation site (Fig.4.1 b). Furthermore, being a small. 
uncharged residue it is less likely than other amino acids to cause 
conformational changes to a protein. After sequencing confirmed that Ser364 
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had been successfully substituted with alanine, over-expression in U20S cells 
and western blot analysis of cell extracts confinned that the S364A mutant was 
expressed to a similar level as E2F -I (Fig. 4.1 c, compare lanes 2 and 3). 
4.3. E2F-1 is phosphorylated in vitro by Chk2 
To explore the idea that E2F-I is phosphorylated by Chk2, ill vitro 
phosphorylation reactions were perfonned with recombinant E2F-I proteins. 
E2F-I and the mutant derivative, S364A, were expressed as GST-fusion 
proteins in bacteria. When the purified preparations were subjected to SDS-
P AGE and coomassie blue staining, a 96kDa band, the predicted size of the 
GST-fusion protein, was detected (Figure 4.2a). In addition a smaller band was 
detected, probably as a result of protein degradation or bacterial contamination 
in the preparation. The identity of full-length E2F-l was con finned by 
immunoblotting with an anti-E2F-l antibody. A strong band at 96 kDa, was 
detected (Figure 4.2b). 
In vitro kinase assays were perfonned using GST-E2F-I and either His-
tagged Chk2 purified from bacteria, or cyclinNcdk2 purified from baculovirus 
infected Sj9 cells. Initially, in vitro kinase assays supplemented with unlabelled, 
cold ATP were perfonned. Immunoblotting the reaction products with an anti-
E2F -I antibody revealed that a slower mobility fonn of E2F -I was evident only 
with the wild-type protein upon addition of Chk2 kinase and a supply of ATP, 
and was abrogated with the S364A mutant (Fig. 4.2c, compare lanes 2 and 4). 
As a control the specificity of the S364A mutant was assessed by detennining 
whether it could be phosphorylated by another kinase, namely cyclinNcdk2, 
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which phosphorylates E2F-l (Krek et al., 1994). E2F-l and S364A were 
phosphorylated at about equivalent efficiency by cyclinNcdk2 (Fig. 4.2d, 
compare lanes 2 and 4), as estimated from the amount of slower mobility E2F 
protein, suggesting that the absence of S364A phosphorylation results from 
altering a specific Chk2 kinase site. 
Next in vitro kinase assays supplemented with y_32p were perfomled. 
Again Chk2 was able to phosphorylate E2F-I when reactions were 
supplemented with a source of ATP (Figure 4.2e, compare lanes 1 and 2). The 
efficiency of phosphorylation was similar to the level observed for an 
established Chk2 substrate, namely Cdc25C (Fig. 4.2e, compare lanes 2 and 5). 
Importantly, the S364A mutant derivative failed to be phosphorylated (Fig. 
4.2e, lane 3), suggesting that Ser364 is phosphorylated by Chk2 kinase. As a 
control, the specificity of the S364A mutant was again assessed by determining 
whether it could be phosphorylated by cyclinNcdk2. E2F-I and S364A were 
phosphorylated at about equivalent efficiency by cyclinNcdk2 (Fig. 4.2f, 
compare lanes 2 and 3), confirming that the absence of S364A phosphorylation 
results from altering a specific Chk2 kinase site. 
4.4. Generation of a phospho-Ser364 specific antibody 
To confirm that Ser364 is phosphorylated by Chk2 kinase, an anti-
phospho-specific peptide antiserum directed against the consensus site in which 
phosphorylated Ser364 resides was prepared (referred to as P-S364; Fig. 4.3a). 
First of all the reactivity of the crude P-S364 was assessed on in vitro 
phosphorylated E2F-I. P-S364 reacted strongly with Chk2 phosphorylated E2F-
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1 compared to unphosphorylated E2F-I (Figure 4.3b, compare lanes 3 and 4), in 
contrast to a general E2F-I antibody which exhibited similar reactivity to both 
un- and phosphorylated E2F-l (Fig. 4.3b, compare lanes 1 and 2). Additionally, 
P-S364 had greatly reduced activity on the S364A mutant derivative (Fig. 4.3c, 
compare lanes 2 and 4, top). Importantly, the reactivity of the antiserum for 
phosphorylated Ser364 E2F-I was specific, as the signal was competed only by 
inclusion of the phosphorylated E2F -I peptide, and not by the un-
phosphorylated E2F-I peptide (Figure 4.3d, compare lanes 1 and 2, top). These 
results support the view that the Ser364 site is phosphorylated by Chk2 kinase, 
and confirm that P-S364 recognises the phosphorylated site in E2F -1. 
4.5. E2F-1 is phosphorylated on Ser364 in vivo 
Whilst E2F-I was found to be phosphorylated by Chk2 in vitro, it was 
important to substantiate these findings in vivo. After peptide affinity 
purification (see Materials and Methods), the reactivity of the P-S364 antiserum 
was very much more specific for the phosphorylated Ser364 peptide compared 
to the non-phosphorylated Ser364 peptide (Fig. 4.4a). Furthermore, purified P-
S364 reacted strongly in vitro with Chk2 phosphorylated E2F-I compared to 
unphosphorylated E2F-I (Figure 4.4b, compare lanes 1 and 3, top). Importantly 
the affinity purified P-S364 showed no reactivity on the S364A mutant (Figure 
4.4b, lane 2, top). In contrast, a general E2F -I antibody exhibited similar 
reactivity to both un- and phosphorylated E2F-I (Figure 4.4b, bottom). 
Purified P-S364 was then used to study the regulation of endogenous E2F-
1 under DNA damage conditions, to ascertain whether Ser364 is subject to 
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phosphorylation control in cells. MCF7 cells were treated with etoposide for 2 h 
and E2F-l was monitored by western blot analysis with P-S364. The reactivity 
of P-S364 was compared to the general anti-E2F-l antibody (KH-95). Under 
these experimental conditions, there was little change in the steady-state level of 
E2F-l when measured with the general E2F-l antibody (Fig.4.4c, compare 
lanes 1 and 3). In non-stressed MCF7 cells P-S364 exhibited no activity, in 
contrast to etoposide-treated MCF7 cells where the antiserum clearly reacted 
with E2F-l (Fig. 4.4c, compare lanes 2 and 4). Furthermore, when antibody 
that had been affinity purified using the phosphorylated Ser364 peptide was 
used on the same cell extracts, E2F-l was detected only in etoposide treated 
cells (Fig. 4.4d, compare lanes 1 and 2, top). In contrast, the phosphorylated 
Ser364 peptide affinity depleted antiserum (aS364), which should include 
antibodies against the non-phosphorylated Ser364 residue, recognised an 
equivalent level of E2F-l in treated and untreated cells (Fig. 4.4d, compare 
lanes 3 and 4, top). To ensure that the polypeptide recognised by P-S364 in 
extracts of etoposide treated cells was E2F-l, immunoprecipitation assays were 
performed with the general E2F-l antibody, KH-95, prior to western blot 
analysis. Immunoprecipitated E2F-l from etoposide treated cells was clearly 
recognised by P-S364, in contrast to E2F-l from non-stressed cells (Fig. 4.4e, 
compare lanes 3 and 4, top). These results support the idea that Ser364 on E2F-
1 undergoes DNA damage-responsive phosphorylation in vivo. 
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4.6. Conclusions 
Chld is an Ser/Thr-specific kinase for which a small number of 
physiological substrates have been identified (Bartek and Lukas, 2003). A 
consensus sequence motif for phosphorylation, derived from Chk 
phosphorylation sites in different substrates has recently been identified 
(Hutchins et at., 2000; O'Neill et at., 2002; Seo et ai., 2003). In this chapter, the 
consensus sequence motif was used to screen the amino-acid sequence of E2F-l 
and, in the C-terminal region of E2F -1 centred on serine residue 364, a site was 
identified that fitted the consensus phosphorylation site. 
The importance of the hypothetical Chk2 phosphorylation site was 
explored by site-directed mutagenesis. E2F -I served as an in vitro substrate for 
Chk2 kinase, whereas a mutant E2F-l derivative in which Ser364 was altered to 
an alanine residue failed to be phosphorylated, suggesting that Ser364 is the 
only target site on E2F -I phosphorylated by Chk2 kinase. 
Further evidence that Chk2 phosphorylates Ser364 was gained by 
prepanng an anti-phospho-specific peptide antibody directed against the 
phosphorylated Ser364 residue. In vitro the P-S364 antibody reacted strongly 
with Chk2 phosphorylated E2F-I compared to unphosphorylated E2F-l, and 
showed little or no activity towards the S364A mutant. E2F -1 is also 
phosphorylated on the same site in vivo in response to DNA damage, illustrated 
by the observation that in etoposide treated MCF7 cells, the P-S364 antiserum 
clearly reacted with E2F-I, in contrast to E2F-l from non-stressed cells. Thus, 
Ser364 on E2F-I undergoes DNA damage-responsive phosphorylation in cells 
in a Chk2 dependent manner. 
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Figure 4.1. Identification of a Chk2 kinase phosphorylation site in E2F-t 
a) Comparison of the Chk2 phosphorylation sites in Cdc25A, Cdc25C, BRCA 1, 
PML and p53 with E2F-I. Residues in red form the consensus Chk2 kinase 
site. Residues that fall within the consensus Chk2 kinase site are in bold. 
b) Diagram of E2F-I together with relevant protein domains. The location of the 
Chk2 phosphorylation site is indicated between the marked box and 
activation/pocket protein (PP) binding domain. The serine residue (S364) that 
was mutated to alanine (A) is shown, the mutant derivative being referred to as 
S364A. CyA (cyclinA-binding domain). 
c) U20S cells were co-transfected with expression vectors for CMV -DP-I (lllg) 
and either HA-tagged E2F-I (5Ilg) or HA-tagged S364A (5Ilg). CMV-p-gal was 
also transfected to monitor transfection efficiency. Extracts were prepared from 
transfected cells and subjected to immunoblotting with aHA-specific 
monoclonal antibody. 
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Figure 4.2. Chk2 phosphorylates E2F-l in vitro 
a) Recombinant E2F-l and S364A (l J.lg) were resolved by denaturing gel 
electrophoresis and stained with coomassie blue. 
b) Recombinant E2F-l and S364A (lOOng) were resolved by denaturing gel 
electrophoresis and analysed by western blotting with an E2F-I specific antibody 
(KH-95). 
c) Recombinant Chk2 (O.2Ilg) was incubated with or without ATP in the presence or 
absence of recombinant E2F -1 (lllg) or S364A (lllg). The reaction products were 
resolved by denaturing gel electrophoresis and visualised by immunoblotting with 
an E2F-l specific antibody. The arrow indicates an E2F-l polypeptide species 
which is present only with the wild-type protein in the presence of ATP. 
d) Recombinant cyclinA/cdk2 (O.2Ilg) was incubated with or without ATP in the 
presence or absence of recombinant E2F -I (lllg) or S364A (lllg). The reaction 
products were resolved by denaturing gel electrophoresis and visualised by 
immunoblotting with an E2F-I specific antibody. The arrow indicates an E2F-I 
polypeptide species that was present only with the wild-type and S364A proteins, 
but only in the presence of A TP. 
e) Recombinant Chk2 (O.2Ilg) was incubated with or without 32p ATP in the 
presence or absence of recombinant E2F-I (Illg) or S364A (lllg). Recombinant 
Cdc25C was used as a positive control for phosphorylation by Chk2. The reaction 
products were resolved by denaturing gel electrophoresis and visualised by 
autoradiography. Phosphorylated E2F-I, auto-phosphorylated Chk2 and 
phosphorylated Cdc25C are indicated. 
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f) Recombinant cyclinAlcdk2 (O.2)lg) was incubated with or without 32p A TP in the 
presence or absence of recombinant E2F-l (l)lg) or S364A (l)lg). Recombinant 
pRb was used as positive control for cyclinAlcdk2 activity (not shown). The 
reaction products were resolved by denaturing gel electrophoresis and visualised 
by autoradiography. Phosphorylated E2F -1 and auto-phosphorylated Cdk2 arc 
indicated. 
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Figure 4.3. E2F-l is phosphorylated on Ser364 ill vitro 
a) Sequence of phospho-peptide derived from E2F-l used to prepare the phospho-
specific antiserum. Bold letters indicate the residues that fall into the consensus 
Chk phosphorylation site. 
b) Recombinant Chk2 (O.2Ilg) was incubated with recombinant E2F-I (lllg) in the 
presence or absence of ATP (50IlM). The reaction products were resolved by 
gel electrophoresis and immunoblotted with either KH95 (tracks 1 and 2) or P-
S364 (tracks 3 and 4). E2F-l is indicated, together with the increased 
specificity of P-S364 for Chk2 phosphorylated E2F -1. 
c) Recombinant E2F -lor S364A (lllg) was incubated with recombinant Chk2 
(O.2Ilg) in the presence or absence of ATP (50IlM). The upper blot was treated 
with affinity purified P-S364 antibodies, and the lower blot with the general 
E2F-l antibody KH-95. 
d) Recombinant E2F-l (lllg) was incubated with recombinant Chk2 (O.2Ilg) 
supplemented with ATP (50IlM), in the presence of either the phosphorylated or 
non-phosphorylated Ser364 peptide (lllg). The reaction products were resolved 
by denaturing gel electrophoresis and immunoblotted with P-S364 antibodies 
(top), or the general E2F-l antibody KH-95 (bottom). 
122 
a) 
b) 
361 P 374 
1 
E2F-1: - R-M -G- S -L-R-A-P-V- D-E - D- R 
ATP: 
WT E2F-1 
+Chk 2 
T 
P-S364 
ex E2F-1 a. P-S364 
....-----..... 1 ,r------, 
+ + 
t.=~--l '--__ ....JI ..... ® E2F-1 
1 2 3 4 
c) 
Chk2 + + + + 
ATP + + 
WT + + 
S364A + + 
P-S364 
E2F1 
1 2 3 4 
d) 
Chk2 + + 
ATP + + 
WT + + 
® -Peptide + 
Non ® -Peptide + 
G P-S364 
~ E2F1 
1 2 
Figure 4.4. E2F-l is phosphorylated on Ser364 in vivo 
a) Two peptides were generated based on the sequence around Ser364, one of 
which was chemically phosphorylated at Ser364. The crude antiserum was 
applied to the phosphorylated Ser364 peptide column, and the bound material 
passed over a second column containing non-phosphorylated peptide. The 
phospho-specific antibodies appeared in the flow-through (FT) of the second 
column. Shown is typical ELISA data derived from the antibodies in the FT 
(from the second column) against either the phosphorylated eX) or non-
phosphorylated e ) Ser364 peptide. Affinity purification and ELISA were 
carried out by Eurogentec. 
b) Recombinant Chk2 (O.2~g) was incubated with recombinant E2F -1 (1 ~g) or 
S364A (1~g), in the presence or absence of ATP (50~M) . For 
imrnunoprecipitation of E2F-l, reaction products were incubated with E2F-1 
antibody (KH-95) bound to protein A beads. Phosphorylation of E2F-l on 
Ser364 was monitored by immunoblotting with P-S364 (top). The level of input 
E2F-l protein is shown below. 
c) MCF7 cells were left untreated or exposed to etoposide (l O~M) and cell 
extracts were prepared 2 h later. Prior to immunoblotting, each lane on the 
membrane was split equally into two halves. Phosphorylation of endogenous 
E2F-l on Ser364 was monitored by imrnunoblotting with the phospho-specific 
antibody P-S364 (tracks 2 and 4). The amounts of extracts used have similar 
levels of total E2F-l as shown by immunoblotting with antibody KH95 (tracks 
1 and 3). 
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d) MCF7 cells were treated as described in a), and probed with either affinity 
purified P-S364 (top left) or the affinity-depleted antiserum containing 
antibodies against the non-phosphorylated epitope (aS364, top right) . 
Underneath each blot the level of E2F-l determined by immunoblotting with 
antibody KH-95 is shown. The E2F-l polypeptide is shown. 
e) MCF7 cells were treated as described in a). For immunoprecipitation of E2F-l, 
cell extract was incubated with anti-E2F-I antibody (KH-95) bound to protein 
A-beads. Phosphorylation of endogenous E2F-l on Ser364 was monitored by 
immunoblotting with the phospho-specific antibody P-S364 (upper panel) . The 
level of immunoprecipitated E2F-l is shown (middle panel) and input E2F-J 
protein is shown below (bottom panel). 
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Chapter 5. Regulation of E2F-1 stability 
5.1. Introduction 
Many proteins involved in cell cycle regulation are degraded at defined 
points in the cell cycle, for example cyclins and cdis. E2F -1 and E2F -4 are 
unstable proteins and their degradation is mediated by the ubiquitin-proteasome 
pathway (Hateboer et al., 1996; Hofinann et al., 1996; Campenero and 
Flemington, 1997). A domain in the C-tenninus of E2F-l and E2F-4 is 
responsible for their instability, and pocket protein binding masks the domain 
and stabilises both E2F-l and E2F-4 (Hateboer et al., 1996; Hofmann et al., 
1996; Campenero and Flemington, 1997). 
E2F -1 becomes ubiquitinated on binding to a component of the SCF 
ubiquitin-protein ligase p45SKP2 (Marti et al., 1999), and it has been suggested 
that disruption of this interaction by ATM mediated phosphorylation of E2F-1 
in response to DNA damage may account for the increase observed in E2F-1 
stability (Lin et al., 2001). Furthennore, E2F -1 and DP-1 levels are 
downregulated by the E3 ubiquitin ligase MDM2 (Loughran and La Thangue, 
2000), and p 19ARF targets certain E2F species, including E2F -1, for proteasomal 
degradation (Martelli et al., 2001). 
Data presented in the previous chapters revealed that stabilisation of E2F-
1 in response to DNA damage is regulated by both A TM and Chk2 kinases. In 
addition, E2F-1 is phosphorylated on Ser364 by Chk2 in vitro, and on the same 
site in vivo in response to DNA damage. In this chapter the S364A mutant 
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derivative ofE2F-l was studied to explore the role of Ser364 in the stabilisation 
ofE2F-l in response to DNA damage. 
Results 
5.2. The Chk2 phosphorylation site in E2F-1 is required 
for DNA damage induction 
E2F-l is stabilised in response to etoposide treatment (Figure 3.3a). To 
explore whether Ser364 in E2F-I is important for DNA damage induction, the 
level of exogenous HA-tagged E2F-l and S364A were compared in MCF7 
cells. Under similar conditions of etoposide treatment, western blot analysis 
with a HA-specific antibody revealed that the temporal accumulation of S364A 
was about three or four times less than wild-type E2F -1 at 6 h (Figure 5.1, lane 
3, compare top and bottom). Some accumulation of the S364A mutant was 
observed, possibly reflecting the activities of ATM, which has been shown 
recently to regulate E2F -1 stability through Ser31 phosphorylation (Lin et al., 
2001). This result suggests that Ser364 is an important site, involved in the 
control ofE2F-l stability in response to DNA damage. 
5.3. Chk2 regulates E2F-1 stability 
One possibility to explain the results on the regulation of E2F-I by 
Chk2, was that Chk2 controls E2F-l abundance through protein stability. To 
test this idea, the overall protein synthesis of cells was blocked by addition of 
cycloheximide, and the degradation of exogenous HA-E2F-I or S364A was 
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monitored by western blot analysis with a HA-specific antibody in etoposide 
treated and non-treated cells. Whilst E2F-1 and the S364A mutant were similar 
in the absence of etoposide (compare figure S.2a, lane 3, top with figure S.2b, 
lane 3, top), E2F-1 was significantly more stable than the S364A mutant in the 
presence of etoposide (compare figure S.2a, lane 3, upper bottom with figure 
S.2b, lane 3, upper bottom). Based on several different experiments, in the 
presence of etoposide E2F-I persisted in cells for longer than the S364A 
mutant. As an internal control, PCNA was studied which was not affected by 
etoposide treatment. 
5.4. E2F·1 interacts with Chk2 kinase in vitro and in vivo 
Chk2 interacts physically with some of its substrates, for example pS3, 
PML and BRCAI (Falck et ai., 2001b; Yang et ai., 2002; Lee et at., 2000). In 
the previous chapter it was shown that Chk2 phosphorylates E2F-1 in vitro and 
in vivo in response to DNA damage. In order to investigate whether Chk2 
physically interacts with E2F-I, in vitro binding experiments were performed 
using purified GST-E2F-I and S364A proteins with 35S-labelled in vitro 
transcribed and translated (NT) Chk2. Chk2 interacted with GST-E2F-I and 
S364A with similar efficiency (Figure 5.3a, compare lanes 3 and 4, top), but not 
with a GST alone control (Figure S.3a, lane 2, top). The binding efficiency was 
compared to (5 %) Chk2 input (Figure S.3a, lane 1, top). These results confirm 
that Chk2 and E2F-I efficiently form a complex in vitro, and suggest that 
Ser364 is unlikely to reside within the region that binds to Chk2. Whilst the in 
vitro binding assay shows that the interaction is direct, it does not discriminate 
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between the binding efficiency of E2F-I and S364A with Chk2. Therefore, an 
immunoprecipitation assay was performed to determine whether E2F -1 and 
S364A have different affinities for Chk2. MCF7 cells were transiently 
transfected with either HA-tagged E2F-I or S364A. The levels of E2F-I and 
S364A proteins were equal in extracts from these cells as confirmed by western 
blotting (Figure 5.3b, compare lanes 2 and 3, bottom). The extracts were 
immunoprecipitated with an anti HA-monoc1onal antibody, followed by 
immunoblotting with an anti Chk2 polyc1onal antibody to assess whether E2F-l 
or S364A formed a complex with endogenous Chk2. As control, non-
transfected extract was precipitated with HA-monoc1onal antibody. Consistent 
with the in vitro data, both E2F-l and S364A co-immunoprecipitated Chk2 with 
equal efficiency (Figure 5.3b, compare lanes 5 and 6, top). Therefore, Ser364 is 
unlikely to regulate the ability ofE2F-l to interact with Chk2. 
It does not always follow that an interaction that occurs readily in vitro, 
or in over-expression studies will also occur under physiological conditions. In 
order to explore whether Chk2 and E2F-l interact in cells, endogenous co-
immunoprecipitation experiments were performed. Extracts from MCF7 cells 
were immunoprecipitated with an anti-E2F-l antibody, followed by 
immunoblotting with an anti-Chk2 antibody to assess whether endogenous E2F-
1 and Chk2 formed a complex. As control, precipitating antibody was omitted, 
or a non-specific antibody was used. The levels of E2F-l and Chk2 proteins 
were equal in extracts from these cells as confirmed by western blotting (Figure 
5.3c, compare lanes 1-3, top and bottom). Consistent with the in vitro and over-
expression data, Chk2 and E2F-l readily interact in cells, as Chk2 was present 
in E2F-l immunoprecipitates (Figure 5.3c, lane 7, top). To investigate whether 
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the interaction is regulated in response to DNA damage, the same 
immunoprecipitation was performed using etoposide treated MCF7 cell extract. 
As expected, the level of E2F-l protein was significantly increased in response 
to etoposide treatment (Figure 5.3c, compare lanes 3 and 4, bottom). In contrast 
Chk2 protein levels were unaffected (Figure 5.3c, compare lanes 3 and 4, top). 
The amount of E2F-l immunoprecipitated increased in response to etoposide 
treatment (Figure 5.3c, compare lanes 7 and 8, bottom) as did the amount of co-
immunoprecipitated Chk2 (Figure 5.3c, compare lanes 7 and 8, top). These 
results confirm that Chk2 and E2F-l can interact under physiological 
conditions, and suggest that DNA damage is not essential for complex 
formation. 
5.5. Mutation of E2F-1 to 5364A does not affect binding to 
pRb 
pRb has been shown to regulate the stability of E2F-l by preventing its 
degradation by the ubiquitin-proteasome pathway (Hateboer et at., 1996; 
Hofmann et ai., 1996; Campenero and Flemington, 1997). It is possible that this 
function of pRb may be regulated, for instance in response to DNA damage. In 
order to investigate whether E2F-l and S364A have different affinities for pRb, 
in vitro binding experiments were performed using purified GST-E2F-l and 
S364A proteins with 35S-labelled IVT pRb. pRb interacted with GST -E2F-l 
and S364A with similar efficiency (Figure 5.4a, compare lanes 3 and 4, top), but 
not with a GST alone control (Figure 5.4a, lane 2, top). The binding efficiency 
was compared to (5 %) pRb input (Figure 5.4a, lane 1, top). As expected, these 
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results confinn that pRb and E2F-l efficiently fonn a complex in vitro, and 
suggest that substitution of Ser364 with alanine does not affect binding to pRb. 
In an attempt to discriminate between the binding efficiency of E2F -1 and 
S364A with pRb, an immunoprecipitation assay was perfonned. T98G cells 
were transiently transfected with either HA-tagged E2F-l or S364A. The levels 
of E2F-l and S364A proteins were equal in extracts from these cells as 
confinned by western blotting (Figure 5.4b, compare lanes 2 and 3, bottom). 
The extracts were immunoprecipitated with an anti HA-monoclonal antibody, 
followed by immunoblotting with an anti pRb monoclonal antibody to assess 
whether E2F-l or S364A fonned a complex with endogenous pRb. As control, 
non-transfected extract was precipitated with HA-monoc1onal antibody. 
Consistent with the in vitro data, both E2F-l and S364A co-immunoprecipitated 
pRb (Figure 5.4b, compare lanes 5 and 6, top and bottom). To investigate 
whether the interaction is regulated in response to DNA damage, endogenous 
co-immunoprecipitation experiments were perfonned using etoposide treated or 
non-stressed T98G cell extract. As expected, the level of E2F-I protein was 
significantly increased in response to etoposide treatment (Figure 5.4c, compare 
lane 2 and 3, bottom). In contrast pRb protein levels were unaffected (Figure 
5.4c, compare lane 2 and 3, top). The amount of E2F-l immunoprecipitated 
increased in response to etoposide treatment (Figure 5.4c, compare lanes 5 and 
6, bottom) as did the amount of co-immunoprecipitated pRb (Figure 5.4c, 
compare lanes 5 and 6, top). Taken together, these results suggest that pRb 
binds to both E2F-l and S364A, and under DNA damage conditions, induced 
E2F-I in the cell is in complex with pRb. 
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5.6. Conclusions 
The prevIOus chapters established that the increase in E2F-l 
accumulation observed in response to DNA damage is dependent on active 
Chk2, and that Chk2 phosphorylates Ser364 on E2F-l in response to DNA 
damage. Work in this chapter has combined these two aspects to show that 
phosphorylation of Ser364 is required for stabilisation of E2F -1 in response to 
DNA damage. 
Evidence was presented that Chk2 and E2F-I are capable of forming a 
complex, and the interaction is likely to be direct as determined in vitro. 
Furthermore, Chk2 and E2F-l interact 10 cells, signifying a potential 
physiological role for Chk2 in the regulation of E2F-l. These results suggest 
that Chk2 may regulate E2F-l via two distinct mechanisms, by phosphorylating 
Ser364, and through their physical association. 
In normal cells E2F activity is tightly regulated during the cell cycle 
through the temporal association and release of pocket proteins, and the binding 
of pRb to a domain of E2F-l and E2F-4 has been shown to prevent their 
degradation by the ubiquitin-proteasome pathway. The possibility that pRb is 
involved in the stabilisation of E2F-l in response to DNA damage, and that it 
may be mediated via Ser364 was also investigated. The results show that E2F-l 
and S364A interact with pRb in vitro and in cells, and suggest that substitution 
of Ser364 with alanine does not affect the pRb-E2F-l interaction. In addition, 
the amount of endogenous E2F-l and pRb immunoprecipitated from cells 
increased in response to etoposide treatment. This suggests that induced E2F-l 
in the cell is in complex with pRb, and likely reflects the hypo-phosphorylation 
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of pRb that has been observed in response to DNA damage (Amell em et af., 
1996; Krtolica et af., 1998). 
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Figure 5.1. Dependence on Ser364 for E2F-l accumulation 
a) MCF7 cells were transfected with 500ng HA-E2F-l or HA-S364A along with 
CMV -p-gal (500ng) to monitor transfection efficiency, and then treated with 
etoposide (l O~M) for the indicated time. Extracts were resolved by denaturing 
gel electrophoresis and HA-tagged E2F proteins were detected by 
immunoblotting with an HA-specific antibody. Quantification was carried out 
on a standard personal computer using Total-lab V1.11 (Phoretix) 
densitometery software. 
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Figure 5.2. Chk2 regulates E2F-l stability 
a) and b) U20S cells were transfected with HA-E2F-I (a) or HA-S364A (b) along 
with CMV-DPl, and treated with or without etoposide (lOIlM) for 4 h as 
indicated. Cycloheximide (50llg) was then added and extracts prepared and 
resolved for HA-tagged E2F-I or HA-S364A at the indicated times by 
immunoblotting. The level of PCNA is shown underneath each treatment. To 
facilitate the analysis of E2F-I stability, the exposure time of wild-type E2F-l 
in the presence of etoposide was reduced such that each immunoblot was of 
similar intensity. Quantification was carried out on a standard personal 
computer using Total-lab VI.II (Phoretix) densitometery software. 
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Figure 5.3. E2F-l interacts with Chk2 in vitro and in vivo 
a) In vitro translated Chk2 was incubated with glutathione beads bound to GST 
alone, GST-E2F-l or GST-S364A. After extensive washing of the beads, 
proteins were released by addition of Ix SDS loading buffer and resolved by 
denaturing gel electrophoresis. Proteins were visualised by autoradiography. 
b) MCF7 cells were transiently transfected with HA-E2F-I (5f.lg) or HA-S364A 
(5f.lg) in combination with CMV-DP-l (If.lg). As a control cells were left 
untransfected. For immunoprecipitation of exogenous E2F-I, cell extract was 
incubated with anti-HA-ll antibody bound to protein A beads. The 
immunoprecipitate was resolved by denaturing gel electrophoresis and 
subsequently immunoblotted with anti-Chk2, or anti-E2F-l antibodies. 
c) Extracts from asynchronously growing MCF7 cells were immunoprecipitated 
with anti-E2F-I antibody after the presence (+) or absence (-) of etoposide 
treatment. The immunoprecipitate was resolved by denaturing gel 
electrophoresis and subsequently immunoblotted with an anti-Chk2 (lanes 5-8, 
upper panel), and anti-E2F -1 antibody (lanes 5-8, lower panel). Lanes 1-4 show 
the input (5%) reactivity of the anti-E2F-I (lower panel) and anti-Chk2 (upper 
panel) antibodies with the crude MCF7 extract. 
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Figure 5.4. Ser364 does not regulate binding to pRb 
a) In vitro translated pRb was incubated with glutathione beads bound to GST 
alone, GST-E2F-I or GST-S364A. After extensive washing of the beads 
proteins were released by addition of I x SDS loading buffer and resolved by 
denaturing gel electrophoresis. Proteins were visualised by autoradiography. 
b) T98G cells were transiently transfected with HA-E2F-I (5Ilg) or HA-S364A 
(5Ilg) in combination with CMV-DP-I (Illg). As a control cells were left 
untransfected. For immunoprecipitation of exogenous E2F-I, cell extract was 
incubated with anti-HA-ll antibody bound to protein A beads. The 
immunoprecipitate was resolved by denaturing gel electrophoresis and 
subsequently immunoblotted with anti-pRb, or anti-E2F-I antibodies. 
c) Extracts from asynchronously growing T98G cells were immunoprecipitated 
with anti-E2F-I antibody after the presence (+) or absence (-) of etoposide 
treatment. The immunoprecipitate was resolved by denaturing gel 
electrophoresis and subsequently immunoblotted with an anti-pRb (lanes 4-6, 
upper panel), and anti E2F-l (lanes 4-6, lower panel) antibodies. Tracks 1-3 
show the input (5%) reactivity of the anti-E2F-l (lower panel) and anti-pRb 
(upper panel) antibodies with the crude T98G extract. 
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Chapter 6. Regulation of E2F-1 activity by 
Chk2 
6.1. Introduction 
E2F-l is a transcription factor that controls cell cycle progression by 
binding to DNA and regulating the expression of genes involved in the G lIS-
phase transition. It has been shown recently that there is an increase in the 
DNA-binding activity of E2F-l in response to DNA damage (Hofferer et al., 
1999), suggesting that DNA damage may induce changes in gene expression 
profiles. In addition to its role in proliferation, E2F -1 is able to stimulate 
apoptosis, and thus possesses the properties of both an oncogene and tumour 
suppressor. E2F-l can trigger apoptosis through both p53-dependent and 
independent pathways, and although transcription-independent functions of 
E2F-I have been ascribed to apoptosis (Hsieh et al., 1997; Phillips et ai., 1997; 
Phillips et al., 1999), a number of genes involved in apoptosis are regulated at 
the transcriptional level by E2F-l (Bates et al., 1998; Moroni et al., 2001; Irwin 
et al., 2000; Stiewe et al., 2001). Interestingly, it has also been reported that 
DNA damage induced E2F-l is transcriptionally inactive (O'Connor et al., 
2000). In this chapter the functional consequence of phosphorylation of the 
Ser364 site in E2F-l with respect to DNA-binding, transcriptional activation, 
and apoptosis are explored. 
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Results 
6.2. Mutation of E2F-1 to S364A does not affect 
heterodimer formation or DNA-binding 
The E2F family of proteins bind to DNA and regulate the transcription 
of target genes as part of an active heterodimer with a member of the DP family 
(Bandara et al., 1993). To determine the functional consequences of E2F-l 
phosphorylation at Ser364, the mutant derivative S364A was assessed in its 
ability to bind to DNA in association with DP-I. First, the ability of E2F-l or 
S364A to dimerise with DP-l, and thus have the ability to efficiently bind DNA 
was tested. In vitro binding assays using purified GST -tagged E2F-l proteins 
and 35S-labelled NT DP-l revealed no difference between E2F-l and S364A in 
their ability to bind to and form heterodimers with DP-l (Figure 6.1 a, compare 
lanes 3 and 4, top). 
Next the DNA binding properties of GST-E2F-l and S364A were 
examined in vitro. Gel retardation analysis using an E2A probe that contains 
E2F binding sites revealed that E2F-l or S364A in combination with IVT DP-l 
had a similar level of DNA-binding activity (Figure 6.1 b, compare lanes 1-4 and 
5-8). 
Finally U20S cells were left untransfected as control, or were 
transfected with HA-E2F-l or S364A, in combination with DP-l. Gel 
retardation analysis with the E2A probe revealed that extracts from cells 
transfected with E2F-l or S364A had a similar level of DNA-binding activity 
(Figure 6.lc, compare lanes 2 and 5). It has been reported that E2F-I DNA 
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binding activity increases in response to IR (Hofferer et al., 1999). However, 
when cells were DNA damaged by the addition of etoposide, E2F-l and S364A 
exhibited a similar level of DNA binding that was unchanged from non-stressed 
cells (Figure 6.1 c, compare lanes 8 and 11). Specificity was confirmed by 
shifting E2A bound complexes with E2F-l (Figure 6.1c, lanes 3, 6, 9, and 12) or 
DP-l antibodies (Figure 6.1c, lanes 4, 7, 10 and 13). The results suggest that 
substitution of Ser364 with alanine does not affect the ability of E2F -1 to 
heterodimerise with DP-l or bind to DNA. 
6.3. S364A has a compromised transcriptional activity 
The functional importance of the Ser364 site for E2F-l dependent 
transcription was assessed by comparing the properties ofE2F-l and S364A on 
E2F-responsive promoters. For this, several promoters were employed 
including the cyclinE, ARF and Apaf-l promoters, which are directly 
responsive to E2F -1 (Botz et al., 1996, Bates et al., 1998., Moroni et al., 2001). 
U20S cells were transiently transfected with a cyclinE-luciferase reporter gene 
and expression vectors for E2F-l or S364A in combination with DP-l. 
Consistent with reports that E2F and DP bind synergistically to the E2F site in 
target genes (Dyson, 1998), transfection of DP-l in the absence of E2F-l 
resulted in an insignificant stimulation of reporter activity (Figure 6.2a, lane 2). 
Co-transfection of E2F-l with DP-l resulted in a significant induction of 
reporter assay activity (Figure 6.2a, lane 3), and titration of E2F-l in the 
presence of a constant amount of DP-l induced reporter activity in a dose-
dependent manner (Figure 6.2a, lanes 3-6). Co-transfection of S364A with DP-l 
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revealed that the activity of S364A was significantly lower than E2F-l (Figure 
6.2a, lanes 7-10), even though the protein levels of S364A and E2F -1 were 
similar (Figure 6.2a, bottom panel). These observations imply that S364A has a 
compromised transcriptional activity. 
It has been demonstrated that the p19ARF promoter is sensitive to E2F-l 
over-expression (Bates et ai., 1998), therefore a p 19ARF -luciferase reporter that 
consists of the exonll3 promoter region, which contains four potential E2F 
consensus sites was employed (Bates et ai., 1998). Consistent with the results 
using the cyclinE-luciferase reporter gene, U20S cells transfected with exon 113-
luciferase and E2F-l or S364A in combination with DP-l revealed that the 
activity of the S364A mutant was compromised compared to E2F-l (Figure 
6.2b compare lanes 3-6 with 7-10). In order to see whether an increase in E2F-l 
transcriptional activity could be observed in response to DNA damage, U20S 
cells were transfected as before and treated with etoposide for 16 h prior to 
harvesting. No increase in either E2F-l or S364A activity was observed in 
response to etoposide treatment (Figure 6.2b, lanes 11-14 and 15-18). 
Conversely, there was a decrease in the level ofE2F-dependent transcription. 
Recent studies have identified the gene for the apoptosis promoting 
factor Apaf-l as a transcriptional target of E2F-l (Moroni et ai., 2001). The 
Apaf-l promoter can be activated by both E2F-l and p53 (Moroni et al., 2001), 
therefore an Apaf-l reporter construct (-396/+208), which contains only E2F 
responsive elements was used to rule out any contribution from endogenous p53 
(Moroni et ai., 2001). In U20S cells, transiently transfected with Apaf-l (-
396/+208)-luciferase and E2F-l or S364A in combination with DP-l, once 
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again the activity of the S364A mutant was compromised compared to E2F-l 
(Figure 6.2c, compare lanes 3-6 and 7-10). 
It has been reported that Chk2 IS required for p53-dependent 
transcription in mouse cells (Takai et al., 2002), and Chk2 dominant-negative 
can down-regulate both p53 and E2F-l at the protein level in response to 
etoposide treatment (Figure 3.5a). Therefore, a Chk2 dominant-negative mutant 
(Asp34 7 Ala) was employed to assess if Chk2 could influence the ability of 
E2F-l to transactivate the Apaf-l promoter. U20S cells were transfected with 
Apaf-l (-396/+208)-luciferase and fixed amounts of E2F-I in combination with 
DP-l. Titration of Chk2 dominant-negative in the presence of E2F -1 and DP-I 
yielded no change in transcriptional activation of the Apaf-I-Iuciferase reporter 
gene (Figure 6.2d, lanes 4-6). Data presented previously showed that expression 
of Chk2 dominant-negative in the absence of etoposide treatment had no effect 
on E2F-l protein levels, however in the presence of etoposide treatment a 
significant down-regulation of E2F-l protein was observed (Figure 3.5a). 
Therefore, U20S cells transfected as described before were treated for 6 h with 
etoposide prior to harvesting. No change in E2F-l dependent transcription was 
observed when Chk2 dominant-negative was over-expressed in the presence of 
etoposide treatment (Figure 6.2d, lanes 10-12). 
In a manner similar to the previous experiment, U20S cells were 
transiently transfected with Apaf-l(-396/+208)-luciferase and fixed amounts of 
E2F-l in combination with DP-l. Titration of Chk2 wild-type in the presence of 
E2F-l and DP-l yielded no change in the transcriptional activation of the Apaf-
1-luciferase reporter gene (Figure 6.2e, lanes 4-6). Exogenous Chk2 is Thr68 
phosphorylated and activated after 6 h of etoposide treatment (Figure 3.5d), 
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however no effect on E2F-l transcriptional activity was observed when Chk2 
wild-type was over-expressed under similar conditions of etoposide treatment 
(Figure 6.2e lanes 10-12). 
These results suggest that Ser364 is a functionally important site that 
contributes to the ability of E2F-l to activate transcription, however no direct 
effect of Chk2 on E2F -1 dependent transcription was observed. 
6.4. Chk2 regulates E2F-1-dependent apoptosis 
Over-expression of E2F -1 can induce apoptosis (Degregori et al., 1997; 
Loughran and La Thangue, 2000). If Chk2 is involved in regulating E2F-l-
dependent apoptosis, then dominant-negative Chk2 should interfere with E2F-l 
apoptotic activity. Evidence for a role for Chk2 in the control of E2F-l activity 
came from comparing E2F -1 to S364A, where in U20S cells apoptosis induced 
by E2F-l was considerably greater than observed with S364A (Figure 6.3a). 
Moreover, whilst the co-expression of the Chk2 dominant-negative with E2F-l 
reduced the level of apoptosis, this was not apparent with apoptosis induced by 
S364A (Figure 6.3a). 
In order to rule out a contribution to apoptotic activity from p53, 
apoptosis in SAOS2 cells (P53-/) was investigated. As in U20S cells, E2F-l 
possessed greater apoptotic activity than S364A, and co-expression of the Chk2 
dominant-negative reduced the apoptotic activity of E2F -1, but failed to 
significantly affect the activity of S364A (Figure 6.3b). These results support 
the notion that Chk2 regulates E2F-l-dependent apoptosis in response to DNA 
damage. 
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6.5. Induction of E2F-1 correlates with the induction of 
genes involved in apoptosis 
E2F-l can induce apoptosis independently ofp53, and E2F-I responsive 
genes involved in apoptosis include p73, Apaf-l and ARF (Irwin et al., 2000; 
Moroni et al., 200 1; Bates et al., 1999). To investigate the mechanism through 
which E2F-l induces apoptosis in response to DNA damage, SAOS2 cells (p53-
1-) were stimulated to enter apoptosis by treatment with etoposide. Western blot 
analysis of cell extracts revealed that the induction of endogenous E2F-l 
correlated well with the induction of Apaf-l, p73 and ARF (Figure 6.4a, b, and 
c). These results support a role, independent of p53, for E2F-l in etoposide-
induced apoptosis via the transcriptional activation of E2F-l target genes such 
as p73, Apaf-l and ARF. 
6.6. Conclusions 
E2F-l must form a heterodimer with DP-l to efficiently bind DNA and 
activate, or repress transcription of E2F target genes (Dyson, 1998). To gain 
insight into the functional consequence of E2F-I phosphorylation by Chk2, 
DNA-binding activity was examined. In vitro binding assays showed that 
mutation ofSer364 to alanine has no significant effect on the ability ofE2F-1 to 
dimerise with DP-I or bind to DNA. Moreover, transfection based experiments 
revealed no difference in E2F-l or S364A DNA-binding activity in cells under 
non-stress or stress conditions. 
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Transcription based assays using various reporter genes established that 
Ser364 is an important site for E2F-I-dependent transcription. The activity of 
the S364A mutant derivative was reproducibly lower than E2F-l under non-
stress conditions. Treatment of cells with etoposide failed to stimulate E2F -lor 
S364A transcriptional activity, therefore the compromised S364A activity may 
be due to altered binding to a cellular co-factor, such as p300/CBP which has 
been previously shown to co-activate E2F-I transcription (Trouche et al., 1996). 
Finally, over-expression of Chk2 or a Chk2 dominant-negative derivative was 
unable to significantly alter E2F-I transcriptional activity, even when cells were 
stressed by treatment with etoposide. 
E2F-I can induce apoptosis independently ofp53. In SAOS2 cells (P53-1-), 
it was shown that S364A has a compromised ability to induce apoptosis, 
suggesting that phosphorylation by Chk2 may regulate E2F-I dependent 
apoptosis through the Ser364 site. Further evidence in support of this idea came 
from the observation that Chk2 dominant-negative can overcome E2F-I but not 
S364A mediated apoptosis. 
The observed effects on apoptosis were linked to E2F-I-dependent 
transcription. In SAOS2 cells stimulated to enter apoptosis, the induction of 
endogenous E2F -1 correlated well with the induction of proteins encoded by 
E2F responsive genes involved in apoptosis, such as Apaf-l, p73 and ARF. 
Data presented in this chapter support a role, independently of p53, for 
Chk2 in the regulation ofE2F-I-dependent apoptosis through a transcription-
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based mechanism. 
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Figure 6.1. E2F-l DNA-binding activity 
a) In vitro translated DP-l was incubated with glutathione beads bound to GST 
alone (1~g), GST-E2F-l (1~g) or GST-S364A (1~g). After extensive washing 
of the beads, bound proteins were released by addition of 1 xSDS loading buffer 
and resolved by gel electrophoresis. Proteins were visualised by 
autoradiography. 
b) Gel retardation analysis of a mixture of recombinant E2F-l (0.25, 0.5, 1, or 
2~g) or S364A (0.25, 0.5, 1, or 2~g), with in vitro translated DP-l (1 ~g). 
Complexes bound to 32p labelled DNA were visualised by autoradiography. 
c) Gel retardation analysis of extracts from U20S cells either untransfected or 
transfected with expression vectors for HA-tagged E2F-lor HA-tagged S364A 
(5~g) and CMV-DP-l (1~g) as indicated. Cells were left untreated as control or 
treated with lO~M etoposide for 6 h. Positions of the free E2F -IIDP-l 
heterodimer, E2F-IIDP-lIpRb complex and the E2F-IIDP-1/pRb complex 
shifted with antibodies specific to E2F-l or DP-l are indicated. Complexes 
bound to 32p labelled DNA were visualised by autoradiography. 
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Figure 6.2. Ser364 regulates E2F-l transcriptional activity 
a) U20S cells were transfected with expression vectors for HA-E2F-I or HA-
S364A (100, 250, 500ng or Illg) together with CMV-DP-I (lllg), cyc1inE-
luciferase (illg) and the internal control CMV-p-gal (500ng). After 48 h cells 
were harvested and the indicated data derived from triplicate readings. The 
levels of the exogenous E2F-l and S364A protein levels determined by 
immunoblotting with a HA-specific antibody are shown. 
b) U20S cells were transfected with expression vectors for HA-E2F-I or HA-
S364A (100, 250, 500ng or lllg) together with CMV-DP-l (lllg), exonl-p-
luciferase (1Ilg) and the internal control CMV-p-gal (500ng). After 30 h cells 
were treated with etoposide as indicated for a further 16 h before being 
harvested and the indicated data derived from duplicate readings. 
c) d) and e) U20S cells were transfected with expression vectors for HA-E2F-l or 
HA-S364A (l00, 250, 500ng or Illg) together with CMV-DP-l (1Ilg), Apaf-
luciferase (-396/+208) (1Ilg), the internal control CMV-p-gal (500ng), and 
Chk2 dominant-negative (1,3, and 51lg; d) or Chk2 wild-type (1, 3, and 5f.lg; e). 
After 36 h cells were treated with etoposide as indicated for a further 6 h before 
being harvested and the indicated data derived from duplicate readings. 
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Figure 6.3. Apoptosis and cell cycle arrest through E2F-l requires Chk2 
a) U20S cells were transfected with vector for E2F-I (5Jlg) or S364A (5Jlg) and 
DP-I (5Jlg), together with dominant-negative Chk2 (lOJlg) as indicated, and 
treated as described above. The graph shows the percentage cells in the 
apoptosing (sub-G 1 DNA content) population with respect to the vector alone 
treatment without etoposide (sub-G 1 14.1 %). 
b) SOAS2 (P53-/) cells were transfected with vectors for E2F-l (300ng) or S364A 
(300ng) and DP-l (300ng) and together with dominant-negative Chk2 (lOJlg) 
treated as described with etoposide (20JlM) for 6 h. The graph shows the 
percentage cells in the apoptosing (sub-G 1 DNA content) population with 
respect to the vector alone treatment without etoposide (sub-Gl 16.7%). 
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Figure 6.4. Pathways to E2F-l mediated apoptosis 
a) SAOS2 (P53 olo) cells were treated with etoposide (lO~M) for 0, 8, and 16 ho 
Extracts were prepared and immunoblotted for endogenous Apaf-l (top), E2F-l 
(middle) and peNA (bottom). 
b) SAOS2 (P53olo) cells were treated with etoposide (lO~M) for 0, 8, and 16 h. 
Extracts were prepared and immunoblotted for endogenous p73 (top), E2F-l 
(middle) and peNA (bottom). 
c) SAOS2 (P53olo ) cells were treated with etoposide (lO~M) for 0, 8, and 16 h. 
Extracts were prepared and immunoblotted for endogenous ARF (top), E2F-l 
(middle) and peNA (bottom). 
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Chapter 7. Cellular localisation of E2F-1 
7.1 Introduction 
Previous work has demonstrated that the activity of certain E2F family 
members, namely E2F-4 and E2F-5 are controlled via cellular localisation (de la 
luna et al., 1996; Lindeman et al., 1997; Magae et al., 1996). Whereas E2Fs 1-3 
possess an intrinsic NLS, E2F-4 and 5 do not, and instead have a NES (Gaubatz 
et al., 2001). They can however be imported into the nucleus in association with 
a bound pocket protein or appropriate DP family member (Allen et al., 1997; 
Verona et al., 1997). 
In mammalian cells, indirect immunofluoresence analyses have shown 
that many proteins that play key roles in the DNA damage response become 
physically localised to sites of DNA damage. They are often observed as 
brightly staining spots or "foci" within the cell nucleus. Such proteins include 
ATR, the MrellIRad50lNbsl complex, BRCAl, 53BPl and the activated form 
of Chk2 (Rouse and Jackson, 2002). In addition PML protein localises to PML 
bodies along with proteins such as p53 and pRb (Zhong et al., 2000). 
It has been shown previously that E2F-l possesses an inherent nuclear 
localisation signal and that both endogenous, and exogenous E2F-l are nuclear 
in localisation (Magae et al., 1996; Allen et al., 1997; Lindeman et al., 1997). 
The phosphorylation status of a protein can control its cellular localisation, for 
example export ofCdc25C from the nucleus by 14-3-3 proteins is dependent on 
the phosphorylation of Cdc25C by Chk kinases (Peng et al., 1997). It was 
possible that phosphorylation of E2F-l by Chk2, or the physical association of 
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E2F-l with Chk2 could affect its ability to localise to the nucleus. The 
objectives of this chapter were to investigate whether Chk2 regulates E2F-I 
activity by influencing its cellular localisation. 
Results 
7.2. Endogenous E2F-1 is a nuclear protein 
First, the cellular location and staining pattern of endogenous E2F -1 was 
detennined using the general E2F-l antibody KH-95. As shown in (Figure 7.1a) 
E2F-l is exclusively nuclear, exhibiting diffuse but even staining. To explore 
whether endogenous E2F-l would be affected by DNA damage, MCF7 cells 
were treated with etoposide or UV -irradiation (which are believed to activate 
different arms of the signalling pathway), and the cellular distribution 
detennined by indirect immunofluoresence using the KH-95 antibody. No 
significant change in distribution of the protein, or in its intensity of staining 
was observed with either treatment (Figure 7.1 b and c). 
7.3. S364A is a nuclear protein 
Next the cellular distribution of HA-tagged verSIOns of E2F -1 and 
S364A were compared. HA-tagged E2F-l and S364A were expressed in U20S 
cells by transient transfection and their cellular distribution detennined by 
indirect immunofluoresence. In MCF7 cells E2F-I and S364A proteins 
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exhibited nuclear only staining with an HA-specific antibody (Fig. 7.2a and 
7.3a). 
To explore whether HA-E2F-l or S364A would be affected by DNA 
damage, transiently transfected MCF7 cells were treated with UV -irradiation or 
etoposide prior to immunostaining. No change in the cellular localisation or 
staining intensity of E2F-l or S364A was observed in response to UV treatment 
(Fig. 7.2b and 7.3b), or etoposide treatment (Fig. 7.2c and 7 .3c). 
Therefore the S364A mutant derivative did not differ from E2F-l in its 
cellular localisation in the absence or presence of DNA damage, suggesting that 
phosphorylation ofE2F-l on Ser364 does not affect its cellular localisation. 
7.4. E2F-1 is unaffected by co-expression of Chk2 
Data presented in chapter 5 revealed that Chk2 can fonn a complex with 
E2F-l in vitro and in vivo. It remained possible that Chk2 could regulate the 
intracellular localisation of E2F-l through their direct binding. To explore this 
possibility U20S cells were co-transfected with HA-E2F-l and Flag-Chk2. As 
expected Chk2 is a nuclear protein and exhibited diffuse staining throughout the 
nucleus with a general Chk2 antibody (Figure 7.4 d). U20S cells have low 
levels of endogenous Chk2 (Chehab et al., 2000), therefore cells transfected 
with Flag-Chk2 were easily distinguishable with the Chk2 antibody (Figure 7.4, 
compare d with g). In cells that co-expressed E2F-l and Chk2, no change in 
E2F-l intensity or cellular localisation was observed (compare figures 7.2a and 
7.4a). Since Chk2 is activated in response to DNA damage in an ATM-
dependent manner (Matsuoka et al., 1998), it was possible that Chk2 would 
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modulate E2F-l localisation only under DNA damage conditions. To explore 
this idea, U20S cells co-transfected with HA-E2F-I and Flag-Chk2 were 
treated with UV -irradiation or etoposide prior to immunostaining. Under these 
conditions there was no obvious change in the intensity or cellular localisation 
of either E2F-l (Figure 7.4, b and c) or Chk2 (Figure 7.4, e and f). 
To explore whether Chk2 dominant-negative could regulate E2F-I 
through altered cellular localisation, U20S cells were co-transfected with HA-
E2F-l and Flag-Chk2 dominant-negative. As expected Chk2 dominant-negative 
exhibited diffuse staining throughout the nucleus with a general Chk2 antibody 
(Figure 7.5, d). Similar to the results observed with Chk2, co-expression of 
Chk2 dominant-negative had no effect on E2F-l intensity, or cellular 
localisation (compare figures 7.2a and 7.5a). 
Since Chk2 dominant-negative can block the induction of endogenous 
E2F-I only when cells are exposed to etoposide treatment, it was possible that it 
would modulate E2F-l localisation only under DNA damage conditions. To test 
this idea U20S cells over-expressing HA-E2F-l in combination with Flag-Chk2 
dominant-negative were treated with UV -irradiation or etoposide prior to 
immunostaining. Under these conditions, there was no obvious change in the 
intensity or cellular localisation of either E2F-l (Figure 7.5, b and c) or Chk2 
dominant-negative (Figure 7.5, e and f). Therefore, Chk2 does not regulate the 
intracellular localisation of E2F-l. 
172 
7.5. E2F-1 phosphorylated on Ser364 resides in discrete 
nuclear structures 
Some proteins, such as Chk2, that exhibit a diffuse nuclear staining with a 
general antibody, localise to discrete nuclear foci when activated and detected 
using a phosphorylation-specific antibody (Zhou and Elledge, 2000; Ward et al., 
2000). To study the location of E2F-l protein phosphorylated on Ser364, the 
affinity purified P-S364 antibodies were used. In nonnal cells immunostaining 
with the affinity purified antibody produced a low level of diffuse but evenly 
distributed nuclear staining (Figure 7.6, a and b). The immunostaining pattern 
produced by P-S364 was specific since stained nuclei were competed only by 
inclusion of the phosphorylated Ser364 peptide and not by the 
unphosphorylated E2F-l peptide (Figure 7.6, compare c and d), indicating that a 
low level of E2F -1 phosphorylated on Ser364 exists in non-stressed cells. 
To explore whether the staining pattern would be affected by DNA 
damage, MCF7 cells were treated with etoposide before indirect 
immunofluorescence with the P-S364 antibody was perfonned. In etoposide 
treated cells, whilst the overall level of nuclear stain exhibited a moderate 
increase, the increase occurred in parallel with the appearance of discrete 
nuclear structures with intense staining (Figure 7.7, a and b). Again, this 
staining pattern was specific for E2F -1 phosphorylated on Ser364 since it was 
competed by the phosphorylated and not the unphosphorylated peptide (Figure 
7.7, compare c and d). These results support the conclusion that the Chk2 
phosphorylation of Ser364 is induced by etoposide treatment, and further imply 
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the existence of specific nuclear sub-structures in which the phosphorylated 
species ofE2F-1 can reside. 
7.6. E2F-1 co-localisation 
The sub-nuclear structures or foci observed in which P-S364 E2F-1 
resides are large and not very numerous (Figure 7.7a and b). Other nuclear 
structures that occur with a similar frequency, and of a similar size within the 
nucleus include PML bodies (Lamond and Earnshaw, 1998). To check if P-
S364 E2F-1 colocalises to PML bodies, SAOS2 cells were treated with 
etoposide over increasing time. Whilst P-S364 E2F-1 foci fonned from 3 hand 
persisted to 16 h, they decreased in number and increased in size (Figure 7.8, a-
d). Conversely, staining with a PML antibody was apparent in the absence of 
etoposide treatment and remained unchanged up to the 8 h timepoint, however 
after 16 h of etoposide treatment, a marked reduction in PML staining was 
observed (Figure 7.8, e-h). Importantly, merging of the P-S364 and PML fields 
revealed that no co-localisation ofP-S364-E2F-1 and PML was observed under 
any conditions (Figure 7.8, i-I). Therefore phosphorylated Ser364 E2F-1 does 
not reside within PML bodies. 
7.7. Conclusions 
In this chapter the cellular distribution of E2F-I has been explored. 
Endogenous and exogenous E2F-1 localised to the nucleus, and no significant 
change in the intracellular distribution or intensity of staining was observed 
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when cells were DNA damaged by etoposide or UV -irradiation. In addition, the 
sub-cellular localisation of the mutant derivative S364A did not differ from 
E2F-l under any of the conditions tested. Co-expression studies ofE2F-l with 
Chk2 (wild-type and dominant-negative) revealed no significant change in E2F-
1 intensity or cellular localisation. 
However, use of the P-S364 antiserum revealed that E2F-l 
phosphorylated on Ser364 resides within discrete nuclear structures with intense 
staining, supporting the earlier conclusion that E2F-l is phosphorylated by 
Chk2 in cells in response to DNA damage. Based upon their size and frequency 
within the nucleus, the possibility that these structures were PML bodies was 
assessed. However the results suggest that P-S364-E2F -1 is unlikely to localise 
to these sub-nuclear structures. Further investigation of the specific structures 
will be required to reveal their functional significance. 
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Figure 7.1. Cellular localisation of endogenous E2F-l 
Representative fields from asynchronous MCF7 cells immunostained with the 
anti-E2F-1 antibody KH-95 and studied by indirect immunofluorescence (a, b 
and c). d, e and f show the same fields stained with DAFI. Cells were treated 
with etoposide (lOIlM) or UV-irradiation (50 11m2) as indicated for 16 h prior to 
immunostaining. Images were captured at 40x magnification. For picture clarity 
the brightness of the images was increased. 
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Figure 7.2. Cellular localisation of HA-E2F-l 
Representative fields from asynchronous MCF7 cells transfected with HA-
tagged E2F-l (5J.lg) and CMV-DP-l (lJ.lg), and studied by indirect 
immunofluorescence with the anti-HA antibody (HA-ll; a, b and c). d, e and f 
show the same fields stained with DAPI. Cells were treated with etoposide 
(lOJ.lM) or UV-irradiation (50 J/m2) as indicated for 16 h prior to 
immunostaining. Images were captured at 60x magnification. 
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Figure 7.3. Cellular localisation of HA-S364A 
Representative fields from asynchronous MCF7 cells transfected with HA-
tagged S364A (5Ilg) and CMV -DP-l (lllg), and studied by indirect 
immunofluorescence with the anti-HA antibody (HA-ll; a, b and c). d, e and f 
show the same fields stained with DAPI. Cells were treated with etoposide 
(IOIlM) or UV -irradiation (50 J/m2) as indicated for 16 h prior to 
immunostaining. Images were captured at 60x magnification. 
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Figure 7.4. Co-expression of E2F-l and Chk2 wild-type 
Representative fields from asynchronous U20S cells transfected with HA-
tagged E2F-l (5J.lg) and CMV-DP-l (lJ.lg), and Flag-Chk2 wild-type (5J.lg), and 
immunostained with anti-HA monoclonal antibody (HA-ll; a, b and c), or anti-
Chk2 polyclonal antibodies (d, e and f). g, hand i show the same fields stained 
with DAPI. Cells were treated with etoposide (lOJ.lM) or UV-irradiation (50 
J/m2) as indicated for 16 h prior to immunostaining. Images were captured at 
60x magnification. 
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Figure 7.5. Co-expression of E2F-l and Chk2 dominant-negative 
Representative fields from asynchronous U20S cells transfected with HA-
tagged E2F-l (5~g) and CMV-DP-l (l~g), and Flag-Chk2 dominant-negative 
(5~g), and immunostained with anti-HA monoclonal antibody (HA-ll; a, band 
c), or anti-Chk2 polyc1onal antibodies (d, e and f). g, h and i show the same 
fields stained with DAPI. Cells were treated with etoposide (IOIlM) or UV-
irradiation (50 J/m2) as indicated for 16 h prior to immunostaining. Images were 
captured at 60x magnification. 
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Figure 7.6. Phosphorylated Ser364 E2F-l in normal cells. 
Representative fields from asynchronous MCF7 cells immunostained with the 
affinity purified P-S364 antibody and studied by indirect immunofluorescence 
(a and b); e and fshow the same fields stained with DAPI. Peptide competition 
was performed with the affinity purified P-S364 antibody either in the presence 
of the phosphorylated peptide (2/-lg) (c) or non-phosphorylated peptide (2Ilg) 
(d); g and h show the same fields stained with DAPI. Images were captured at 
60x magnification. 
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Figure 7.7. Phosphorylated Ser364 E2F-l in etoposide-treated cells. 
Representative fields from MCF7 cells treated with etoposide (lOIJ.M) for 16 h 
and immunostained with the affinity purified P-S364 antibody and studied by 
indirect immunofluorescence (a and b); e and f show the same fields stained 
with DAPI. Peptide competition was performed with the affinity purified P-
S364 antibody either in the presence of the phosphorylated peptide (2IJ.g) (c) or 
non-phosphorylated peptide (2IJ.g) (d); g and h show the same fields stained 
with DAPI. Images were captured at 60x magnification. 
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Fig 7.8. Co-localisation ofE2F-l with PML 
Representative fields from asynchronous SAOS2 cells left untreated (a, e, i and 
m) or treated with etoposide (lOJ..lM) for 3 h (b f, j and n); 8 h (c, g, k and 0) or 
16 h (d, h, I and p) and immunostained with affinity purified P-S364 antibody 
(a, b, c and d), or anti-PML monoclonal antibody (e, f, g and h). i,j k and I show 
the merged P-S364 and PML fields. m, n, 0, and p show the same fields stained 
with DAPI. Images were captured at 60x magnification. 
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Chapter 8. Discussion 
8.1. Introduction 
It is well established that the E2F family of transcription factors plays a 
central role in co-ordinating cell cycle progression at the G 1 to S-phase 
transition. In addition, the ability of E2F -1 to induce apoptosis provides the cell 
with a safeguard mechanism against oncogenic as well as genotoxic stress. The 
activity of E2F must be tightly regulated in order to ensure the timely activation 
and repression ofE2F target genes during normal cellular growth. In response to 
DNA damage, cells must be able to arrest cell cycle progression and suppress 
the induction of apoptosis to allow time for DNA to be repaired. Conversely, if 
the damage is too severe cells must be able to efficiently activate apoptotic 
genes. In this study, phosphorylation of E2F -1, and the regulation of E2F-l 
activity in response to DNA damage, has been investigated. 
8.2. E2F-1 is regulated by the DNA damage Signalling 
pathway 
The proteins that detect and signal DNA damage have been the subjects 
of intense study over recent years. In the DNA damage signalling pathway, the 
related kinases ATM and ATR are regarded to be sensors of DNA damage, 
whereas the checkpoint kinases Chkl and Chk2 function as effectors of the 
response (Durocher and Jackson, 2001). Despite the recent explosion of 
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infonnation regarding the components of the cell cycle checkpoints, the 
mechanisms through which checkpoints arrest the cell cycle, repair DNA or 
induce apoptosis are not yet clear. Therefore, the identification of additional 
substrates of these kinases is particularly important. 
Recent studies have shown that E2F-I is regulated in response to DNA 
damage. For example, treating cells with DNA damaging agents such as those 
used in cancer chemotherapy, increases E2F-l protein levels (Blattner et al., 
1999; O'Connor et al., 2000; Lin et al., 2001). Consistent with these reports, the 
results presented in chapter 3 show that E2F-1 is induced in response to various 
DNA damaging agents, in a variety of cell lines, and suggest that the induction 
of E2F-1 is a general response to DNA damage. The extent of induction did 
vary depending on the cell line and the drug being used suggesting that different 
signalling pathways were being activated. However, it is likely that a common 
mechanism is used by each of these pathways to regulate E2F-1 accumulation. 
E2F-1 is specifically induced by DNA damage, as no change in the E2F-
2 or E2F-3 family members was evident after treatment with etoposide or other 
DNA damaging agents (Figure 3.2, and data not shown). This strongly suggests 
that the induction of E2F-1 is not simply a consequence of enrichment of G 1 
arrested cells and constitutes a bone-fide part of the cells defence against DNA 
damage. 
The observation that E2F-l and p53 are up-regulated in response to the 
same DNA damaging agents with similar kinetics suggested that they may be 
commonly regulated by the DNA damage signalling pathway. Accumulation of 
p53 in response to IR requires both ATM and Chk2 (Siliciano et al., 1997; 
Chehab et al., 2000), therefore if E2F-l and p53 are commonly regulated, then 
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it was expected that E2F-l would also be subject to regulation by ATM and 
Chk2. During the course of this study the involvement of A TM in the 
phosphorylation and accumulation of E2F-l in response to DNA damage was 
reported (Lin et al., 2001). In agreement with this, E2F-l failed to be induced 
by etoposide in a cell line deficient in ATM gene function. Consistent with the 
notion that ATM responds primarily to DNA dis breaks (Abraham, 2001), E2F-
1 protein rapidly accumulated in the same cells in response to replication 
inhibition induced by UV -irradiation. 
Several lines of evidence are presented in support of the idea that Chk2 
regulates E2F-I. First of all, a dominant-negative Chk2 blocked the induction of 
p53 and E2F-l in response to etoposide treatment, with negligible effect on UV-
irradiated cells. In HCT -15 cells, which are deficient in Chk2 gene function, 
E2F-l failed to accumulate in response to treatment with etoposide, yet retained 
the ability to respond to UV -irradiation. Further evidence in support of this idea 
was gained by transfection of Chk2 into U20S cells, which allowed a greater 
level of E2F -1 induction in response to etoposide treatment, and in HCT -15 
cells, introduction ofChk2 restored the ability ofE2F-l to respond to etoposide. 
Taken together these studies confirm that the induction of E2F -1 in response to 
DNA damage involves ATM, and reveal a new role for Chk2 in the regulation 
of E2F-l in response to DNA damage. More specifically, these results suggest 
that ATM and Chk2 are involved in signalling to E2F-l in response to agents 
that induce DNA dis breaks, and infer that E2F-l is regulated in an ATM and 
Chk2 independent manner in response to replication inhibition caused by UV-
irradiation. 
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At present, it is unclear how Chk2 and A TM co-operate to regulate E2F-
1 activity, and more studies are needed to clarify the molecular mechanisms 
involved. However, it is interesting that other proteins involved in cell cycle 
checkpoint control, such as p53 and BRCA1, are similarly phosphorylated by 
both ATM and Chk2 (Canman et al., 1998; Hirao et al., 2000; Lee et al., 2000; 
Cortez et al., 1999). Moreover, several proteins that exist in the same complex 
can be phosphorylated by ATM and Chk2, for example p53 and MDM2 
(Chehab et al., 2000; Shieh et al., 2000; Maya et ai., 2001), or BRCAI and its 
inhibitory interacting partner CtiP (Lee et ai., 2000; Li et ai., 2000; Cortez et 
ai., 1999; Tibbets et ai., 2000). 
Multiple phosphorylations may be required to recruit and activate 
effector proteins only when checkpoint responses are fully activated. For 
example, ATM phosphorylation may be required to prime a substrate for 
subsequent phosphorylation and activation by Chk2. Alternatively, the level of 
phosphorylation could be used to modulate protein function. For example, 
phosphorylation by A TM alone may be sufficient to cause cell cycle arrest, 
whereas induction of apoptosis requires both ATM and Chk2 phosphorylation. 
The fact that multiple phosphorylations apply mainly to targets with 
pleiotrophic cellular effects such as p53, BRCAI and E2F-l lends some weight 
to this idea. 
The requirement for two interacting proteins to both be phosphorylated 
may provide a safeguard mechanism that prevents the spurious activation of 
checkpoints. In this respect it is interesting that MDM2, an E2F -1 interacting 
protein, is also phosphorylated by ATM and possibly Chk2 (Maya et al., 2001; 
Shieh et al., 2000). It will be interesting to see whether other E2F -1 interacting 
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proteins, such as DP-1 and pRb are also subject to phosphorylation control in 
response to DNA damage. 
The observation that E2F-1 and p53 are both phosphorylated by ATM 
and Chk2 suggests that they may act in concert to induce cell cycle arrest or 
apoptosis. Given the role of E2F-1 in inducing p53 accumulation through 
activation of pI9ARF, the effect of E2F-1 induction could be to amplify the 
accumulation of p53. E2F-1 could further contribute to the p53 apoptotic 
response through the activation of genes involved in apoptosis such as p73 and 
Apaf-l. Alternatively, when p53 is absent or non-functional through mutation, 
E2F-1 may compensate for p53 loss, thus providing the cell with a safeguard 
mechanism. Consistent with this idea, cells that lack p53 can undergo cell cycle 
arrest (Agami and Bernards, 2000) and E2F-1 can induce apoptosis 
independently ofp53 through the transcriptional activation of genes involved in 
apoptosis such as p 73 and Apaf-1. 
Functional redundancy exists within the DNA damage signalling 
pathway (Bartek and Lukas, 2003), and the possibility that E2F-1 may be 
subject to regulation by ATR and Chk1 can not be excluded. Accumulation of 
p53 in response to UV -irradiation requires functional ATR (Tibbets et ai., 
1999), and ChId can phosphorylate p53 on Ser20 in vitro (Shieh et ai., 2000). 
Given the similarities in the regulation ofp53 and E2F-1, it is likely that E2F-I 
is also subject to regulation by ATR and ChId in response to UV-irradiation. In 
support of this idea, E2F-1 can be phosphorylated in vitro by ATR on Ser31 
(Lin et a/., 2001). The fact that gene disruption of ATR or Chkl causes 
embryonic lethality in the mouse has hampered studies into the role of ATR and 
Chk1 in checkpoint signalling. More studies are needed to address the role of 
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these proteins in signalling to E2F-l, perhaps by using siRNA to knock down 
gene function in human cells. 
To conclude, the results presented in chapter 3 suggests that E2F -1 and 
p53 are commonly regulated by ATM and Chk2 in response to agents that cause 
DNA dis breaks, and establish E2F-l as a likely effector protein in the cellular 
response to DNA damage. 
8.3. E2F-1 is phosphorylated on Ser364 by Chk2 
To further explore the mechanism for the involvement of Chk2 in the 
accumulation of E2F-I, the possibility that E2F-I might be a direct substrate of 
Chk2 was investigated. Several lines of evidence are presented in chapter 4 
suggesting that Chk2 phosphorylates E2F-I. The Chk kinases are Ser/Thr 
specific kinases for which a small number of physiological substrates have been 
identified (Bartek and Lukas, 2003). The consensus amino acid sequence for 
phosphorylation by Chk kinases has been determined (Hutchins et ai., 2000; 
O'Neill et ai., 2002; Seo et ai., 2003), and this was used to search the amino-
acid sequence of E2F-1. Serine residue 364 in the C-terminal half of the protein 
was identified as fitting the consensus Chk phosphorylation site. The amino 
acids surrounding Ser364 are more similar to identified Chk2 kinase substrates 
such as Cdc25A, Cdc25C, BRCAI and PML, than to p53. It has been suggested 
recently that two different classes of Chk2 substrate may exist, those similar to 
Cdc25 and others more similar to p53 (Bartek and Lukas, 2003). Whilst 
Cdc25C serves as a good substrate for Chk2 in vitro, activation of Chk2 as a 
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kinase towards p53 requires allosteric changes in Chk2 induced by its binding to 
full-length p53 (Craig et al., 2003). 
To investigate whether E2F-l is regulated by Chk2 phosphorylation, a 
mutational analysis was performed at the potential Chk2 phosphorylation site. 
Phosphorylation of GST-E2F-l in vitro with purified His-Chk2 results in a 
mobility shift of E2F-l in SDS-PAGE that is not apparent with the S364A 
mutant derivative. However, an equivalent mobility shift of E2F-l and S364A 
was observed when cyclinAlcdk2 purified from baculovirus-infected Sj9cells 
was used as the source of kinase. These results infer that the absence of the 
mobility shift observed with S364A when incubated with Chk2 results from 
altering a specific Chk2 kinase site. 
Phosphorylation of GST-E2F-l in vitro with purified His-Chk2 results 
in the labelling ofE2F-l with y 32p ATP to a level comparable with Cdc25C, in 
contrast to the S364A mutant that failed to be phosphorylated. The observation 
that E2F-I and S364A could be phosphorylated to about equivalent efficiency 
by cyclinAlcdk2 consolidated the previous results suggesting that the absence of 
S364A phosphorylation results from altering a specific Chk2 kinase site. 
While E2F-l does not fall into the same class of substrate as p53, it can 
form a complex with Chk2 (see chapter 5). Thus it is possible that the activation 
of Chk2 as a kinase towards E2F-l is dependent on its ability to bind to full 
length E2F-I. It will be interesting to compare phosphorylation of the full-
length E2F -1 protein with the C-terminal part of E2F -I, or an E2F -1 peptide 
that contains the Ser364 site. Furthermore, the fact that E2F-l and Chk2 can 
form a complex in cells may explain why E2F-l fails to become stabilised in 
HCT-15 cells. 
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To establish whether Chk2 phosphorylates Ser364 of E2F-l in vivo, an 
anti-phospho-specific antiserum directed against the consensus site in which 
Ser364 resides was prepared. First the reactivity of the antibody was tested on in 
vitro phosphorylated E2F-I. The antibody reacted strongly with E2F-l 
phosphorylated in vitro by Chk2 compared to un-phosphorylated E2F -1, and 
had a greatly reduced activity towards the S364A derivative. Inclusion of the 
phosphorylated peptide, and not the unphosphorylated peptide efficiently 
competed out the signal confirming the reactivity of the antibody for 
phosphorylated Ser364 was specific. These results support the view that the 
Ser364 site is phosphorylated by Chk2 kinase, and importantly that the P-S364 
antibody recognises the phosphorylated site in E2F-I. 
Next, the anti-P-S364 antibody was used to establish that Ser364 is 
subject to phosphorylation control in vivo in response to DNA damage caused 
by etoposide treatment. Because E2F-l is stabilised in response to etoposide 
treatment, it was possible that any increase in reactivity observed with the P-
S364 antibody would simply reflect an increased abundance of E2F-I protein. 
To exclude this possibility, cells were immunoblotted with P-S364 under 
experimental conditions in which there was little change in the steady state level 
of E2F-I. Under these experimental conditions the antiserum clearly reacted 
with E2F-I in etoposide treated cells, but not in non-stressed cells. 
Although the polypeptide recognised by P-S364 migrated to exactly the 
same size as the polypeptide recognised by the general E2F-I antibody (KH-
95), it cannot be taken as proof that they are the same. Therefore, to confirm 
that the antibody is recognising phosphorylated E2F-I, immunoprecipitation 
was performed with the general E2F-I antibody KH-95 prior to western blot 
199 
analysis with P-S364. lmmunoprecipitated E2F-l was clearly recognised by P-
S364 only in etoposide treated cells. Taken together, these findings suggest that 
Chk2 phosphorylates E2F-l on Ser364 in vitro and on the same site in vivo in 
response to DNA damage, and firmly establish E2F-l as a physiological target 
for Chk2 kinase. 
A comparison of amino-acid sequences of the different E2F family 
members reveals that the serine at 364 is unique to E2F-l. This suggests that 
E2F-l is the only E2F family member that is phosphorylated by Chk2, although 
it remains possible that Chk2 may phosphorylate different sites on the other E2F 
family members. In addition, Chk2 shares overlapping substrate specificity in 
vitro with the other identified checkpoint kinase Chkl, thus there is a distinct 
possibility that the same site on E2F-l will be phosphorylated by ChId in vivo 
in response to a different kind of DNA damaging agent, such as UV -irradiation. 
8.4. Phosphorylation of Ser364 regulates E2F-1 stability 
The mechanisms that control the accumulation of E2F-l activity in 
normally growing cells are complex and involve transcriptional control of the 
E2F-l promoter (Hsiao et al., 1994; Johnson et al., 1994; Sellers et al., 1995), 
control of E2F-l DNA-binding activity through the action of cyclinNcdk2 
(Krek et al., 1994), and control of E2F-l protein stability through ubiquitin-
mediated degradation by the proteasome (Hateboer et al., 1996). 
In chapter 5 the mechanism through which E2F -1 is induced was 
investigated. First, the S364A mutant devoid of Chk2 phosphorylation was 
compared with E2F-l in its ability to respond to DNA damage. The comparison 
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of exogenous E2F proteins revealed that the temporal accumulation of S364A 
was about 3-4 times less than E2F-l under similar conditions of etoposide 
treatment, indicating that Ser364 plays a significant role in the regulation of 
E2F-l stability. The S364A mutant does still retain some ability to respond to 
DNA damage, and it is likely that this is through the ATM phosphorylation site. 
A double mutant containing S364A and S31A should therefore be unresponsive 
to agents that cause DNA dis breaks, and will be a useful mutant to have for 
future studies aimed at unravelling the contribution of ATM and Chk2 to E2F-l 
induction. 
A possible explanation for the increase in E2F-l, but not S364A 
abundance in response to etoposide treatment is that Chk2 controls the stability 
of E2F-1. Although the stability of E2F-l and S364A were similar in the 
absence of etoposide, S364A was significantly less stable in the presence of 
etoposide. The observation that E2F-l induction in response to DNA damage 
reflects an increase in protein stability suggests that the mechanism responsible 
for the normal turnover ofE2F-l in cells is being disrupted. 
Two activities have been implicated in the control ofE2F-l degradation, 
the binding of pRb to the carboxy terminus of E2F-l (Hateboer et ai., 1996; 
Hofinan et ai., 1996), and the binding of p45sKP2 to the amino-terminal 
sequences of the protein (Marti et ai., 1999). In response to DNA damage and 
other stress signals, pRb becomes hypo-phosphorylated (Amellem et ai., 1996; 
Krtolica et ai., 1998). The increase in p53 in response to stress signals can cause 
the hypo-phosphorylation of pRb via the induction of the cdi p21, which can 
inhibit the phosphorylation of pRb via cdks. As E2F-l favours the binding to 
hypo-phosphorylated pRb, in response to DNA damage, it was anticipated that 
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there would be an increase in the amount of E2F-l in complex with pRb. An 
increase in the pRb/E2F-I complex could be responsible for the accumulation of 
E2F-I in response to DNA damage, since pRb binding can protect E2F-l from 
ubiquitination (Hofman et al., 1996). 
Several lines of evidence are presented to suggest that pRb is not 
responsible for the induction of E2F-I. Results presented in chapter 3 showed 
that E2F-I is still induced in SAOS2 cells which lack both p53 and pRb 
proteins, and argue strongly that the accumulation ofE2F-l in response to DNA 
damage can be independent ofp53 and pRb. Moreover, E2F-l and S364A form 
a complex with pRb in vitro and in vivo implying that phosphorylation by Chk2 
stabilises E2F-I in a pRb-independent manner. 
Consistent with pRb becoming hypo-phosphorylated m response to 
DNA damage (Amellem et al., 1996; Krtolica et ai., 1998), an increase in the 
pRb/E2F-l complex is observed in response to etoposide treatment. As pRb 
binds to a region within the E2F-l transactivation domain, this infers that the 
induced E2F -1 is held in a transcriptionally inactive state. However, the ratio of 
E2F-l complexed with pRb is similar in stressed and non-stressed cells. Since 
E2F -1 is still transcriptionally active in non-stressed cells, this result suggests 
that a population of E2F exists in stressed cells that is not complexed with pRb, 
and thus free to activate gene transcription. 
Recently, p45SKP2 was reported to bind to the amino-terminus of E2F-l 
and target E2F-l for degradation (Marti et ai., 1999). It has been suggested 
recently that ATM-mediated phosphorylation might alter the degradation of 
E2F-l by inhibiting the binding and function of Skp2 and thus prevents the 
normal degradation of E2F-l, however this is only speculative and no 
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experimental evidence exists to support this idea (Lin et al., 2001). Nonetheless, 
p45sKP2 remains an attractive candidate, and future studies should address the 
contribution that A TM and Chk2 make to the E2F -lISkp2 interaction. 
Interestingly, it has also been shown that E2F-l binds and co-
precipitates with MDM2, and a domain in E2F-l shows striking similarity to the 
MDM2 binding domain of p53 (Martin et ai., 1995). The interaction of MDM2 
with p53 through this domain is required for the degradation ofp53. In response 
to DNA damage, phosphorylation on Thr18 and Ser20 ofp53 by Chk2 disrupts 
its interaction with MDM2 (Craig et ai., 1999; Schon et ai., 2002; Chehab et ai., 
2000). In addition, phosphorylation of MDM2 by ATM has been suggested to 
disrupt its interaction with p53 leading to p53 accumulation (Maya et ai., 2001). 
Given that E2F-l and p53 are similarly regulated by ATM and Chk2 (chapter 
3), it is possible that disruption of the MDM21E2F-l interaction mediated by 
Chk2 phosphorylation plays a major role in the induction of E2F -1 in response 
to genotoxic stress. In support of this idea, Ser364, the site phosphorylated by 
Chk2 is next to the MDM2 binding domain, and MDM2 can act as an inhibitor 
of E2F -1 induced apoptosis (Mason et ai., 2001) and can target both E2F -1 and 
DP-1 proteins for degradation (Loughran and La Thangue, 2000). 
It was recently shown that polyubiquitination of p53, which is required 
for degradation by the ubiquitin proteasome pathway, requires the activities of 
both p300 and MDM2 (Grossman et ai., 2003). E2F-l also interacts with and is 
acetylated by p300 (Trouche et al., 1996; Martinez-Balbas et ai., 2000). The 
consequence ofE2F-l acetylation was to potentiate E2F-l activity by increasing 
its DNA-binding ability, transactivation potential, and extension of its protein 
half-life. Although extension of E2F-l half-life may seem counter-intuitive to 
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p300 being involved in the ubiquitination and degradation of E2F -1, it is worth 
noting that similarly to E2F-l, acetylation of p53 by p300 has been reported to 
potentiate p53 DNA-binding and transcriptional activity (Gu and Roeder, 1997; 
Dumaz and Meek. 1999). Thus it remains a distinct possibility that p300 plays a 
role, possibly in combination with MDM2 in the regulation ofE2F-1 stability. 
P 19ARF has also been implicated in the regulation of E2F stability, and 
has been shown to target certain E2F species including E2F-l for degradation. 
P 19ARf induced degradation of E2F-I depends on a functional proteasome, 
therefore ARF mediated E2F degradation may be connected with E2F 
ubiquitination (Hofman et al., 1996; Hateboer et al., 1996; Campanero and 
Flemmington, 1997; Marti et al., 2001), where ARF might act as an adapter that 
brings E2F-I and the ubiquitination apparatus together. ARF can localise to 
nucleoli along with MDM2, and whether MDM2 is the ubiquitin ligase involved 
in the degradation of E2F-l by ARF remains to be determined, although a 
necessary role for MDM2 in E2F-l degradation has been suggested (Blattner et 
al., 1999). 
Thus, ARF, MDM2 and p300 are proteins that associate with E2F-l and 
can regulate its function, and may be involved in the regulation of its stability. 
The availability of ceIJs deficient in MDM2, ARF or p300 gene function would 
greatly assist in determining the contribution made by these proteins to the 
induction ofE2F-1 in response to DNA damage. 
The observation that Chk2 and E2F-l form a complex in vitro and under 
physiological conditions infers that in addition to phosphorylation, Chk2 may 
regulate E2F-l through additional mechanisms. In analogy to pRb, Chk2 may 
stably bind to E2F-I and mask a signal for degradation, or the formation of a 
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transient complex may induce a conformational change that is sufficient to 
disrupt E2F-ls interaction with other proteins such as MDM2. 
Interestingly, it has been shown recently that phosphorylation of E2F-l 
at residues 403 and 433 can down-regulate its stability (Vandel and Kouzarides, 
1999). Therefore, stress signals may increase the stability of E2F -1 by inhibiting 
the phosphorylation ofE2F-I at these sites. This raises the possibility that E2F-
1 stability may also be regulated by protein phosphatases that become activated 
in response to DNA damage. 
In summary, although evidence has been presented that links Chk2 to 
the regulation ofE2F-l stability in response to DNA damage, more studies are 
required to determine the mechanism. However it is likely that it will involve 
the modulation of E2F-Is interaction with another cellular protein that remains 
to be determined. 
8.5. Regulation of E2F-1 activity by Chk2 
Phosphorylation can affect the activity of a transcription factor by 
modulating its DNA-binding activity and its interaction with co-activators and 
components of the basal transcription machinery (Hill and Triesman, 1995). Gel 
retardation showed that the mutant derivative of E2F-l that is incapable of 
phosphorylation on Ser364 was competent in its ability to form a heterodimer 
with DP-l and bind to the E2F-recognition site. Moreover, E2F-l and S364A 
DNA-binding were unaffected by etoposide treatment. Taken together, these 
results imply that phosphorylation at Ser364 does not regulate E2F-l DNA-
binding activity. However, more studies using the P-S364 antibody in gel 
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retardation or Chip assays are required to properly address this question. 
Importantly, these results do demonstrate that the integrity of E2F-I was not 
altered by mutagenesis. 
The results presented in chapter 6 demonstrate that Ser364 is important 
for the transcriptional activity of E2F-I. S364A has a reduced transcriptional 
activity when assessed for its ability to activate several E2F-responsive 
promoters under non-stress conditions. Furthermore, the rise in reporter activity 
in response to increasing amounts of S364A was not as significant as that 
detected when equivalent amounts of E2F -1 were transfected. There are a 
number of possible explanations for this observation. One possibility is that 
S364A has a lower affinity for an endogenous protein involved in 
transcriptional activation, such as p300/CBP or Spl (Trouche et ai., 1996; 
Morris et ai., 2000; Dyson, 1998), and thus can not efficiently recruit it to the 
promoter. Another possibility is that S364A can not efficiently interact with 
components of the basal transcriptional machinery, such as TBP (Dyson, 1998; 
Ross et al., 1999). Alternatively, transfection may stress the cells enough for 
Chk2 to become activated, or low levels of active Chk2 may exist under non-
stress conditions (DiTullio et al., 2002). Consistent with this idea, low levels of 
Ser364 phosphorylated E2F-l are detected by immunofluoresence in non-
stressed cells (Figure 7.6). Having ruled out other possible explanations, such as 
differences in protein expression, DNA-binding or rate of degradation, the idea 
that phosphorylation of E2F-l on Ser364 plays a role in recruiting co-activator 
proteins to the promoter, or promotes the assembly of the transcription initiation 
complex warrants further investigation. 
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Under nonnal conditions, the steady state levels of E2F-l and S364A are 
the same. However, etoposide treatment significantly increased the stability and 
half-life of E2F-l, but not the S364A mutant (see chapter 5). Therefore, under 
DNA damage conditions, it was expected that the rise in E2F-l protein levels 
would be accompanied by an increase in the level of transcription. Contrary to 
expectation, etoposide treatment failed to stimulate E2F -I-dependent gene 
expression from the ARF promoter. Conversely, there was a decrease in both 
E2F-I and S364A dependent transcription. This was not due to a general shut 
down of transcription as the expression of the internal control, p-gal, was 
unaffected. Therefore hypo-phosphorylation of pRb and the subsequent increase 
in binding to E2F proteins could account for the repression of E2F -dependent 
transcription observed. 
If phosphorylation of Ser364 augments E2F-I-dependent transcription, 
then under conditions of etoposide treatment in which exogenous Chk2 is 
activated, the co-expression of Chk2 or Chk2 dominant-negative was expected 
to regulate E2F-l dependent transcription. Unexpectedly, co-transfection of 
Chk2 or Chk2 dominant-negative had no effect on E2F-l dependent 
transcription. 
It is difficult to draw a conclusion from these experiments, partly due to 
the lack of a suitable positive control. However the use of an integrated reporter 
gene, and a cell line deficient in pRb may be necessary when looking at the 
effect that DNA damage has on E2F-l dependent transcription. 
Having established E2F-l as a substrate of Chk2 (chapter 4), and that 
phosphorylation of Ser364 by Chk2 regulates E2F-l stabilisation (chapter 5), 
the consequence of increased E2F-l abundance observed in response to DNA 
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damage was connected with apoptosis. In SAOS2 tumour cells, which carry an 
inactive p53 gene, over-expression of E2F-l increased apoptosis after etoposide 
treatment significantly more than the S364A mutant lacking the Chk2 
phosphorylation site. Moreover, the expression of the dominant-negative Chk2 
mutant, Asp347Ala, reduced the level of apoptosis induced by E2F-I, but had 
no effect on S364A, thus providing evidence that E2F-I-dependent apoptosis is 
regulated by Chk2 phosphorylation. 
Additionally, in SAOS2 cells, induction of E2F-l correlated well with 
E2F-l target genes involved in apoptosis such as Apaf-l, p73 and ARF. These 
results argue that induced E2F-l protein is transcriptionally active, and support 
the idea that a population of E2F-l exists that is not complexed with hypo-
phosphorylated pRb. Therefore, the compromised ability of S364A to induce 
apoptosis likely reflects its inability to properly activate the transcription of 
these genes. These results provide a plausible pathway through which Chk2 can 
directly act to increase E2F-l activity and stimulate the transcription of E2F 
target genes involved in apoptosis. 
8.6. Mechanism of E2F-1 induced apoptosis 
Whilst Chk2 phosphorylation provides a signal for E2F -1 to induce 
apoptosis, the mechanism through which E2F-l causes apoptosis rather than cell 
cycle progression remains unclear. Nevertheless, it is believed that different 
target promoters may be occupied by distinct E2F sub-units, for example as 
cells progress through the cycle, but to date there is little evidence to support 
any promoter-specificity of complexes (Takahashi et al., 2000). Against this 
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background, it remains possible that the level of E2F-l protein influences its 
outcome in cells, namely proliferation or apoptosis, through a transcription-
based mechanism. For example, a threshold level, such as the high level 
reached in response to DNA damage, could determine whether apoptosis 
occurs. Mechanistically, under these conditions a different, even overlapping. 
spectrum of genes may be activated compared to those involved in cell cycle 
progression, perhaps through binding to promoters containing lower affinity or 
diverged sequences within the binding sites (Figure 8.1). Alternatively, DNA 
damage may promote the interaction of E2F -1 with other cellular proteins to 
synergistically activate transcription of apoptotic target genes (Figure 8.1). In 
support of this idea, the YYl-binding protein RYBP was identified as a factor 
that binds to E2F-2 and E2F-3 and recruits these E2Fs to a subset of E2F target 
promoters containing YYl binding sites (Schlisio et al., 2002). Additionally, the 
physical interaction of the E-box factor TFE3 and E2F-3 facilitates 
transcriptional activation of the p68 gene which has both E2F binding sites and 
E-box elements within its promoter (Giangrande et al., 2003). Damage-
dependent acetylation of E2F-l has been suggested to target E2F-l to the p73 
promoter (Pediconi et al., 2003), and it will be interesting to understand how the 
different DNA damage-dependent post-translational modifications of E2F -1 are 
integrated. An important goal for future studies will be to use Chip assays to 
probe target gene specificity under DNA damage conditions. In this respect, use 
of the P-S364 antibody should yield some fascinating results. 
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Figure 8.1 Mechanism of E2F-1 induced apoptosis 
Under normal circumstances, E2F-l regulates the expression of genes required 
for cell cycle progression. In response to DNA damage, E2F-l is stabilised and 
reaches a threshold level allowing the binding and activation of a different 
spectrwn of genes, such as those involved in the induction of apoptosis. This 
could be achieved by the binding of E2F-IIDP complexes to lower affinity 
promoters, perhaps with diverged sequences in their binding sites. Alternatively, 
DNA damage may promote the interaction ofE2F-1 with other cellular proteins 
to synergistically activate transcription of apoptotic genes. 
8.7. Cellular localisation of E2F-1 
The mechanism of nuclear uptake of E2F is an important consideration 
in the regulation of E2F activity as E2F must be present in the nucleus to 
regulate transcription. E2F-l, E2F-2 and E2F-3 contain a NLS and are 
predominantly nuclear when overexpressed (Magae et af., 1996; Allen et af., 
1997; Lindeman et aI., 1997). In contrast, ectopically expressed E2F-4 and E2F-
5 are predominantly cytoplasmic, being devoid of an NLS (Allen et af., 1997). 
As expected, endogenous E2F-l was nuclear in localisation as 
determined by indirect immunofluorescence. In response to DNA damage the 
cellular localisation of E2F-l remained unaltered. Given that western blot 
analysis shows that E2F-l is substantially induced at the protein level in 
response to etoposide and UV -irradiation, it was surprising that there was no 
increase in the intensity of irnmunostaining under similar conditions. While no 
conclusive reason can be provided for this discrepancy, it is possible that it 
reflects a limitation of the immunofluorescence assay. 
To explore the possibility that the phosphorylation status of E2F-1 
affected its ability to localise in the nucleus, the cellular localisation of E2F-I 
and the S364A mutant derivative was determined. The cellular localisation of 
the S364A mutant derivative did not differ from E2F-l in either the absence or 
presence of etoposide or UV -irradiation. Moreover, co-transfection of Chk2 or 
the dominant negative-derivative of Chk2 did not affect the localisation of E2F-
1 or S364A under any of the conditions tested. Therefore, phosphorylation of 
E2F-l on Ser364 does not effect the ability ofE2F-l to localise to the nucleus. 
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Interestingly, use of the P-S364 antibody revealed that E2F-l, when 
phosphorylated by Chk2, localised to distinct nuclear bodies with intense 
staining. Given the size and frequency of the nuclear bodies, it was reasoned 
that they may be PML nuclear bodies. PML nuclear bodies are nuclear domains 
that are specifically disrupted in human acute promyelocytic leukemia (APL) 
cells. A typical mammalian nucleus has -10 to 20 PML bodies, which vary in 
size (Lamond and Earnshaw, 1998). The role of PML bodies remains largely 
unknown, however several components of the nuclear body have been identified 
and include CBP, pRb and p53 (Zhong et ai., 2000). Furthermore, PML is itself 
a substrate of Chk2 (Yang et ai., 2002), and PML has been shown to recruit 
Chk2 into PML bodies, where it enhances the p53-Chk2 interaction thereby 
neutralising the inhibitory effects that MDM2 has on p53 (Louria-Hayon et ai., 
2003). Co-localisation studies using P-S364 and an antibody directed against 
PML failed to show any co-localisation ofE2F-l with PML thus ruling out the 
possibility that phosphorylated E2F-l resides in PML bodies. 
Many proteins involved in the recognition and repair of DNA damage, 
including activated Chk2, localise to distinct nuclear foci most probably at sites 
of DNA damage. It is attractive to speculate therefore that in addition to 
regulating apoptosis, E2F-l may playa role in the detection of DNA damage, 
and its subsequent repair. In support of this idea, the Mrell-Rad50-Nbsl 
checkpoint protein complex that is involved in responses to DNA dis breaks 
(D' Amours and Jackson, 2002) associates with E2F-l through the Nbs-l N-
terminus (Maser et ai., 2001). Furthermore, the Nbsl/E2F-l interaction occurs 
near origins of replication, suggesting that E2F is required to target the Mre 11 
complex to origins of replication to suppress origin firing in the presence of 
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damaged DNA. Moreover, Drosophila E2F and DP are present in ongm 
recognition complexes (Bosco et al., 2001), implying a direct role for E2F -1 in 
the regulation of DNA replication. 
A recent study demonstrated that TopBP 1 relocalises E2F -1 to nuclear 
foci along with BRCAI in response to DNA damage. Upon DNA damage 
TopBPl is recruited to stalled replication forks, where it participates in a DNA 
damage checkpoint. The recruitment of E2F-l to foci along with the BRCAl-
repair complex and TopBPI further supports to the idea that E2F-l is directly 
involved in DNA damage checkpoint/repair and replication control in 
mammalian cells (Liu et ai., 2003). Interestingly the E2F -1 immunostaining 
pattern observed by Liu and colleagues is very similar to that of P-S364 E2F -1, 
therefore future studies aimed towards looking at the interaction of 
phosphorylated S364-E2F-l with TopBPl and BRCAI should be very 
interesting. 
Furthermore, exploring the genome-wide effects of E2F-l using DNA 
micro arrays has revealed a large number of genes that are regulated by E2F-l in 
diverse cellular processes, including replication, apoptosis, checkpoint control 
and DNA repair (Ren et at., 2002; Ma et at., 2002; Polager et ai., 2002; Stanelle 
et ai., 2002 and Table 1. 1). Taken together with the results presented in this 
thesis, these studies suggest a role for E2F-l in regulating DNA damage 
checkpoint responses, DNA replication and possibly facilitating efficient DNA 
repair. Studies aimed at determining whether P-S364 E2F-l co-localises to 
damage induced nuclear foci with activated Chk2 have been hampered by the 
fact that the P-S364 antibody and the P-Thr68 Chk2 antibody are both rabbit 
polyclonal in origin. More studies are required to determine whether P-S364 
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E2F-1 co-localises with other proteins involved in checkpoint control such as 
BRCA1 and the Mre11 complex. 
8.8. General discussion 
The results presented in this thesis establish E2F -1 as a physiological 
target for Chk2 kinase in response to DNA damage. In response to etoposide 
treatment, Chk2 phosphorylates E2F-1 on Ser364 leading to an increase in the 
stability of E2F-1, and in turn the increased abundance of E2F-l leads to cell 
cycle arrest and apoptosis through a transcription based mechanism. The 
observation that E2F-l phosphorylation is induced by DNA damage defines 
E2F-l as a likely effector protein in the cellular response to DNA damage. 
E2F-l can regulate cellular growth in both a positive and negative 
manner. For example, while E2F-l can stimulate cell cycle progression by 
controlling the expression of genes required for DNA synthesis and entry into 
S-phase, it can also playa role in cell cycle arrest and apoptosis (Trimarchi and 
Lees, 2001). A number of reports have illustrated this duality in E2F -1 function. 
For example, E2F-l can function as an oncogene in vitro and in vivo (Johnson et 
at., 1993; Johnson et at., 1994; Lukas et at., 1996; Yamasaki et at., 1998), and 
cells lacking E2F-l exhibit cell cycle defects (Degregori et at., 1997). In 
contrast, several reports have described the apoptotic activity of E2F-l (Qin et 
at., 1994; Shan et al., 1994; Wu et al., 1994), which may explain the increased 
tumour incidence and reduced levels of apoptosis observed in E2F-rl- mice 
(Field et al., 1996; Yamasaki et al., 1996). The pathway described here for 
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Chk2 in regulating E2F-l abundance and apoptosis may be involved In 
controlling the tumour suppressor-like activity previously ascribed to E2F-t. 
The results argue that Chk2 induces E2F-l and in tum provides a signal 
for cell cycle arrest and apoptosis. In this respect, the damage induction of E2F-
1 resembles the p53 response, which similarly results in cell cycle arrest and 
apoptosis. The physiological significance of the apoptosis signalled by p53 and 
E2F-l may relate to the severity of damage where, in situations of extreme 
damage, it is beneficial for the cell to activate apoptosis rather than attempt 
DNA repair. Alternatively, it makes sense that the cell has more than one 
mechanism through which it can cause cell cycle arrest or apoptosis. Thus E2F-
I may provide a safeguard mechanism in the event that p53 function is disabled. 
Whilst it has already been reported that E2F-l and p53 can act synergistically to 
induce apoptosis (Wu and Levine, 1994), the molecular mechanisms involved 
are not yet clear. Future studies aimed at identifying genes such as Apaf-l that 
are regulated by both E2F-I and p53 will provide a better mechanistic 
understanding ofthe integration ofthese two checkpoint pathways. 
Taken together with another study (Lin et al., 2001) the results presented 
here establish that both Chk2 and ATM signal DNA damage to E2F-I. Thus, in 
normally growing cells, E2F-l along with E2F-2 and E2F-3 is involved in the 
control of the transition from G I into S-phase. However, in response to DNA 
damage, genes such as ARF, p73 and Apaf-l are induced through damage-
responsive signalling to E2F-l which, in tum and perhaps in concert with p53 
target genes, result in cell cycle arrest or apoptosis (Figure 8.2). 
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Figure 8.2 Summary of the E2F-1 pathway and the p53 response 
to DNA damage 
A summary of the pRblE2F pathway (left) and p53 response to DNA damage (right), 
together with ATMlATR and Chk2 kinases involved in DNA damage signalling to 
p53. Targets that may result in E2F-dependent apoptosis, such as ARF, p73, and 
Apaf-l are indicated. The arrow connecting Chk2 directly with E2F-l is derived from 
the conclusions in this thesis and emphasises the interplay between the DNA damage 
signalling pathway and the pRblE2F pathway. The connection between A TMI A TR 
and E2F-l is based on the study by Lin et al., 2001. 
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